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Abstract: This project was designed to study the in vivo immunomodulatory effects of CpG-containing
oligonucleotides in the domestic cat and to determine their potential to induce short-term protection
against FIV infection. The prophylactic treatment of the cats was carried out with dSLIM™, a non-
coding DNA molecule containing several unmethylated CpG motifs, previously shown to induce strong
cellular immune responses and production of IFN-￿, both highly desirable in the combat against viral
infections. A group of 10 spf cats was treated during 5 consecutive days; a second group, equally of
10 spf cats, was simultaneously treated with a placebo. Both groups were challenge infected with FIV
24 hours after the end of the treatment. Clinical and immunological parameters were closely monitored
in the cats throughout the experiment. When compared to the cats of the control group, 2 individuals
treated with dSLIM™ indicated a 3-week delay in detection of proviral and viral loads in blood as well as
isolation of infectious virus from plasma. A cytokine pattern representative of deviation to Th1 immune
responses after treatment, as well as comparatively low antibody production after challenge enabled to
attribute the partial resistance observed in these cats to cellular mechanisms. Despite promising results
in this study, further investigations are necessary to determine the feasibility of stimulation of innate
immunity as alternative to the development of a vaccine against FIV. Sowohl die immunmodulatorische
Wirkungen von CpG Oligonukleotiden als auch ihr Potenzial einen kurzzeitigen Schutz gegen die FIV
Infektion der Hauskatze zu erzeugen, wurden in dieser Studie in vivo untersucht. Die prophylaktische
Behandlung der Katzen erfolgte mit dSLIM™, ein nicht-kodierendes DNA Molekül, das mehrere un-
methylierte CpG Motive enthält und antivirale Eigenschaften besitzt, u.a. die Induktion einer zellulären
Immunantwort und die Förderung der Produktion von IFN￿. Eine Gruppe von 10 SPF Katzen wurde
während 5 Tagen mit dSLIM ™ behandelt. Eine weitere Gruppe von 10 Katzen wurde gleichzeitig mit
einem Placebo behandelt. 24 Stunden nach Ende der Behandlung wurden alle Katzen einer Testinfek-
tion mit FIV unterzogen. Klinische und immunologische Parameter wurden über einen Zeitraum von
12 Wochen regelmässig gemessen. In zwei mit dSLIM™ behandelten Katzen konnte im Blut provirale
DNA, virale RNA und infektiöses Virus erst 3 Wochen später nachgewiesen werden als in den Katzen
der Kontrollgruppe. Der beobachtete partielle Schutz konnte anhand des Th1 Zytokinmusters und des
tiefen Antikörpertiters im Blut dieser zwei Katzen in den ersten Tagen nach der Testinfektion auf eine
zelluläre Immunantwort zurückgeführt werden. Obwohl die Stimulierung des angeborenen Immunsys-
tems im Kontext einer FIV Infektion versprechende Ergebnisse zeigte, sind weitere Studien erforderlich
um diese Methode als Alternative zur Impfung zu erwägen.
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1. Summary
This project was designed to study the in vivo immunomodulatory effects of 
CpG-containing oligonucleotides in the domestic cat and to determine their 
potential to induce short-term protection against FIV infection. 
The prophylactic treatment of the cats was carried out with dSLIM™, 
a non-coding DNA molecule containing several unmethylated CpG motifs, 
previously shown to induce strong cellular immune responses and production of 
IFN-α, both highly desirable in the combat against viral infections. 
A group of 10 spf cats was treated during 5 consecutive days; a second group, 
equally of 10 spf cats, was simultaneously treated with a placebo. Both groups 
were challenge infected with FIV 24 hours after the end of the treatment. Clinical 
and immunological parameters were closely monitored in the cats throughout 
the experiment.
When compared to the cats of the control group, 2 individuals treated with 
dSLIM™ indicated a 3-week delay in detection of proviral and viral loads in 
blood as well as isolation of infectious virus from plasma. A cytokine pattern 
representative of deviation to Th1 immune responses after treatment, as well as 
comparatively low antibody production after challenge enabled to attribute the 
partial resistance observed in these cats to cellular mechanisms.
Despite promising results in this study, further investigations are necessary to 
determine the feasibility of stimulation of innate immunity as alternative to the 
development of a vaccine against FIV.
1

32. Introduction
First isolated from a domestic cat (Felis catus) by Pedersen and colleagues in 1986,
the Feline Immunodeficiency virus (FIV) is a retrovirus of the genus lentivirus, which 
causes progressive loss of CD4+ T lymphocytes in infected individuals. FIV disease 
persists lifelong, and most infected cats eventually succumb due to direct viral 
effects or, more commonly, to secondary infections resulting from virus-induced 
immunosuppression. Although the occurrence of infection in Switzerland remains 
relatively low, FIV is considered a main source of viral disease in stray and pet cat 
populations worldwide, with an overall prevalence of approximately 11%. 
Among retroviral diseases affecting non-primate vertebrates, FIV infection in the 
cat is considered to be the closest model of Human Immunodeficiency virus (HIV) 
infection and acquired immunodeficiency syndrome (AIDS). Indeed, human 
HIV/AIDS and disease induced by FIV in cats not only share many biological 
and clinical properties, but host-virus immunological interactions indicate high 
similarities. Moreover, the diversity of primary FIV strains can be exploited to mirror 
the range of disease manifestations associated with HIV infection. The FIV model 
thus offers the opportunity to study lentiviral infection and immunopathology 
in natural, out-bred hosts, and enables valuable evaluation of preventive and 
therapeutic approaches to AIDS in both human and veterinary medicine.
Elaborating specific medical care or prevention methods against HIV and FIV 
infections has proven to be particularly tricky, as these viruses are very susceptible to 
evolutionary genetic alterations and possess highly developed adaptation faculties. 
Thus, simple mutational alterations result in resistant strains, considerably limiting 
the potential of existing antiviral drugs, and rendering prophylactic measures 
especially important in the combat against such viruses. However, the development 
of an effective vaccine is limited by the genetic and phenotypic diversities of these 
viruses in the field, and the numerous attempts to the development of specific 
prophylactic protection have unfortunately to date not indicated satisfying results. 
Stimulation of innate immunity represents an alternative method to specific 
immunization. Indeed, in the last 10 to 15 years, scientists have shown growing 
interest in better understanding the complexity of the innate immune system. It 
became rapidly clear that stimulation of the organism’s first line of defence could 
be exploited to enhance short term resistance to a variety of infections. Innate 
immunity not only initiates immediate reaction to a wide range of pathogens, but 
greatly supports the subsequent development of a specific immune response.
Cytosine-phosphate-guanosine (CpG) dinucleotides are unmethylated and 
frequently present in bacterial DNA, whereas they are under-represented and 
selectively methylated in vertebrate genomes. Due to these differences, a non-self 
pattern recognition mechanism has evolved in vertebrate innate immune systems 
enabling them to counter invading pathogens. The early recognition of CpG 
DNA molecules by the immune system relies on Toll-like receptor 9 (TLR9), 
an ancient pattern recognition receptor (PRR) present in the main effector cells 
of innate immunity. Triggering of this receptor initiates intracellular cascades of 
events, enabling the expression of specific genes, thus leading to the induction of 
broad antimicrobial mechanisms. The most important response to activation of 
TLR9-linked mechanisms is probably the production of interferon-α (IFN-α), a 
type I IFN which happens to be a potent antiviral agent. IFN-α not only activates a 
wide variety of effector immune cell populations involved in both the first reaction 
to invading organisms and the mounting of a subsequent adaptive immune response, 
but induces, in yet uninfected cells, the synthesis of various proteins including 
enzymes, signaling proteins, antigen-presenting proteins and transcription factors, 
which specifically interfere with proper viral replication. Thus, by initiating potent 
mechanisms against viral dissemination, IFN-α altogether plays a major role in the 
induction of a global « antiviral state ».
In recent years, great interest has been attributed to the development of diverse 
4
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5synthetic analogues of CpG-containing bacterial DNA, capable of inducing similar 
immune responses. Relative ease in the production and modulation of such synthetic 
compounds as well as early promising results of in vitro and in vivo experimentations 
rapidly rendered synthetic immunomodulatory CpG oligonucleotides (ODNs) 
particularly interesting in terms of prophylactic and therapeutic use for many 
diseases. In fact, synthetic CpG-containing molecules have gained such popularity 
in medical research, that current human clinical trials involve various types of cancer, 
allergies, as well as a broad range of infectious disease settings. 
Due to the domestic cat’s ancestral solitary way of life, feline viruses have developed 
very efficient transmission strategies to infect new hosts upon the rare contact 
between individuals, as well as the capability to induce latent and/or asymptomatic 
infections of the carrier cat. Although modern civilisation has considerably changed 
the living habits of the domestic cat populations, feline viruses, including FIV, have 
conserved their opportunistic behaviour throughout evolution. As a consequence, 
infections with viruses adapted to the domestic cat readily affect every individual 
living in a group. This most likely explains the very high frequency and importance 
of FIV, among other feline viral infections, observed in catteries and shelters, where 
cats from different backgrounds have narrow contact with each other. Agents capable 
of transiently conferring resistance to viral infection would be highly desirable to 
temporarily protect cats in such situations with increased risks of infection. 
 
 Targeting the innate immune system with highly selective synthetic CpG molecules 
seemingly offers a powerful means to enhance a broad spectrum antiviral resistance 
in the host. It was the aim of the present work to study in vivo, using the FIV model, 
the potential of a synthetic compound containing CpG motifs to confer short term 
resistance against viral infection. Elaboration of preventive measures against this 
feline virus appears particularly challenging, and promising results would create an 
exciting new opening for the development of novel short term antiviral preventive 
measures in both human and veterinary medicine.
Introduction

3.1.1 Viral Morphology and Genomic Structure
3. Literature
3.1 FIV Literature overview
Various publications concerning the Feline Immunodeficiency virus (FIV) have been 
highlighted in the dissertations of Kim Bauer (1994), Christian Leutenegger (1995) 
and Felicitas Boretti (1999). Besides important general aspects of FIV discussed in 
the early years after discovery of the virus, this work will mainly focus on the more 
recent studies aiding further characterization and understanding of FIV infection.
1)
2)
3)
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First discovered in California by Pedersen and colleagues in 1986, FIV is a typical 
lentivirus of the family retroviridae. Mature viral particles are spherical to ellipsoid, 
measure slightly over 100 nm in diameter, and present few, short spikes on the 
outer side of their envelope [1]. FIV virions contain two copies of a positive 
sense ribonucleic acid (RNA). Of approximately 10 kB in length, the FIV genome 
presents several typical characteristics of the retrovirus family. First, it contains from 
5’ to 3’ three standard genes, gag, pol, env, that encode for proteins essential to viral 
structure and replication [2] :
 gag (group specific antigen) : encodes for the viral matrix (MA), capsid  
 (CA) and nucleocapsid (NC) proteins 
 pol (polymerase) : encodes for specific enzymes, including reverse 
 transcriptase (RT), protease (PR), integrase (IN), and dUTPase
 env (envelope) : encodes for retroviral coat proteins designated 
 as surface glycoprotein (SU) and transmembrane polyprotein (TM)
Additionally, the genome is flanked at each end by repeated sequences called long 
terminal repeats (LTR), comprised of untranslated 3’ (U3, promoter/enhancer 
elements), repeat (R) and untranslated 5’ (U5) regions. General functions of LTR 
include insertion of the viral genetic information in the host’s cellular genome and 
enhancement of its transcription. Moreover, mutational analyzes have revealed 
numerous elements in the LTR U3 region such as AP-1, AP-4, ATF and NF1 
binding sites, which constitute promoter sequences influencing viral gene expression 
[3]. Recent studies have also described  elements both within U5 and the 5’ end of 
gag, which are required for efficient packaging of newly produced FIV, thus allowing 
expansion of infection in the host [4]. Figures 1 and 2 are schematic representations 
of the FIV viral particle and the FIV genomic structure.
Literature
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Figure 1 :  Structure of the feline immunodeficiency virus
Other important regulatory genes of the FIV genome, shared with all or only certain 
members of the retrovirus family, include a rev gene (regulator of virion protein 
expression), a vif gene (viral infectivity factor ), and an orf-2 gene (also designated 
orf-A). Rev is vital for replication and packaging of all lentiviruses. Its translated 
protein acts as transporter of viral messenger RNA (mRNA) from nuclear 
localization to the cytoplasm, after interaction with a viral factor, the rev-responsive 
element (RRE) [5]. Most known lentiviruses include a vif gene, coding a viral 
infectivity factor responsible for production of infectious viral particles in producer 
cells and spread of infection to new target cells or tissues [6]. FIV transactivation 
was earlier thought to be dependent on orf-2, a short fragment placed within the 
vif sequence, with characteristics similar to those of the tat (transactivator) gene of 
the ungulate lentiviruses [7]. Interestingly, unlike other lentiviral transactivators, 
FIV orf-2 was reported to require additional LTR elements for transactivation [8]. 
Moreover, recent studies indicated that orf-2 function is involved in multiple steps 
of the FIV life cycle including both virion formation and infectivity [9]. The possibility 
that orf-2 function resembles the vpr accessory genes of other lentiviruses rather 
than tat, is currently discussed.
Table 1 : Main structural proteins and enzymes of FIV, their functions and genetic origins
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FIV replication is similar to that of other retroviruses. The first essential step for 
effective infection of the target cell is the attachment of the virion to the cell surface. 
For efficient binding, viral surface glycoproteins and receptors of the outer cellular 
membrane both play an important role. Unlike the Human Immunodeficiency virus 
(HIV), the CD4 molecule is not used by the feline virus as primary receptor or 
co-receptor [10]. CD9 was earlier thought to be a main receptor for FIV, but further 
studies have demonstrated that antibodies directed against CD9 block virus release 
rather than viral entry [11].  
With reference to knowledge on receptor usage by HIV, importance of chemokine 
receptors as means of target cell entry by FIV were more deeply studied. FIV was 
soon shown to utilize CXCR4 as a receptor for env-mediated fusion, and both 
primary as well as laboratory-adapted strains proved to need the receptor for host 
cell infection [12]. Further studies identified the second extracellular loop of 
CXCR4 as the primary determinant of target cell infection by FIV [13]. Moreover, 
in vitro FIV infection was shown to be inhibited by two different CXCR4 ligands, 
stromal cell derived factor 1 alpha (SDF1α) [14] and the bicyclam, AMD3100 [15]. 
However, some CXCR4 positive cell lines were resistant to FIV infection indicating 
the probable role of an additional receptor. The use of other chemokine receptors, 
such as CCR5 and CCR3 has also been demonstrated, as antibodies against CCR3 
as well as RANTES, a ligand to CCR5, were able to inhibit  FIV infection of target 
cells [16].
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Figure 2 : Schematic representation of the FIV genome
3.1.2 Viral Life Cycle
3.1.2.1 Receptor Usage and Cell Entry
The recent identification of CD134, a T cell antigen and co-stimulatory molecule 
as primary receptor for FIV represents a tremendous step in the understanding of 
FIV interactions with its target cells [17]. CD134 expression was demonstrated 
to promote viral binding and render cells permissive for viral entry, but productive 
infection remained CXCR4 dependent. The tropism of FIV in vivo seems to be 
consistent with the predicted expression of CD134. 
Viral characteristics critical for fusion with target cells appear to rely on a limited 
number of regions of the surface and transmembrane glycoproteins. The V3 loop of 
the viral SU glycoprotein 120 (gp120) has been shown to be critical for viral binding 
[18], and the V3-V5 region mediates chemokine receptor use [19]. Additionally, a 
tryptophan-rich motif, present membrane-proximally in the ectodomain of the FIV 
TM glycoprotein, proved to be essential in the processes of fusion and viral entry [20].
3.1.2.2 Cellular Tropism
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The set of receptors present on the target cell surface determine the ability of FIV to 
gain entry into the cell and establish productive infection. 
In vivo, FIV replicates in CD4+ and CD8+ T lymphocytes [21],  B lymphocytes 
[22],  macrophages [23], monocytes [24] and in astrocytes and microglia [25]. Some 
strains replicate preferentially in lymphoctytes (lymphocytotropic strains) and only 
minimally in monocytes, while other strains are able to replicate equally well in 
both cell types (monocytotropic strains). Moreover, certain strains have been shown 
to replicate in Kupffer cells [26], suggesting that these cells may play a role in the 
pathophysiology of FIV infection.
In vitro, the cellular tropism of primary isolates is restricted to mitogen-activated 
peripheral blood mononuclear cells (PBMCs), dendritic cells (DCs), macrophages 
and thymocytes. Tissue culture adapted strains can infect a wide range of cell types. 
In this way, various  IL-2 dependent or independent T lymphblastoid cell lines 
have proven to satisfyingly simulate in vivo cytokine and major histocompatibility 
complex (MHC) class II molecule expression [27]. Only one T lymphoblastoid  cell 
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3.1.2.3 Replication and Production of Infectious Virions
After fusion of external viral and cellular proteins and FIV penetration of the cell, 
the viral core is freed in the cytoplasm and simultaneously undergoes specific 
structural changes (uncoating). The retroviral RNA within the modified core is 
reverse transcribed by the viral RT to a linear double-stranded deoxiribonucleic acid 
(DNA) with LTR. The newly produced retroviral DNA is still associated with some 
viral enzymes and core proteins; together they form the pre-integration complex. 
FIV possesses the capacity to infect both non-dividing and dividing cells. In the 
latter, the pre-integration complex can access the host DNA easily during mitosis. 
For infection of non-replicating cells, active transport of the pre-integration 
complex in the cellular nucleus is necessary. A polypurine tract located centrally in 
the FIV genome and designated as central DNA flap has been held responsible for 
this function [32]. The viral IN catalyzes the integration of viral DNA in the host’s 
cell DNA. Interestingly, the integration of the virus does not take place at a specific 
site in the host genome, but rather occurs randomly at different sites.
line, obtained from a specific pathogen free (spf ) cat and characterized as Pan T+, 
CD4-, CD8-, was described to show a cytopathic effect upon inoculation with FIV 
[28]. Adapted strains can replicate in fibroblastoid cell lines, the most commonly 
used being Crandell-Rees Feline Kidney (CRFK) cells.
Interestingly, a human lymphoblastoid cell line [29], as well as human PBMCs 
[30], have efficiently been infected with FIV, but failure in the transcription step 
of replication caused latency of the virus in these cells. Infection of human cells by 
FIV was the first evidence of shared chemokine receptor use between primate and 
non-primate lentiviruses [31]. This finding represented a relevant step in the further 
knowledge of AIDS pathogenesis. Indeed, as FIV induces an immunodeficiency in 
the cat similar to AIDS in humans without using CD4 as a primary receptor for 
infection, the interaction between the virus and the chemokine receptor becomes a 
critical determinant of the pathogenesis of AIDS.
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Integrated viral DNA, called provirus, behaves very much like a eukaryotic gene. 
It may be transcribed into full-length transcripts using host cell RNA Polymerase 
II in order to produce more virus, or it may remain latent for long periods of time 
and replicate when cellular DNA is replicated by the cell. Each infected cell thus 
transmits the viral genome to its descendants. 
For the efficient production of new virus particles, the full-length transcripts follow 
three different routes. Some are exported from the nucleus and serve as mRNA 
for viral gag and pol protein precursors, which are translated by cytoplasmic 
ribosomes. Other full-length RNA molecules are spliced directly in the nucleus 
to form mRNA for the env protein precursors. env mRNA is translated 
by ribosomes bound to the endoplasmatic reticulum, and thereby produced 
proteins are glycosylated in the Golgi apparatus and cleaved by cellular proteases 
to form the mature TM-SU complex. These mature proteins are then delivered to 
the surface of the cell. Finally, other full-length transcripts are transported into the 
cytoplasm and serve directly as progeny viral genomes. 
All viral parts produced in this way assemble at budding sites at the inner surface of 
the plasma membrane. During budding, the virus receives its envelope, consisting of 
parts of the cell membrane and viral glycoproteins. Simultaneously, the virally encoded 
PR, which is itself a component of the core precursor protein, cleaves at specific 
sites within gag and pol precursors to produce mature, infectious viral particles, now 
free to infect new target cells in the host. The main steps of FIV replication are 
summarized in figure 3.
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Figure 3 : Main steps of the FIV replication cycle
3.1.3 Pathogenesis
3.1.3.1 Viral transmission
FIV can be isolated from blood, serum, plasma, cerebrospinal fluid and saliva of 
experimentally or naturally infected cats by cell or tissue culture methods [25, 33]. 
In field conditions, shedding in saliva is most relevant, and aggressive biting is 
considered the most important route of transmission. Indeed, older, free-roaming 
male cats are more prone to infection due to exhibition of territorial behaviour. In 
addition, cats living in environments with high population density belong to high 
risk groups, although the virus is not efficiently spread by casual non-aggressive 
contact between cats. When kept strictly indoors, cats rarely become infected and a 
low prevalence in breeding cats is predominantly due to the fact that they are mostly 
kept under restricted living conditions. 
FIV is present in semen of naturally and experimentally infected cats [34], and 
3.1.3.2 Course of Disease
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veneral transmission seems possible. Artificial insemination performed with fresh 
semen from experimentally infected cats effectively infected FIV-naïve queens in 
50% of the cases [35]. Transmission of FIV by mating however remains relevant 
under field conditions mainly due to the fact that male cats most often bite the 
queens during mating. 
Of particular interest is the possibility of vertical transmission resulting in productive 
infection and disease in offspring. FIV-infected mothers in phases of high viral 
load (see 3.1.3.2) can effectively transmit the virus to their kittens. Transplacental 
transmission of FIV to the kittens occurred in 2/3 cases after either intravenous or 
subcutaneous infection of the queen three weeks prior to parturition [36]. Moreover, 
mothers inoculated with FIV immediately post-partum can infect newborn kittens 
via milk [37]. Interestingly, more recent studies show that the frequency of perinatal 
FIV transmission from infected queens to their kittens seems to correlate with 
chronicity of infection and maternal symptoms of clinical immunodeficiency [38]. 
In experimental studies, transmission via mucosal and parenteral (intravenous, 
intraperitoneal, subcutaneous) routes have proven to be efficient. Virus strains 
representing at least three clades of FIV can be transmitted across the vaginal, rectal, 
or oral mucosa [39]. However, up to 104 fold more virus is required for infection by 
mucosal routes in comparison to parenteral routes [40].
 
The kinetics of FIV infection vary according to virus isolate and route of exposure. 
The following refers to a general pattern of infection, which can be approximately 
extrapolated to the various forms of FIV disease. 
The course of FIV infection is divided into five clinically recognizable phases, which 
naturally correlate with pathogenetic progression of disease : 1) acute infection, 2) 
asymptomatic phase, 3) persistent generalized lymphadenopathy, 4) AIDS-related 
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complex (ARC), and 5) AIDS phase. The clinical aspects of theses stages are 
described in more detail under 3.1.5.
FIV infection is characterized by progressive immune deterioration. Hallmarks of 
disease progression include CD4+ lymphocyte counts in blood and CD4+:CD8+ 
lymphocyte ratio [41], specific cytotoxic lymphocyte (CTL) counts, antibody titers 
as well as proviral load in PBMCs [42] and viral load in plasma [43] (figure 4). 
Lymphoctyes of CD4+ phenotype are primary targets of infection. Additionally, 
a significant infection of macrophages takes place already during the acute phase 
of the disease. Proviral DNA can thus be detected in PBMCs as early as five 
days after infection, and infectious virus can be isolated from lymphocytes as of 
day 10 post-infection. Viremia then rapidly increases until week 3, peaks between 
weeks 7 and 8 and then decreases again during the asymptomatic phase of disease. 
In the terminal stage, virus replicates again efficiently and viral load increases 
accordingly in plasma. When virus peaks in the acute phase of infection, CD4+ 
cells decrease by approximately one third due to primary viral replication in these 
cells. However, a slow rise can be observed as the severity of viremia decreases. 
During the asymptomatic phase, CD4+ cells decrease only very slowly, while a very 
rapid decrease occurs together with the terminal AIDS stage of disease. As early as 
two weeks after the onset of infection, the CD8+ lymphocyte population expands 
rapidly. The antiviral activity of this population subset induces reduction of viremia. 
During the asymptomatic phase of disease, the total CD8+ lymphocyte count tends 
to remain at a rate higher than normal, and decreases again to very low counts in 
terminal stages of disease.
Antibodies against FIV have been detected in experimentally and naturally infected 
cats as early as 2-3 weeks following infection and persist throughout the different 
phases of disease. High antibody levels correlate with the viremia peak in the acute 
phase of infection. 
3.1.3.3.1 CD4+ T Lymphocyte Depletion
Figure 4 : Graphical representation of the course of viremia, antibody production, circulating CD4+ and 
specific cytotoxic lymphocytes in the blood of infected cats during the different stages of infection.
3.1.3.3 Immunological Aspects
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The pathogenesis of FIV is to date not completely understood. Infected cats develop 
latency despite elaboration of defence mechanisms such as specific cellular immune 
responses and production of neutralizing antibodies. 
This chapter represents an overview of the important known immunological processes 
during FIV infection of the domestic cat. 
All FIV isolates and all routes of infection commonly lead to a decline of CD4+ 
lymphocyte count in the peripheral blood of the infected cat. AIDS stage of disease 
is often defined by a concentration of less than 200 CD4+ T cells/μl whole blood, 
although CD4+ cytopenia is clearly not responsible alone for terminal stage 
immune dysfunction. 
Decrease in CD4+ cells depends on several mechanisms but is usually due to a reduced 
life span of the cells. The quantitative decrease, however, cannot just be explained 
by cytolysis as a result of viral infection, because the percentage of infected cells is 
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3.1.3.3.2 CD8+ T Lymphocyte Antiviral Activity
significantly lower than the number of cells dying. As a consequence, FIV-mediated 
T cell depletion and lymphocyte activation have been related to an accelerated cell 
death or apoptosis and it has been shown that lymphocytes from FIV-infected cats 
are prone to die after short term culture in vitro [44]. Additionally, the extent of in 
vitro lymphocyte apoptosis was shown to correlate with progression of disease [45]. 
More recent and detailed information on T cell depletion and apoptosis is discussed 
under 3.1.3.3.3. 
Rapid expansion of the CD8+ lymphocyte subset, along with specific anti-FIV 
cytolytic and non-cytolytic mechanisms, arise early in the course of FIV infection, even 
before a noticeable humoral immune response. Appearance of this antiviral activity 
corresponds to a reduction in viremia and transition to the asymptomatic stage of 
disease [46]. Interestingly, although CTL responses against gag and env antigens have 
been described, persistent high-level circulating antiviral CTL could not be detected 
during FIV infection, as has been observed in HIV-infected humans [47]. CTL 
responses seem to become localized in the lymph nodes and spleen with progression 
of disease [48]. Non-cytolytic CD8+ lymphocyte responses are detectable earlier than 
cytotoxic mechanisms. Also, since non-cytolytic processes are not MHC-restricted, 
they have a more diverse action potential. The inhibitory effect is mediated by soluble 
factors and, as a consequence, is not dependent on direct cell-to-cell contact [49]. 
Further studies allowed to more precisely allot this CD8+ T cell anti-FIV activity at the 
level of FIV mRNA synthesis from the FIV proviral DNA [50]. Moreover, acute stage 
of FIV infection is characterized by the appearance of a CD8+ T cell subpopulation 
showing reduced expression of the CD8 b chain and complete disappearance of the 
L-selectin CD62L surface molecule [51]. These CD8blowCD62L T cells then persist 
throughout the course of infection, and recent studies have demonstrated that a subset 
of T cells, the TNFα+CD8+ T cells,  that specifically respond to FIV antigens in the 
course of infection by production of tumor necrosis factor α (TNFα), are contained 
in this CD8blowCD62L T cell subpopulation [52].   
3.1.3.3.3 T Cell Dysfunction, Anergy and Apoptosis
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Already in the acute phase of infection, defects in T cell responses are encountered. 
Mitogen and antigen induced IL-2 production and lymphoproliferation are reduced 
in the acute phase and continue to decline with progression of disease [41].
The B7.1 and B7.2 co-stimulatory molecules on antigen-presenting cells provide 
second signals for regulating T cell immune responses via CD28 and CTL antigen 
4 (CTLA4) on T cells. CD28 signals cell proliferation, whereas CTLA4 signals for 
anergy or apoptosis, terminating the immune response. Flow cytometry revealed 
high percentages of CD8+ and CD4+ cells expressing B7.1, B7.2, and CTLA4 in 
lymph nodes of FIV-NCSU1-positive cats and a large fraction of CTLA4+ T cells 
co-expressing B7.1 and B7.2 [53]. Moreover, anti-B7.1 antibodies significantly 
inhibited T cell apoptosis in FIV-infected cats with low level plasma viremia, 
further suggesting that lymph node apoptosis and immune deterioration in FIV-infected 
cats may result from chronic B7-CTLA4-mediated T-T negative signalling in-
teractions [54].
Further understanding of mechanisms for T cell depletion and dysfunction comes 
from studies of regulatory T cells (Treg). CD4+ regulatory cells prevent the activation 
of autoreactive T cells, and help to maintain self-tolerance. Detection of CD25 (the 
IL-2 receptor alpha chain) has been used to identify the subpopulation of CD4+ 
T cells which have regulatory function. CD25+ subsets of CD4+ as well as CD8+ 
T cells increase in lymph node of FIV-NCSU1 infected cats very early after 
exposure to the virus. The CD4+CTLA4+B7+ phenotype described in 
FIV-positive cats interestingly resembles the CD4+CD25+CTLA4+ phenotype 
described for immunosuppressive Treg cells. Additionally, similar to Treg cells, 
feline CD4+CD25+ T cells directly isolated from lymph nodes of FIV-infected 
cats do not produce IL-2, fail to proliferate in response to mitogen stimulation, 
and suppress the proliferative response and the IL-2 production of Concanavalin 
A (Con A)-stimulated autologous CD4+CD25- T cells. These FIV-negative, 
activated, anergic, immunosuppressive CD25+CTLA4+B7+CD4+ Treg-like cells 
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3.1.3.3.4 Cytokine Production
Dysregulation in cytokine expression has been well described in acute and chronic 
FIV infection. In FIV-infected cats, CD4+ lymphocytes produce TNF-α, Interferon 
(INF)-g, Interkeukin (IL)-2, IL-4, and IL-10, while CD8+ lymphocytes express 
TNF-α, INF-g and IL-2. Monocytes and macrophages are the source of IL-1, IL-6, 
TNF-α, IL-10 and IL-12 [57]. Whole blood and relevant lymphoid tissues such 
as lymph nodes, spleen and thymus demonstrate unique cytokine profiles that differ 
qualitatively and quantitatively during infection, and correlate with virus replication 
in each tissue or organ [58].
Serum levels of IL-1, IL-6, TNF-α and IFN-g are increased with FIV infection and 
are higher in symptomatic versus asymptomatic cats [59]. 
It is well established that cytokines such as IFN-g and TNF-α, produced by T cells 
upon antigen stimulation, are important for controlling viral infections. Increasing 
TNF-α levels during the acute phase of infection are associated with virus replication [60]. 
It has now also been demonstrated, that FIV-infected cats develop both IFN-g+ and 
TNF-α+ FIV-specific T cell subpopulations early in the course of infection [52].
may contribute to the progressive loss of T cell immune function that is typical of 
FIV infection [55]. 
Further characterization of these T cell subpopulations indicate possible 
mechanisms of FIV latency, typically encountered during FIV infection. While 
both CD4+CD25+ and CD4+CD25- cells are susceptible to FIV infection in vitro 
and in vivo, only CD4+CD25+ cells produce infectious virions when cultured with 
IL-2. Latently infected CD4+CD25- cells produce infectious virions only following 
ConA stimulation. Furthermore, CD4+CD25+ cells remain relatively resistant to 
apoptosis, independent of their infection with FIV. Altogether, these findings define 
CD4+CD25+ cells as main characters for productive FIV infection. CD4+CD25- cells 
however, represent a potential latent viral reservoir capable of being reactivated after 
stimulation [56].
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IFN-g, also called type II IFN, is produced by activated T cells and natural killer 
(NK) cells and is known for its immunomodulatory and antiviral activities. 
Surprisingly, in contrast to feline type I IFN, which have been reported to inhibit 
in vitro replication of FIV as well as other common feline viruses, feline INF-g 
seemingly lacks potential to inhibit infection of PBMCs [61]. These results suggest 
that the main function of IFN-g produced during infection may not be the direct 
inhibition of FIV replication. Instead, indirect effects of IFN-g such as increase of 
cytotoxic T cell and NK cell responses to virus-infected cells may play a more central 
role in controlling the infection. Nevertheless, it is accepted that presence of IFN-g 
production during FIV infection reflects a functional immune system, whereas the 
loss of IFN-g production correlates with progression to AIDS.
TNF-α production plays an important role in the pathogenesis of FIV. Production 
of this cytokine correlates with appearance of virus in plasma and tissues [60]. 
Moreover, TNF-α is apparently associated with an increased apoptosis susceptibility 
of FIV- infected cells and might be involved in FIV-specific T cell depletion [62]. 
Whether TNF-α production by FIV-specific T cells is beneficial or detrimental for 
FIV-infected cats still needs to be determined. 
IL-1 and IL-6 are cytokines generally produced in the course of infectious processes. In 
addition to pro-inflammatory effects, the elevated production of  IL-6 may contribute 
to polyclonal B cell activation and gammopathies [63].
Peak production of IL-1, IL-6 and TNF during FIV infection coincided with 
periods of depressed immune responses in vivo and the presence of clinical signs. 
Additionally, high expression of these pro-inflammotory cytokines concurs with 
depressed responsiveness of PBMCs to mitogenic stimulation in vitro [59]. 
Dysregulation of cytokine responses in FIV-infected versus FIV-naïve cats induces 
inability to effectively fight against secondary pathogens. Observed cytokine profile 
during secondary opportunistic infections with Toxoplasma gondii [64] or Listeria 
monocytogenes [65]  indicate a loss of the important T helper (Th) 1 cellular immune 
response during FIV infection. 
Although controversed for a long time, it is now overall accepted that the cytokine 
FIV-infected cats develop a strong immune response against the viral gag and env 
proteins. Moreover, parts of the SU, the TM and gag proteins are considered major 
B cell epitopes. Cats infected experimentally can seroconvert already 2-3 weeks 
post-challenge, and antibodies against envelope proteins seem to arise first, followed 
by a response against gag elements [66].
Antigen stimulation of infected B cells is increased compared to non-infected cells, 
and a polyclonal gammopathy directed against non-viral proteins may be seen in 
FIV-infected cats as early as 6 weeks post infection [63].
The development of virus-neutralizing antibodies (VN) during many viral infections 
is one of the most effective host defence mechanisms. Interestingly, FIV infection 
in vivo persists in spite of the production of high VN titres. The V3-V5 areas of the 
env gene are known to code for neutralizing epitopes of FIV. It has been shown 
that single amino acid substitution mutations in the envelope glycoprotein, within 
or outside the VN epitopes, may confer resistance to monoclonal or polyclonal VN 
[67]. In vitro sensitive FIV strains have shown reversion to neutralization resistance 
due to mutations in V4 and V5 regions of the env gene, after passage in vivo for 4-15 
months. This mutated phenotype appears to be essential for survival and persistence 
of virus in vivo [68]. 
A long term study following experimentally infected cats has indicated a progressive 
increase in VN titres during the first 30 weeks post-inoculation, followed by stably 
high titres for an observation period of 7 years thereafter [69]. Cross-clade 
neutralization is common [70], indicating that important neutralization-inducing 
epitopes are universally shared in spite of the high antigenic diversity in FIV strains 
prevailing in the field.
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3.1.3.3.5 Antibody Responses
patterns seen in the course of FIV infection implicate a dominating Th2 type 
immune response, and that attempts to elaborate effective vaccines should concentrate 
on supporting and enhancing Th1-orientated T helper responses.
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FIV is endemic in cats throughout the world. Five distinct clades of FIV (A-E) have 
been identified based on greater than 15-30 % variability in envelope amino acid 
sequence. The majority of viruses identified to date belong to either clade A or clade 
B. The prototype virus, FIV-Petaluma, discovered in 1986 by Pedersen and colleagues, 
is attributed to clade A, a group of strains significantly less diverse than clade B, 
and containing fewer genomic mutations, suggesting more recent, less host-adapted 
strains [71]. Clade A viruses are present worldwide with a predominance in the 
western United States, northern Japan, Germany, and South Africa. Also distributed 
worldwide, clade B viruses have been more consistently identified in eastern Japan, 
Italy, Portugal, and the central and eastern United States. With the exception of 
northern Taiwan, detection of clade C FIV remains uncommon, and has often only 
been attributed to single animals or small groups of cats from Vancouver, Munich and 
Japan [72]. Clade D includes several viruses characterized mainly in western Japan 
[73]. Finally, two Argentinian strains comprise clade E [74].  
Similarly to other lentiviruses, FIV is very susceptible to evolutionary genetic alterations 
and, as a consequence, phenotypic variability. Genetic diversity both due to evolution 
of the virus within an infected individual and to recombination following dual 
infection have been described for FIV. Indeed, intra-individual env variation is known 
to be the major determinant of viral diversity in virus isolates [75]. Recent studies 
have however demonstrated stable maintenance of the V3-V5 env gene encoding 
neutralizing epitopes for 1-2 years after infection [76]. Co-infection with two strains, 
although uncommon, has been successfully established under experimental conditions 
[77] and its occurrence confirmed in naturally infected animals [71]. It has also been 
demonstrated that biological behaviour and pathogenicity differ from one isolate to 
another [78]. Thus, properties identified for a specific strain cannot be generalized, and 
regular phylogenetic studies allowing evaluation of evolutionary viral adaptation to the 
host are a prerequisite when developing new treatments or prophylactic measures.
3.1.4 Epidemology
3.1.4.1 Viral Clades
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Figure 5 : The phylogenetic tree distinction of the main known FIV subtypes and strains. Isolates 
from Japan JN and isolates from the USA are designated with the state abbreviation followed 
by the name of the virus. The scale indicates 1% difference in envelope sequences. Adapted from 
[197].
3.1.4.2 Host Range
Domestic cats (felis catus) are the natural hosts for FIV. However, cross-reactive 
antibodies have been detected in over half of the species of the family Felidae [79]. 
Transmission of FIV from domestic to non-domestic cats has been reported [80], 
but the majority of FIV-reactive antibodies in non-domestic cats are induced by 
other FIV-related species-specific lentiviruses, as described for the puma, Puma 
concolor [81],  the lion, Panthera leo [82], and the Pallas’ cat, Otocolobus manul [83]. 
These viruses are known to be older and more stable than FIV, and recent studies 
surprisingly indicate that they diverge greatly in amino acid sequences, host cell 
susceptibility, receptor affinity, neutralizing antibody binding sites, and pathogenicity, 
when compared to FIV [84]. Non-domestic cat lentiviruses can also establish 
persistent infection in domestic cats, however clinical disease is frequently absent 
[85]. Interestingly, infection of domestic cats with a non-domestic lentivirus 
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3.1.4.3 Occurrence and Prevalence Studies
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generates humoral and cell-mediated immune responses and thus provides partial 
protection from disease induced by superinfection with FIV [86].  
Infection of human cell lines with FIV result in proviral integration [29] and at 
least two FIV strains have been able to infect human PBMCs and macrophages in 
vitro [30]. Moreover, experimental FIV infection of cynomolgus macaques resulted 
in loss of CD4+ cells and weight loss [87]. Cross packaging of HIV-1, SIV and FIV 
RNA have been demonstrated, suggesting that co-infection could result in stable 
recombinant viruses [88]. However, these findings must be considered with precaution, 
and should not be extrapolated to suggesting that infection of human beings with 
FIV can occur. Replication of FIV has to date not been observed in human cells, and 
lack of human seroreactivity despite significant exposure to infected cats indicate 
Several seroepidemiological surveys have revealed an overall seroprevalence 
worldwide of 11,04 % among both healthy and sick cats screened in North America, 
Asia, Europe and Oceania [90]. It is important to keep in mind that prevalence 
rates vary greatly by region, lifestyle, health status and gender of the cats tested. 
Furthermore, these studies are likely to underestimate reality, since they often fail 
to take into consideration that a considerable portion of FIV-infected cats are 
seronegative (see also 3.1.6). Table 2 represents the more recent prevalence studies 
carried out on different continents.
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3.1.5 Clinical Aspects
Table 2 : Relevant FIV prevalence studies carried out on the different continents
Similarly to HIV infection in humans, FIV causes progressive immune deterioration 
in domestic cats. Since individuals become persistently infected, complete recovery 
is not possible, and infected cats eventually die of the disease. Although all 
categories of domestic cats may become infected, susceptibility to FIV infection 
and disease progression are inversely related to age [111]. The clinical progression of 
FIV can be defined in five stages, using the system described for HIV infection in 
humans [112] : 1) acute infection, 2) asymptomatic phase, 3) persistent generalized 
lymphadenopathy, 4) AIDS-related complex (ARC), and 5) AIDS phase. Distinct 
clinical features for these stages are summarized in table 3.
During the acute phase of infection, the cat usually shows only little or no symp-
toms at all. Typical are low-grade fever and generalized lymphadenopathy even-
tually accompanied by slight lethargy [113]. Unfortunately, owners often fail to 
notice these rather mild and unspecific signs, and clinical suspicion of disease is 
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Table 3 : Main clinical symptoms of the different stages of FIV infection
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only assessed after greater progression of the infection. Characterization of clincal 
lymphadenopathy in FIV-infected cats has revealed histopathological alterations in 
the lymph nodes of the hindlimb, forelimb and head, in decreasing order of severity, 
with little evidence of involvement of the alimentary tract-associated lymph nodes 
[114]. The popliteal lymph node is thus considered a good indicator for assessment 
of lymph node status in FIV infection.
The clinical signs of the ARC and AIDS stages are diverse in nature because 
symptoms due to primary viral infection are frequently overlapped by those of an 
array of secondary infections [115]. Slow but progressive weight loss is common, 
with severe wasting occurring late in the disease process. Fever of 40˚C or greater is 
often present. Loss of appetite or evidence of pain while eating, caused by gingivitis 
and stomatitis, are also typical. Chronic, non-responsive, or recurrent infections of 
the skin, alimentary tract, upper respiratory tract and eyes are often observed [104]. 
Infection may lead to abortion of kittens or other reproductive failures in pregnant 
queens [116]. Encephalopathy-linked neurological abnormalities, although rather 
rare, mostly induce behavioural alterations. However, dementia, twitching 
movements of the face and tongue, loss of bladder and rectal control, cognitive 
and behavioural alterations and compulsive roaming have all been recognized in 
FIV-infected cats. Seizures, ataxia and intentions tremor have also been described 
[117]. Renal involvement in FIV disease has been described as a frequent occurrence 
and direct consequence of viral infection. Moreover,  presence of immuncomplexes 
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in renal tissue suggest that immunological processes in the course of FIV infection 
play a role in the pathogenesis of renal damage [118]. Interestingly, no link has 
been established between FIV infection and lower urinary tract disease, a relatively 
common disorder in adult cats [119].
The role of FIV in tumorigenesis is still quite controversial. As reported for SIV 
and HIV, it has been postulated that occurrence of lymphoma could be related to 
infection in FIV seropositive cats. [120]. The majority of presumed FIV-associated 
lymphomas are of B cell blastic phenotype and usually occur at a single extranodal 
site [121]. Examination for FIV provirus in tumorous cells has however been 
inconsistent in both experimentally and naturally infected cats, and the amount of 
cases remains small. Lymphoid malignancies, myeloproliferative diseases, and several 
carcinomas and sarcomas have also been more frequently detected in FIV-infected, 
feline leukaemia virus (FeLV)-naïve cats, suggesting a potential association between 
FIV and malignancy. 
Secondary infection during ARC and AIDS stages of disease can be due to various 
microorganisms which take advantage of the weakened immune system, including 
other viruses, bacteria, parasites and fungi. The most commonly detected 
opportunistic microorganisms detected in the course of FIV infections are 
summarized in table 4.
Among predisposition to other parasitical infections related to FIV disease, 
toxoplasmosis, as an opportunistic infection in HIV-infected humans, is of high 
interest. Primary infection of cats with FIV markedly enhance their susceptibility 
to a secondary Toxoplasma gondii infection [122]. Furthermore, FIV-infected cats 
develop higher T.gondii IgM antibody levels and show increased replication rate of 
T.gondii [123].
Another f requently studied association is that of FIV and FeLV infections. 
Seroepidemiologic surveys have indicated that dual infection is not uncommon, and 
that cats infected with both viruses tend to have a more severe disease course and 
die sooner than mono-infected animals [124]. Moreover, FeLV infection has proven 
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to enhance FIV infection in vitro and in vivo by facilitating expression and spread 
of FIV in the body, leading to faster decline of the immune system and earlier signs 
of infection [113].
Certain changes in blood and bone marrow parameters are consistently observed in 
FIV-infected animals. In the primary stage, a leucopenia, associated initially with a 
mild lymphopenia and later by both a mild lymphopenia and a severe neutropenia, is 
frequently observed [33, 125]. Towards the end of the disease, in ARC and AIDS 
stages, common findings include anemia, lymphopenia, thrombocytopenia, 
neutropenia in blood, as well as hyperplasia of individual cell lineages and 
dismorphic alterations in bone marrow [126]. In addition, several significant 
alterations in clinical chemistry have been noted as of the ninth month post-infection : 
divergences in glucose, protein, gamma globulin, sodium, urea, phosphorus, lipase, 
cholesterol, and triglyceride levels in serum have been described [127]. However, 
these abnormalities are not pathognomonic for FIV infection and are therefore not 
reliable in characterization of disease progression. Markers representing more 
effectively the impairment of the immune system and allowing prediction of clinical 
outcome are CD4+:CD8+ lymphocyte ratio and plasma viral load [128]. 
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Table 4 : Most common opportunistic pathogens observed in the context of FIV infection
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3.1.6 Diagnostic Approach
In addition to multiple haematological, serum biological and cytological bone 
marrow abnormalities which may lead to suspicion of an FIV infection, several 
elaborated laboratory tests allow confirmation of the diagnosis. The various tools 
developed over time since discovery of the virus are briefly described below.
Enzyme-linked immunosorbent assay (ELISA) tests are available in kit form for 
use in private veterinary clinics, and are usually used as screening tests. One variant, 
which detects antibodies against the FIV TM and gag proteins, is commercially 
available. Since cats do not recover from FIV, detection of antibodies in the serum 
can be directly correlated with presence of FIV infection. Antibodies to FIV can 
be detected as early as 30 days after exposure, and during the rest of the infected 
animal’s life. Clinical signs can however appear before seroconversion and some 
cats show no detectable levels of antibodies in their blood for many weeks [144]. 
Moreover, antibody levels can fall below detection level in the final stage of disease 
[104]. Altogether, these facts can lead to occurrence of false negative reactions. In 
addition, the specificity of ELISA tests is unfortunately not optimal. Positive results 
should always be considered in relation to prevalence, and confirmed by a second 
test in healthy or low-risk cats [145]. Confirmatory tests, performed commonly 
at diagnostic laboratories, include Western Blot or Indirect Fluorescent Antibody 
Immunoassays (IFAI). 
The major advantage of Western Blot immunoassays is the detection, in one reaction, 
of antibodies against various viral proteins. Methods were described rapidly after 
discovery of FIV [146, 147]. A densitometric analysis of Western Blots enabling to 
quantify the antibodies against FIV proteins has also been described [148]. 
In turn, detection of antibodies by IFAI is based on the binding of specific antibodies 
in diluted serum samples to antigen expressed by FIV-infected T lymphocyte 
enriched PBMCs or CRFK cells as substrate. In a second step, bound antibodies 
are stained with fluorescein labelled anti-cat antibodies and made visible with the 
fluorescence microscope [149].
It is worthwhile mentioning here that kittens can have detectable colostrum-derived 
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antibodies for several months. Therefore, only kittens older than 6 months with 
positive results in both ELISA and confirmatory tests can be considered infected.
ELISA tests detecting antibodies of various specificities have been elaborated 
over the years. It has been demonstrated that over 90 percent of FIV-infected cats 
establish an antibody response to the reverse transcriptase enzyme. This response 
displays increasing in vitro inhibitory effects over time post-infection. Unfortunately, 
significant concentrations of reverse transcriptase inhibiting antibodies are detected 
only 1 to 2 years after infection, rendering their detection rather irrelevant in routine 
diagnostics [150]. In 1992, Furuya and co-workers developed an ELISA system for 
detection of antibodies to FIV gag protein in cat sera [151]. They thereby observed 
increases of the antibody titers to FIV gag protein in all studied cases, already at 
an early stage of infection. However, the establishment of ELISA systems using 
recombinant SU, TM and CA antigens of FIV and comparison of their individual 
efficiency showed highest diagnostic sensitivity (98%), accompanied by a specificity 
of 97 % in the case of detection of TM antibodies. Furthermore, antibodies to TM 
appeared first after infection rendering this antigen most important for diagnostic 
purposes [152]. 
Detection of a FIV antigen in infected cats is of low interest in routine diagnostics 
due to the often insignificant levels of virus in plasma during the asymptomatic 
phase of disease. Moreover, although the establishment of a p24 antigen capture 
ELISA system for research purposes has shown convincing potential for monitoring 
FIV replication in vitro [153], p24 in vivo is commonly decorated with antibodies 
and therefore not reliably detectable.
Various cell culture techniques have also been established to identify cellular or 
plasma-related viremia. Thus, isolation and in vitro stimulation of PBMCs with 
subsequent detection of produced viral antigen allows the assessment of cellular 
infection. With the intention to simplify such experiments, Guiot and co-workers 
developed an assay allowing direct culture of small amounts of whole blood (100 μl), 
followed by detection of FIV core gag antigen released in culture supernatants [154]. 
Avoiding the hassle of leukocyte separation and lymphocyte purification procedures, 
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this technique offers many advantages and shows convincing reproducibility. 
Moreover, several FIV-sensitive cell lines allow the assessment of infectious virus 
in plasma of infected cats (see 3.1.2.2). A T lymphoblastoid cell line obtained from 
the PBMCs of a spf cat and designated MBM was even reported to exhibit a lytic 
cytopathic effect in vitro upon FIV infection [28].
The development of polymerase chain reaction (PCR) assays represents a significant 
step for the identification of the proviral and viral forms of FIV in routine 
diagnostics, as a complement to common methods, as well as in research areas. 
Detection of provirus by a nested PCR method using regions of the gag gene as 
target sequences was described as early as 1992 [155, 156]. Soon after, Matteucci 
and colleagues established an assay allowing detection of FIV RNA [157]. Although 
sophisticated and complex, these early PCR methods often failed to harbour 
satisfying sensitivity levels. The need in further understanding of pathogenesis 
and pressure in the development of new markers of disease progression induced 
establishment of quantitative PCR methods. In this way, Inoshima and colleagues 
described an assay for the measurements of proviral DNA copies in Japanese strains 
[158]. Furthermore, using in vitro synthesized RNA derived from the gag region of 
the FIV genome as competitive control, Vahlenkamp et al. succeeded in quantifying 
FIV RNA from plasma of infected cats [159]. 
The latest evolution in quantification of FIV DNA and RNA is the TaqMan 
fluorogenic real-time detection system [160]. This improved PCR method is based 
on the 5’-3’ exonuclease activity of the Taq DNA polymerase, which results in 
cleavage of a fluorescent dye labelled probe during the amplification cycles. The 
intensity of fluorescence is then measured by a Sequence Detection System. A more 
detailed characterization of the TaqMan system is described in section 4.2.3.
Further characterization of FIV pathogenesis in vivo relies on the localization of 
virus to specific cells in tissues, enabling detection of host-virus interactions at 
different time points in disease. FIV was most often revealed in tissue sections by 
in situ RNA hybridization. Unfortunately, tissue digestion steps required for in situ 
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RNA hybridization often destroy protease sensitive cell specific antigens, limiting 
the number of protein markers available to identify the cells infected. Identification 
of FIV-specific proteins by immunohistochemistry circumvents the need for protease 
digestion steps and RNase free protocols. However, both conventionally used 
mouse monoclonal and rabbit polyclonal antibodies lack specificity and sensitivity 
in binding FIV in tissue sections. In 2002, Rogers and colleagues established 
an immunohistochemical protocol using high antibody titer serum from cats 
chronically infected with FIV-PET [161]. This method includes labeling of native 
species antibodies with horse-radish peroxidase (HRP) before their binding on 
tissues. Presence of FIV in the tissue can then be detected by standard chromogenic 
or fluorescence techniques. In complement to other in situ methodologies, this assay 
allows quantitation of virus in tissues from cats infected with either FIV clade B or 
clade C. Such steps in diagnostic research contribute to the further understanding 
of important processes concerning tropism and replication kinetics of FIV infection 
in vivo.
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3.1.7 Treatement
Unfortunately, there is to date no treatment allowing effective elimination of 
FIV in an infected cat. As a consequence, therapy of FIV-associated disease is 
mostly supportive, with the objective of increasing the patient’s life quality and 
length. In addition to treatments such as antiviral and immune stimulation drugs, 
immunodeficient cats in the late stages of disease may require appropriate long term 
antimicrobial therapy or multiple treatment periods to fight secondary opportunistic 
infections. 
Various approaches in treatment against FIV have been evaluated. Over the years, 
researchers have been greatly inspired by the progress in treatment of HIV. Indeed, 
the most promising results to date include drugs interfering directly with retroviral 
replication, derived from HIV research. 
Four classes of antiretroviral agents are currently available for the treatment of HIV 
infection: nucleoside and nucleotide analogs, also referred to as reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
protease inhibitors (PIs) and fusion inhibitors. The highly active antiretroviral 
therapy (HAART), commonly administered to HIV-infected patients, consists of 
a combination of three drugs from one or more of the above mentioned groups. 
Typically, the therapy includes one NRTI, one PI and either a second NRTI or 
a NNRTI. The major problem encountered during antiretroviral therapy is the 
appearance of resistance to treatment due to mutative adaptation of the virus. 
Chronically HIV-infected patients having received various combinations of 
HAART over several years may develop multi-resistant strains of the virus, rendering 
treatment ineffective. As a consequence, although a wide range of drugs exist, there 
is a constant need for new therapeutic strategies.
Treatment effectiveness of all four classes of antiretroviral agents and in various 
combinations has been experimented for FIV.
The direct target of NRTIs is the retroviral enzyme reverse transcriptase. Acting as 
alternative substrates, they compete with physiological nucleosides, differing from 
them only by a minor modification in their ribose molecule. The incorporation of 
nucleoside analogs aborts DNA synthesis by the RT, as phosphodiester bridges 
can no longer be built to stabilize the double strand. NRTIs are not HIV-specific 
inhibitors as they are broadly effective to other lentiviruses as well, including FIV 
[162]. Azidothymidine (AZT), a thymidine analog also designated zidovudine, 
was the first antiretroviral agent to be put on the market for HIV treatment. 
Early studies still tested AZT as monotherapy. In 1993, Meers and colleagues 
described a significant reduction of plasma virus titre by zidovudine treatments in 
asymptomatic FIV-infected cats, begun 24 hours post-infection and continued for 4 
weeks [163].  The FIV titres in PBMCs however, were high for the whole duration 
of the experiment. Furthermore, in a study evaluating long term effectiveness of 
AZT compared with conventional symptomatical therapy in FIV-seropositive 
diseased cats, AZT led to total recovery from clinical symptoms in six of nine 
FIV-seropositive cats 4-6 weeks after the onset of therapy. Although all the FIV-
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seropositive cats treated symptomatically in this study responded well to antibiotics 
and immunomodulators within as little as 10 to 14 days, recurrence of severe clinical 
symptoms was noticed in most cases [164]. 
In the interest of diminishing undesired adverse effects of AZT monotherapy such 
as anemia and hypoproteinemia, researchers have more recently tested the reliability 
of NRTI combinations. Lamivudine (3TC), is a well tolerated cytosine analog in 
clinical use against HIV. In vitro studies utilizing AZT alone, lamivudine (3TC) 
alone, or AZT/3TC combination against FIV indicated that simultaneous treatments 
of AZT and 3TC generated additive to synergistic effects in primary PBMCs, but 
not in chronically infected cell lines. Similarly, AZT/3TC combination induced a 
significant delay in infection and seroconversion in unprotected cats, but had no 
anti-FIV activity in chronically infected cats. AZT/3TC treatment seems therefore 
effective for prophylaxis but not for therapeutic use in chronically FIV-infected cats 
[165]. An alternative to 3TC is stampidine, the latest nucleoside analog prepared 
for treatment of HIV. It is said to be much more potent than other anti-HIV NRTI 
agents and seems active against phenotypically and/or genotypically NRTI-resistant 
HIV strains. Antiretroviral activity of stampidine in cats chronically infected with 
FIV has also been studied. Notably, a single oral bolus dose of stampidine resulted 
in a significant decrease in the FIV load of circulating PBMCs in five of six FIV-
infected cats [166]. Its antiretroviral properties in NRTI-resistant HIV strains, 
together with its favorable animal toxicity profile, pharmacokinetics, and in vivo 
antiretroviral activity in FIV-infected cats renders stampidine a promising new 
NRTI compound.
Similarly to the nucleoside analogs, the target enzyme of NNRTIs is also the viral 
RT. In contrast to the NRTIs, NNRTIs are not « false » building blocks, but rather 
attach directly and non-competitively to the enzyme, at a position in close proximity 
to the substrate binding site for nucleosides. The resulting complex can thus bind 
fewer nucleosides, slowing polymerization down significantly. In contrast to the 
nucleoside class of inhibitors, NNRTIs are highly specific for HIV-1, and they are 
not active against HIV-2 or any other retrovirus, including SIV and FIV. Indeed, 
despite the high similarity of the NNRTI target sequence between HIV-1 RT and 
FIV RT, no inhibitory effect of NNRTIs against FIV RT has ever been reported, 
even at drug concentrations that are significantly higher than those required to fully 
suppress HIV-1 RT activity [167].  With the objective to map the determinants 
of the lack of susceptibility of FIV RT to anti- HIV-1 NNRTIs, Auwerx and 
colleagues constructed a variety of chimeric FIV RTs, equipping this enzyme with 
the amino acids that have been proven to engender susceptibility of HIV-1 RT 
toward NNRTIs [168]. This study revealed that profound differences between FIV 
RT and HIV-1 RT in terms of structure and/or flexibility are responsible for the 
absence of interaction of FIV RT with NNRTIs. Thus, to date, researchers have 
not yet succeeded in either transforming FIV RT to acquire susceptibility to the 
inhibitory effects of the NNRTI, or elaborating a NNRTI which efficiently binds 
and inhibits FIV RT.
The retroviral PR cuts the viral gag-pol polyprotein into its functional subunits. 
Thus, inhibition of the protease, preventing appropriate splicing and maturation 
of essential structural proteins, leads to the release of virus particles that are unable 
to infect new cells. With knowledge of the molecular structure of the protease 
encoded by HIV, the first protease inhibitors were designed in the early nineties. 
However, the emergence of resistant strains, in which the sequence of the viral PR 
is altered in a way that leads to the impairment of inhibition, has grown rapidly 
problematic. Again, despite high structural homology of both proteases, FIV PR 
demonstrates poor binding of inhibitors in clinical use against HIV-1 PR. Several 
studies have shown that FIV PR contains, at equivalent positions, amino acid 
residues that are identical to those found in drug-resistant forms of HIV-1 PR. 
The PR structure of FIV was then used as a model for the development of a series 
of PIs with broad efficacy. Thus, the most potent FIV PI, designated TL-3, was 
able to block nearly 100% of virus production in an acute infection against HIV, 
FIV, and SIV ex vivo. Furthermore, it was not toxic to cells, and there was no sign 
of resistance development by the different viruses even after 2 months of culture 
[169]. In vivo in the domestic cat, TL-3 treatment engendered modest lowering 
of viral loads and greater survival rates in treated symptomatic animals at 8 weeks 
post-infection with a highly pathogenic FIV-C isolate [170]. Moreover, early TL-3 
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treatment was shown to effectively counteract FIV effects on the central nervous 
system (CNS) of infected cats as well as eliminate FIV-induced changes in the CNS 
[171]. Although continued treatment is required to lower average viral loads and to 
maintain unimpaired CNS function, TL-3 seems to have a considerable therapeutic 
effect against FIV infection.
Inhibition of FIV entry into host cells provides an exciting new and emerging 
approach for the development of antiviral therapies. The identification of the 
peptide sequences responsible for gp120/receptor binding allows the creation of a 
class of pharmaceuticals called fusion inhibitors, whose mechanism of action is to 
competitively antagonize virus binding. In 1996, Lombardi and colleagues, screened 
20- to 23-mer peptides covering the entire env gene of FIV and found especially 
potent in vitro antiviral activity associated with a peptide referred to as peptide 59, 
derived from a region located in the ectodomain of the TM protein. Unfortunately, 
peptide 59 did not appear promising as a therapeutic strategy for naturally occurring 
infections since it could only inhibit tissue culture-adapted FIV in fibroblastoid cells 
(CRFK), but not a primary isolate in feline lymphoid cells [172]. Because the activity 
of peptide 59 mapped to a short sequence containing three conserved tryptophan 
(Trp) residues, further analyses were carried out with a peptide of  eight amino acids, 
designated C8, comprising such a Trp motif. Peptide C8, although rather unstable 
due to its reduced size, exerted a powerful antiviral effect in vitro on all the FIV 
isolates tested, and this activity was dependent on an intact Trp motif [173]. Further 
studies have demonstrated that the C8 retroinverso analog (riC8) possesses similar 
inhibitory potential and a much increased stability, maintaining its concentration 
unchanged for at least 24 hours in cat serum in vitro. Most exciting are the results 
of a short-term monotherapy experiment in chronically FIV-infected cats showing 
that riC8 is well tolerated and also has substantial antiviral activity in vivo [174].
Relatively new treatment perspectives focus on modulation of the host immune 
system, exploring the potential of various immunostimulatory cytokines and 
antioxidants.  Immunomodulatory agents are probably the most widely used 
medications in FIV-infected cats.
In addition to their immunomodulatory effect, both type I and type II IFN also 
exhibit a direct antiviral effect by inducing in non-infected cells a general antiviral 
state, that protects them against virus replication. Strong inhibitory activity of 
human as well as feline type I IFN against FIV replication has been reported in an 
experiment testing in vitro treatment of a feline T cell line and feline PBMCs with 
either recombinant human interferon alpha (rHuIFN-α) or its corresponding feline 
interferon, the recombinant feline interferon omega (rFeIFN-w) [61]. As interferons 
are species-specific, feline and human interferons clearly differ in both antigenicity 
and antiviral efficacy in feline cells. Thus, rHuINF-α showed insignificant effects 
on peripheral blood lymphocyte subsets in FIV-infected cats, and was clearly 
ineffective in immunodeficient animals, which exhibited severe lymphocyte 
depletion. Although monotherapy was thus excluded, rHuINF-α seemed however 
to demonstrate some clinical benefits with no side effects when used in complement 
to antibiotic and symptomatic therapy [175]. In contrast,  rFeIFN-w demonstrated 
significant therapeutic effects and increase in survival rate of cats with clinical signs 
associated with FeLV infection and FeLV/FIV co-infection [176].
The results of several studies concerning effect of human type II IFN (HuIFN-g) 
on HIV replication remain to date controversial. FIV replication seems not to be 
inhibited by recombinant feline IFN gamma (rFeIFN-g) in feline PBMCs, and 
rather enhanced in the FetJ feline T cell line [61]. This finding may be explained 
by the mostly indirect effects of IFN-g in vivo, modulated by CTL and NK cell 
responses to virus-infected cells.
An additional cytokine, the recombinant human granulocyte-macrophage colony 
stimulating factor (rHuGMCSF), was recently evaluated for its antiviral effects in 
the course of FIV disease. Similar to its use in humans, rHuGMCSF can be used 
to increase the production and functional activity of neutrophils in animals with 
infectious disease. However, these drugs are not veterinary-labeled products and 
the potential risks must be considered in relation to the therapeutic benefits for 
veterinary use. Overall, rHuGMCSF treatment increased neutrophil counts in FIV-
infected cats without affecting the infection status. Furthermore, due to production 
of neutralizing antibodies to rHuGMCSF, and the possible development of cross-
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neutralizing antibodies to recombinant feline GMCSF, long term treatment with 
rHuGMCSF may induce severe adverse reactions and is not recommended in cats 
[177].
Another explored route was the therapeutic potential of several immunosuppressive 
drugs on FIV. Indeed, as immune activation may lead to increased FIV replication, 
an attractive treatment hypothesis has been to suppress the immune system in an 
attempt to interfere with viral replication and apoptosis of host cells. Although 
glycocorticoids were shown to enhance the course of infection [178], two potent 
immunosuppressive drugs, Cylosporine A and Tacrolimus, commonly utilized in 
preventing graft rejection following organ transplantation, have proved to protect 
cells against apoptosis and decrease virus production in both acutely and chronically 
infected cats [179]. Use of both immunosuppressants and immunostimulants in the 
therapeutic setting shows the clear discrepancy between defined and hypothetical 
scientific knowledge, and highlights the current difficulties encountered in further 
development of drugs suitable for treatment of FIV.
Despite numerous studies, clinical use of antiviral drugs is still not very common 
in veterinary medicine. Many antiviral drugs that have been experimentally tested 
never appear on the market due to high toxicity. With the exception of the new 
feline IFN-w that is now on the market in some European countries and Japan, no 
antiviral drugs are licensed for veterinary medicine. Therefore, attempts to treat an 
FIV-infected cat must be carried out with human drugs such as AZT.
3.1.8 Prevention
3.1.8.1 General Considerations
Although ethically questioned in areas of low FIV prevalence, keeping cats indoors 
to avoid contact with homeless, feral, abandoned or stray cats is the most effective 
mode of prevention against infection. Outdoor cats should ideally be neutered, in 
order to diminish territorial behaviour and transmission during mating. Additionally, 
3.1.8.2 Vaccination
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Vaccine development is essential, in order to protect the pet cat population from 
FIV infection and to control the high worldwide prevalence within reservoir stray 
cat populations. Furthermore, promising FIV vaccine designs may serve as models 
for the identification of effective prophylactic treatments to HIV. The development 
of lentiviral vaccines remains however a real challenge, due to the viral affection of 
important host immune components. A healthy immune system is indeed crucial 
for efficient vaccine immunity. Cellular tropism of FIV for T and B cell populations 
as well as for the monocyte/macrophage system renders the development of an 
efficacious product extremely difficult.
In addition to their complex pathogenesis, lentiviruses are known for their mutative 
potential and their diversity in the field. The various FIV subtypes differ typically in 
antigenic properties recognized by the immune system, which are, as a consequence, 
also targeted by vaccine studies. The development of a vaccine which harbours 
potency against several, or ideally all subtypes of FIV, is crucial to clinical utility in 
the field, and remains an ongoing challenge.
Efficacious lentiviral vaccine development has indeed revealed itself particularly 
tricky. Many factors influence greatly the outcome of individual studies, and it 
is crucial to take them into consideration when criticizing the different attempts 
elaborated over time. Overall, technical differences in vaccine inactivation procedure 
and composition, such as cell types used for growing vaccine virus, vaccination 
schedule, adjuvant used, vaccine doses, and variable virulence between FIV strains 
have produced conflicting results over time. The analysis of some important 
testing of new cats before introduction in a FIV-seronegative household is crucial. 
Infected cats should be housed indoors at all times to avoid infection of FIV-naive 
cats and to lessen their own risks to acquire opportunistic infections. Finally, although 
the transmission efficacy from queens to kittens is low during the asymptomatic 
phase of disease, kittens of FIV-infected queens should optimally not be allowed to 
nurse in order to avoid transmission by ingestion of milk.
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influencing factors in vaccine studies is detailed below.
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An important facet of vaccine production is the selection of an appropriate adjuvant. 
Although these substances have no specific antigenic effect, their presence in the 
composition of a vaccine reduces the amount of antigen needed to achieve the 
desired immune response, increasing potency of immunization, and lowering cost 
in vaccine production. 
In the search of a vaccine for infections with a complexe pathogenesis such as 
lentiviral infections, the conjunction of an adjuvant may obviously play a determinig 
role in the success of the immunization trial. 
Different adjuvants are chemically highly heterogenous and affect the immune 
system in various ways. Their mode of action generally consists in formation of 
a gradually released depot of antigen at the site of inoculation, presentation of 
antigen and stimulation of immunocompetent cells, as well as production of various 
lymphokines and immunoglobulins. Due to the resultant hyperactivation of the 
host’s immune system, they may however induce variably serious side effects. In 
cats, the occurence of vaccine-related fibrosarcoma, an especially malignant cancer 
originating from fibrous connective tissue at the site of vaccine injection, has grown 
to a serious concern in the past years. There is evidence that adjuvants play an 
inciting role in the formation of these deadly tumours. The choice of an adjuvant 
thus reflects a compromise between requirement for adjuvanticity and an acceptable 
level of adverse reactions. 
Of all adjuvants tested in animal vaccine research, complete Freund’s adjvant 
(CFA) probably remains the most well known. CFA is an aqueous antigen solution 
emulsified in mineral oil, composed of  inactivated and dried mycobacteria, originally 
Mycobacterium tuberculosis, now mostly M.butyricum, stimulating cell-mediated 
immunity and leading to the potentiated production of certain immunoglobins. Due 
3.1.8.2.1 Choice of Adjuvant
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to its toxicity, its use in humans is forbidden, and there are currently a number of 
guidelines associated with its use in animal research. While usually effective, it may 
indeed induce undesirable side effects such as inflammation, induration, pain and 
necrosis at the injection site in mammals. These facts have led to refinement of its 
use and development of alternatives. 
In FIV vaccine trials, a variety of alternatives to Freund’s adjuvant have been tested. 
In this way, incomplete Freund’s adjuvant (IFA), lacking killed mycobacteria which 
represent the most inflammatory component of CFA, was initially used for boosting 
immunizations subsequent to primary vaccination combined with CFA. It may also 
serve for initial immunization, particularly in combination with a « strong » antigen. 
Similarly, the minimal chemical structure from the mycobacterium in CFA, the 
peptidoglycan muramyl dipeptide (MDP), provides adjuvant activity and its use 
significantly decreases the disadvantages encountered with CFA. Moreover, when 
MDP was incorporated into incomplete Freund’s adjuvant it was found to replace 
completely the adjuvant activity of the mycobacterium. MDP was also found to 
have adjuvant activity when used alone. Although its pyrogenic potential remains 
a limiting factor in its use as adjuvant, MDP has been used in various forms and 
combinations in FIV vaccine studies. 
Oil-in-water emulsions represent another class of widely used adjuvants. The Ribi 
adjuvant, for example, contains detoxified endotoxin with mycobacterial cell wall 
components. It presents very low toxicity and is as convenient to use as Freund’s 
complete adjuvant, due to its low viscosity. Similarly, Syntex Adjuvant Formulation 
(SAF) is a stabilized oil-in-water emulsion known to activate complement by the 
alternate pathway. SAF was used quite successfully in early vaccine studies when 
combined to various forms of MDP.
Mineral compounds are also of common use for supplementation of vaccine antigens. 
Aluminium hydroxide, for example, allows particularly slow release of the antigen at 
the injection site, prolonging the time for interaction between antigen and antigen 
presenting cells and lymphocytes. Its use in cats however has been very controversial, 
as this agent has been speculated to play an important role in the induction of lethal 
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tumours at the injection site.
Plant-derived chemicals have also been tested in their adjuvanticity for FIV 
vaccines. Quil-A, a highly refined form of saponin, was also shown to stimulate both 
cell-mediated and humoral immune responses. Additionally, it serves as the main 
component of immune stimulating complexes called ISCOMs, relatively stable but 
non-covalently bound complexes of Quil-A, cholesterol and amphipathic antigen. 
The main characteristic of ISCOM-associated antigen molecules is that they are 
transported to the draining lymph nodes and thus do not deposit at site of injection. 
Furthermore, very low quantities of antigen can elicit a significant immune response, 
thus rendering the use of ISCOMs an interesting approach to stimulation of the 
host immune response towards amphipathic antigens. ISCOMs have only been 
used in veterinary vaccines, partly due to their haemolytic activity and some local 
reactions, all reflecting the detergent activity of the Quil-A molecule.
A new class of adjuvants has arised with the introduction of DNA vaccination, 
which enables co-delivery of specific antigens and molecular adjuvants, such as 
cytokines or unmethylated CpG ODN motifs, as an attempt to favourably alter 
initial immune events in infection. Indeed, the earliest antiviral defences are innate, 
and provide the basis on which the subsequent adaptive immune response is built. 
Moreover, further study of lentiviral pathogenesis has enabled characterization of 
unfavourable alterations or insufficient host response, which take place soon after the 
onset of infection, indicating the importance of influencing the innate immunity in 
the development of effective lentiviral vaccines. In this way, co-expression of vaccine 
antigens with cytokines abnormally produced in the early events of infection, such 
as  IL-12 and IL-16, have indicated promising results. Similarly, CpG motifs, 
comprised of unmethylated CG dinucleotides flanked by two 5’ purines and two 3’ 
pyrimidines, directly activate monocytes, macrophages, and dentritic cells to secrete 
IL-12 and IFN-g. Their utility has been demonstrated for a variety of antigens, 
and they initiated convincing results as adjuvants in DNA vaccines [180]. Further 
characterization of  CpG ODNs as well as their effects on the immune system are 
thouroughly described in the second chapter of this literature overview (3.2).
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3.1.8.2.2 Importance of Challenge Methods
Unfortunately, no independent experiments comparing a wide variety of adjuvants 
with each other have been carried out so far. Only individual studies using certain 
adjuvant combinations allow limited comparison of the different existing adjuvant 
types and combinations. Thus, at the current stage of FIV vaccine development, 
there are no general conclusions as to which adjuvant formulation is more effective.
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The evaluation of vaccine efficacy should readily take into consideration the challenge 
conditions. Indeed, the outcome of the study is greatly influenced by features such 
as quantity and virulence of the strain used, number of subtypes tested, source of the 
challenge inoculum and challenge route.
Since possibly no vaccine may be able to provide complete protection against a 
high-dose challenge or a highly virulent strain, these situations require modifications 
in the standards of judging vaccine efficacy. Generally, vaccines are designed to 
provide immunity capable of destroying all traces of virus in the host. Preclinical 
studies have however demonstrated that protection against disease is easier to achieve 
than prevention of infection. Critical evaluation of a vaccine study should be based 
on the observed effects on hallmarks of active infection, such as virus load, CD4+ 
counts, CD4+/CD8+ ratio, CD8+ cytotoxic activity, and specific FIV antibody titre, 
as well as the duration of positive alterations. Although the achievements of studies 
which failed to demonstrate sterilizing immunity are considered insufficient for 
clinical use, induction of partial immunity in presence of a severe challenge system 
nevertheless represents a great step towards the finding of an efficacious vaccine.
Many studies indicate efficient protection against infection with a homologous 
strain. However, due to the genetic variability of the different FIV subtypes, the 
demonstration of protection against both homologous and heterologous challenges 
has become a standard feature in FIV vaccine development. Multi-subtype vaccines 
not only broaden immunity and protection, but seem to have a synergistic protective 
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potential. In this sense, several dual subtype vaccines have been tested for veterinary 
use against FIV infection. In 2002, the United States department of Agriculture 
approved Fel-O-Vax FIV, a dual subtype FIV vaccine, for commercial use. More 
details concerning the first vaccine against FIV ever released on the market are 
discussed in section 3.1.8.2.4.2.
Vaccine prophylaxis is also influenced by the source of the challenge inoculum. 
Studies suggest that homologous FIV vaccines using in vitro-produced antigen may 
not provide protection against challenges using in vivo-derived inoculum [181]. 
In vitro challenge material is a laboratory grown primary PBMC inoculum, cell 
free and purified, which can be readily produced at high titres, in large quantities, 
and at a relatively low cost. This method is thus commonly used for the screening 
of potential vaccines. In vivo-derived inoculum consists of plasma or infected cells 
derived from cats infected with in vivo-passaged laboratory isolates, which contain 
quasi-species of FIV and more closely simulate natural conditions. This approach, 
however, encounters multiple limitations in inoculum production and achievement 
of high titres, and is associated with increased costs. Furthermore, biological effects 
of the plasma or the cellular component of the inoculum are more variable among 
the recipient animals, in comparison to in vitro-derived inoculum.
At last, it is important to take the route of challenge into consideration when 
judging results of a vaccine study. Conventional methods include subcutaneous (s.c), 
intramuscular (i.m), intraperitoneal (i.p), intravenous (i.v) and mucosal exposures. 
It is still controversial which route most closely mimics the natural infection route 
of biting and fighting. However, it is known that i.v and i.p routes readily infect 
cats, whereas the s.c and mucosal routes require higher challenge doses. Since 
the level of the FIV exposure during natural transmission remains unknown, the 
efficacy evaluation using a contact challenge system represents the ultimate test 
for any commercial FIV vaccine. According to contact studies and epidemiological 
surveys, contact transmission of FIV requires long term exposure (months to years) 
to naturally infected cats, and disease manifestation is not common during the early 
3.1.8.2.3 Immune Correlates of Protection and Passive Immunity
Passive transfer of protection plays a less important role in FIV than in HIV disease, 
where preventing infection after accidental exposure to the virus or interrupting 
transmission of virus from mother to child demands efficacious post-exposure 
prophylaxy possibilities. Although clinical use of passive immunization remains 
insignificant in the case of FIV, several studies concerning passive immunity have 
allowed the characterization of important mechanisms in FIV vaccine protection.
Hohdatsu and co-workers evaluated the role of antiviral antibodies by passive 
immunization against experimental infection [183]. In this study, cats immunized 
with sera from either FIV-infected or FIV-vaccinated cats were protected from 
infection. Furthermore, maternal antiviral antibodies, including VN antibodies, 
from either infected or vaccinated queens were shown to protect neonatal kittens 
from FIV inoculation. Thus, maternal antiviral antibodies play a key role in 
preventing or limiting infection in neonates and vaccinated queens can provide such 
antiviral immunity [184].
In another study, cats were either passively immunized with serum-derived antibodies 
Literature
46
phases of natural infection. These observations support the hypothesis that natural 
transmission occurs at low doses [182]. Although this method most closely mimics 
natural conditions, it remains extremely complicated to carry out experimentally in 
a representative form. As natural strains differ from the more thoroughly studied 
laboratory strains, questions arise concerning the dose requirements for occurrence 
of natural transmission, the virulence of the strains present in naturally infected 
populations, and their potential to maintain high viral loads in body fluids over time. 
In addition to obvious time and cost issues, these obstacles question the feasibility 
of natural transmission studies for commercial vaccine validation. However, in order 
to improve the quality of newly produced promising vaccines, the recourse to such 
studies will become difficult to circumvent.
or transfused with peripheral blood cells from FIV-vaccinated cats. In both cases, 
the immunized animals were protected against an FIV challenge which infected 
all control cats, suggesting that not only humoral, but also cell-mediated immunity 
from vaccinated animals can protect naive animals upon experimental FIV challenge 
[185]. The role of cellular immunity in vaccine protection against FIV infection 
was further evaluated using adoptive cell transfer studies. It could be demonstrated, 
that protection mediated by adoptive transfer of immunocytes from vaccinated cats 
was MHC-restricted, occurred in the absence of antiviral humoral immunity, and 
correlated with the transfer of cells with FIV-specific CTL and T helper activities 
[186]. Thus, both humoral and cellular immunity seem to be able to individually 
confer protection against homologous challenge and should be, as a consequence, 
induced together for optimal vaccine protection.
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3.1.8.2.4 FIV Vaccine Trials
3.1.8.2.4.1 Generalities
Whole virus vaccines, live or killed, constitute the vast majority of vaccines in use at 
present, in both human and veterinary medicine. Approaches using attenuated live 
retroviral vaccines are considered to be impractical for clinical trials in humans, due 
to risk of reversion to virulence. In FIV vaccine trials however, the highest levels of 
success has been achieved with inactivated whole virus or inactivated infected-cell 
vaccines. Heat, chemical or irradiation methods thereby render the virus completely 
non-infectious. It is important to note that since they are incapable of replicating in 
the host, inactivated vaccines require larger amounts of antigen, and require multiple 
doses as well as the use of an appropriate adjuvant for optimal efficacy. 
Recent advances in molecular biology have provided alternative methods for 
producing vaccines. The technology enabling growth of viruses to high titres in cell 
cultures has enabled purification of virus and viral antigens. Furthermore, the iden-
tification of important peptides encompassing the major antigenic sites of important 
viral proteins allows the production of highly purified subunit vaccines. Specific viral 
proteins can be expressed in bacteria, yeast, mammalian cells, and other viruses, and 
used as recombinant vectored vaccines. An additional interesting development 
has been the production of synthetic peptides closely mimicking specific viral 
immunogenic sites. The antigens of synthetic peptide vaccines are precisely defined 
and free from unnecessary components which may be associated with side effects. 
Overall, the production and quality control of such subunit vaccines is simple, and 
this technique is considered safe with viruses which establish a persistent infection. 
Increasing purification may lead to loss of immunogenicity however, and this often 
induces the necessity of coupling the purified peptides to an immunogenic carrier 
protein. Furthermore, the induced immunogenic response is restricted to selected 
antigens and vaccination of this type may not provide significant protection against 
natural challenge.
DNA vaccines represent another recently developed method in use for vaccine trials. 
They usually comprise circular plasmids that include a gene encoding the target 
antigens. This gene is under the transcriptional control of a promoter region active in 
specific host cells, which then directly produce the foreign antigen. DNA vaccines offer 
greater control over the immunization process, because the investigator determines 
which antigens and co-stimulants to use, where to elicit the response, and whether 
to use immunostimulatory DNA sequences to modulate the type of immune 
response induced. In addition, DNA is relatively inexpensive and easier to produce 
than conventional vaccines. Safety issues with regard to DNA vaccines include risks 
of integration into cellular DNA and antibiotic resistance conferred through 
resistance genes present in the plasmid. However, only insignificant adverse 
reactions have been noted so far in the many preclinical trials carried out with such 
vaccines, and this method remains very promising for future studies.
The following chapters describe different strategic approaches to protection against 
lentiviral infection, as well as encountered difficulties, in a series of relevant FIV 
vaccine studies performed mainly in the last 10 years. Tables 5-7 give detailed 
information about the individual studies.
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3.1.8.2.4.2 Conventional Vaccines
The main concern in the use of inactivated whole virus or inactivated infected cell 
vaccines is the event of accidental infection caused by incomplete inactivation of 
the vaccine virus. Thus, alternative methods were more thoroughly investigated 
for the development of prophylactic measures against HIV. However, results from 
animal studies with inactivated vaccines can provide new insights into the immune 
mechanisms of protection against lentiviruses. Such conventional vaccines have 
indeed achieved the majority of success in experimental FIV vaccine trials against 
severe challenge systems. 
Several studies aimed at determining breadth of protection following immunization 
with a single strain inactivated whole virus vaccine. The first successful vaccine 
trial, reported in 1991, described efficient protection of a whole inactivated vaccine 
derived from FIV-PET,  against an in vitro-derived homologous strain [187]. 
Further developing this study, Hosie et al. tested whether vaccination of cats with 
FIV-PET could induce protection against homologous (FIV-PET) or heterologous 
(FIV-GL8) challenge [188]. Although both challenge virus strains belong to the FIV 
clade A, they present significant antigenic differences. As a consequence, vaccinated 
cats became infected following FIV-GL8 challenge. Later on however, the same 
group showed that inactivated FIV-PET vaccination significantly suppressed viral 
load and CD4+ T cell loss in cats challenged with FIV-GL8 [189]. In contrast, 
inactivated FIV-M2, a clade B FIV, conferred protection only following mucosal, 
and not systemic challenge using a primary homologous virus isolate [190]. Similarly, 
Pu et al. could not demonstrate efficient protection of cats vaccinated with whole 
inactivated clade D FIV (FIV-SHI) against homologous in vivo-derived challenge 
[181]. These results suggest that protection against an in vivo-derived homologous 
strain inoculum is difficult to achieve with single-strain immunizations.
Single-subtype infected fixed cell vaccines seem to confer protection at best against 
homologous challenge strains. Various cell types have been experimented over the 
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years for their immunogenic potential as part of a vaccine. Infected cell vaccines 
derived from thymocyte or CRFK fibroblasts were not effective even against low 
dose, in vitro-derived homologous challenges [191]. Overall, successful cell-derived 
conventional vaccines have been developed from infected feline T lymphocyte 
cell lines. Greater than 90% protection was observed with a vaccine derived from 
chronically FIV-PET (subtype A) infected FL-4, an IL-2 independent feline T 
cell line, against in vitro-derived homologous and slightly heterologous challenge 
inoculums [192]. In a similar study, Matteucci and colleagues demonstrated 
homologous protection of cats after vaccination with FIV-M2 (subtype B) infected 
MBM cells, an IL-2 dependent feline T lymphoblastoid cell line developed by the 
same group in 1995 [193]. A study experimenting immunization with autologous 
FIV-M2 infected lymphoblasts however failed to show efficient protection, even 
against a low dose of homologous ex vivo FIV challenge [194].
The lack of heterologous protection of single subtype inactivated infected-cell or 
whole vaccines led to the multi-subtype vaccine approach, aiming at broadening 
immunity and protection. The first dual subtype FIV vaccine, consisting of 
inactivated subtype A- and D-infected cells, provided protection against in vitro 
derived homologous strains, but was unfortunately not tested against heterologous 
strains [195]. An improved dual-subtype FIV vaccine, consisting of inactivated 
whole viruses of subtypes A and D, elicited strong anti-FIV cellular immunity 
and broad spectrum VN antibody activities. In addition, it provided protection 
of cats against homologous and heterologous challenges using in vivo-derived 
inoculum [181]. This vaccine turned out to be the prototype of  Fel-O-Vax FIV, 
a dual subtype vaccine produced with FIV subtypes A and D, and formulated 
with a proprietary adjuvant system, approved by the United States Department 
of Agriculture, and commercially released by Fort Dodge Animal Health in 2002. 
The efficacy of this vaccine was demonstrated in a vaccination study designed to 
meet various requirements for registering the vaccine [196]. Eight week old kittens 
were immunized with the vaccine, challenged 12 months later with a heterologous 
FIV strain, and monitored for FIV viremia. While 90% of the controls became 
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persistently infected with FIV, only 16% of the vaccinated cats developed viremia, 
which demonstrated not only efficacy of the vaccine but also immunity against 
infection lasting for at least 12 months. The same study included a field safety trial 
in which 689 cats of various breeds, ages, and vaccination histories received a total 
of 2051 doses of the vaccine. Based on the fact that only 1% of the vaccinated cats 
presented mild reactions of short duration, the vaccine was considered safe for use in 
the field. Moreover, similarly to its prototype, which had demonstrated the potential 
to protect cats against heterologous challenge, Fel-O-Vax was shown to effectively 
protect cats against virulent challenge with a subtype B isolate, reported to be most 
common in the USA [197]. A contact study, more closely reflecting field conditions, 
confirmed these findings : 6 vaccinated and 8 control cats housed with 5 cats infected 
with a subtype B FIV strain were monitored for infection over several years. All 
vaccinated animals remained protected whereas 50% of the unvaccinated cats 
became infected, suggesting the vaccine exhibits broad efficacy against genetically 
diverse FIV strains, even under contact challenge [198]. Unfortunately, Fel-O-Vax 
has a major conflict with current FIV diagnostics, including ELISA and Western 
Blot technologies. Indeed, this conventional inactivated FIV vaccine induces broad 
spectrum antibody production to different FIV proteins, with long lasting titers. 
This renders differentiation of infected and vaccinated cats possible only with 
more expensive methods such as PCR. As a consequence, an efficient test allowing 
detection of vaccination-specific antibodies still needs to be elaborated.
The precedent for using a whole virus vaccine in cats has been established with 
FeLV vaccination. No known cases of accidental infection due to improper 
inactivation of the virus have been reported with FeLV vaccines. With improved 
inactivation methods of vaccine virus and better adjuvant formulations, inactivated 
or killed vaccine approaches continue to be promising for future veterinary vaccine 
development. 
Table 5 : Whole virus and infected-cell vaccine trials against FIV infection.  
Literature
52
Literature
53
Literature
3.1.8.2.4.3 Subunit Vaccines
Recombinant subunit vaccine trials include purified viral proteins, synthetic 
peptide and live viral or bacterial vector-based vaccines. Unfortunately, although 
such constructs induce high rates of cellular responses accompanied by antibodies 
aimed at specific targeted proteins, limited success has been obtained with this type 
of immunization against lentiviruses.
Many studies have based their trials on envelope antigens, as these are considered 
major targets of the immune system, and, as a consequence, represent appropriate 
vaccine components. The relative ease in production of satisfyingly pure products 
additionally renders recombinant envelope components especially attractive in use 
as immunogens for such studies. Furthermore, presence of antibodies specific for 
viral proteins that are not present in the vaccine allows clear discrepancy 
of seroconversion induced by natural infection from vaccine-induced humoral 
response. Thus, failure to induce protection against homologous and heterologous 
challenge infection despite induction of a considerable humoral response by 
highly purified denatured or native recombinant SU proteins originally expressed 
in the Baculovirus system and in E. coli, was both surprising and disappointing 
[202]. In an effort to increase the immune response and thus the protection rate 
observed in this study, recombinant SU proteins were further tested in a 
series of immunization trials assessing feasibility of combining these peptides 
with either QS-21 adjuvant or Freund’s adjuvant together with the recombinant 
nucleocapsid protein of the rabies virus. Better results in this experiment indicated 
that conjunction of recombinant FIV SU with appropriate adjuvants leads to partial 
protection against FIV challenge infection [203]. With similar objectives, Hosie 
and co-workers tested immunoaffinity purified gp120 for its prophylactic potential 
in FIV infection [204]. Again, although immunized cats presented a lower viral 
load in PBMCs than control cats, this vaccine failed to confer complete protection 
following challenge. A more recent study, aiming at the determination of the level of 
crossreactivity between HIV-1 and FIV, demonstrated an overall protection rate of 
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78% against challenge FIV infection using in vivo-derived inocula of both subtype 
B and recombinant subtype A/B, in cats immunized with adjuvanted recombinant 
HIV-1 p24 [205]. A vaccine consisting of only HIV-1 protein thus appears to be 
efficacious against FIV infection, suggesting that the epitopes shared by members of 
the lentivirus family may have protective properties. Interestingly, such protection 
did not correlate with antibody titres, and Th1-promoting cytokines, supplemented 
in the adjuvant, greatly enhanced the HIV-1 p24 vaccine efficacy. These findings 
indicate that cross-protection observed in HIV-1 p24 vaccinated cats was most 
likely mediated by the cellular immunity. Future studies should determine whether 
the FIV-infected cat is a useful small animal AIDS model to characterize protective 
epitopes for HIV-1 vaccine design.
Another approach to development of subunit vaccines was the production of synthetic 
peptides. Again, most studies have based their immunization trials on envelope 
antigens, with limited success. Thus, immunization with a synthetic peptide, 
containing the immunodominant neutralization epitope located within the V3 
domain of the FIV envelope glycoprotein, failed to confer protection in all of the 
immunized cats, although the peptide had induced both specific cell-mediated and 
humoral immune responses [206]. In the same way, cats immunized with a 
46-residue multiepitopic synthetic peptide of FIV, comprising immunodominant 
epitopes present in V3 of the envelope glycoprotein, TM glycoprotein, and p24 
gag core protein, developed an elaborate humoral immune response, but were not 
protected against challenge infection [207]. Synthetic peptides seem to be more 
effective in vitro however, as Lombardi and colleagues demonstrated a remarkable 
specific antiviral effect against the homologous and heterologous isolates using 
antibodies induced by synthetic peptides representing either a conserved region of 
the SU protein, or a hypervariable region of the TM protein [172].
Live recombinant vector vaccines are able to present the desired viral proteins in 
native conformation more efficiently than the purified subunit vaccines, and thereby 
elicit an immunity that may be more effective. The choice of a vector system that 
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Table 6 : Subunit vaccine trials against FIV infection.
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Table 6 : Subunit vaccine trials against FIV infection.
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optimally expresses the desired proteins remains however challenging. Similar to 
the purified and synthesized subunit vaccines, envelope amino acids remain 
the protective epitopes of choice. A recombinant replication-defective vaccine 
composed of adenovirus type 5 vector expressing FIV env gene, was found to be 
ineffective at inducing env-specific antibody responses and at protecting cats against 
homologous infection [208]. Disappointing results were also reported using a FIV 
mutant expressing the FIV env gene. Despite several booster immunizations, 
FIV-specific antibody responses in vaccinated cats were only weak, and the vaccinates 
did not withstand challenge with a low dose of homologous virus [209]. Recently, 
Burkhard and colleagues used Venezuelan equine encephalitis (VEE) virus replicon 
particles  to generate FIV gag and env expressing vaccine vectors [210]. Despite 
induction of innate as well as FIV-specific immune responses, all cats became 
infected following vaginal challenge with high dose, pathogenic cell-associated 
FIV-NCSU.  Immunized cats, however, indicated a significantly lower drop of CD4+ 
cell counts after FIV infection. The best results in vaccination against FIV with a 
vector-based system came from a recombinant canarypoxvirus (ALVAC) based 
vaccine [211]. In this study, 2 of 3 cats immunized with the ALVAC FIV recombinants 
were protected from homologous FIV challenge in the presence of FIV-specific 
CTL responses, but in the absence of FIV-specific humoral responses. Moreover, all 
3 cats immunized with the ALVAC FIV recombinant and boosted with FIV- infected 
cell vaccine were protected from homologous FIV challenge in the presence of 
both FIV-specific CTL and humoral responses. This vaccine combination 
also induced partial protection against a heterologous challenge, which took place 8 
months after the initial challenge. In conclusion, ALVAC indicates more promising 
results than other vector systems for FIV vaccine studies, and immunization schemes 
employing ALVAC vector in combination with inactivated FIV-infected cell 
vaccine can generate protective immune responses capable of crossreacting with 
FIV isolates that are genetically distinct from the vaccine strains.
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In the 1990s, DNA-mediated immunization emerged as a promising alternative in 
the development of viral vaccines, displaying protective immunity against viral and 
non-viral pathogens. This method had mainly attracted interest in lentiviral research 
for its potential to elicit strong cellular activity. Various trials effectively succeeded in 
reduction of viral load and prevention of disease after challenge, however complete 
protection was not achieved in either the HIV- or SIV-infected non-human primate 
models or FIV-infected domestic cats.
The most common approach to DNA vaccination trials has been the generation of 
live attenuated viruses with replication defective but full length proviral genomes, 
which express both structural and regulatory proteins in vivo. Moreover, inclusion 
of cytokine genes into a DNA vaccine enables increase of its immunogenicity and 
allows induction of desired types of immune responses. In 1998, Hosie and 
colleagues were the first to test DNA vaccination in the FIV model [213]. They 
vaccinated cats with a FIV mutant containing an in-frame deletion in pol (FIVΔRT), 
adjuvanted or not with INF-g DNA. Altogether, the immunization with FIVΔRT 
elicited cytotoxic T cell responses to FIV gag and env in the absence of a serological 
response. After challenge with homologous virus, 4 of the 10 vaccinates remained 
seronegative and virus free, while the rest displayed significantly lower proviral and 
viral loads. Conjunction of INF-g DNA in the vaccine increased the protection rate. 
Unfortunately, further studies failed to demonstrate protection potential of this FIV 
mutant against heterologous strains and more virulent challenges, thus excluding 
its possible utility in the field [189]. In the same way, FIV mutants containing an 
in-frame deletion in the integrase gene (FIVΔIN) conferred protection against 
homologous, but not heterologous challenge [214]. 
A FIV mutant containing deletions in the viral accessory gene vif (FIVΔvif ) [6] or 
in the orf-A gene (FIVΔorf-A) [215], also indicated significant protection against 
homologous challenge. Again, these mutants induced mostly specific cellular 
responses in the host, although anti-env and anti-gag antibodies were isolated in 
3.1.8.2.4.4 DNA Vaccines
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Table 7 : DNA vaccine trials against FIV infection.  
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several cats. In both studies, no reversion to wild type virus occurred in the vaccinated 
cats, indicating relative safety in this type of viral attenuation for use as vaccine. 
Unfortunately, efficacy against genetically diverse strains was not tested, thus not 
allowing definitive conclusions about their relevance in the field. 
As attempt to increase efficiency in expression of the incorporated genes, other 
vaccine trials have experimented the gene gun bombardment as vaccine DNA 
delivery. Such inoculations occur intradermally, whereby DNA-coated gold beads 
are directly shot into the keratinocyte nucleus. Advantages of this method include 
requirement of only low amounts of DNA and constant efficiency of transfection, 
with relative independence of vaccine dose from the size of the animal. In 2000, 
Boretti and colleagues immunized cats by the ballistic transfer of gold particles 
coated with minimalistic, immunogenic defined gene expression (MIDGE) vectors 
coding for FIV surface and partial transmembrane proteins, complemented or not 
with feline IL-12 DNA. These vectors consisted of the double-stranded expression 
sequence flanked by a phosphorylated oligodeoxynucleotide hairpin sequence on 
both ends. MIDGE particles thus lack sequence elements present on conventional 
plasmid constructs that could compromise the safety and immunological efficacy of 
the vaccine. Interestingly, 3 out of 4 cats immunized with MIDGE containing FIV 
env-coding particles together with IL-12 DNA were protected against homologous 
challenge. Indeed, only one cat in this group became provirus positive, displaying 
however a greatly reduced viral load [216]. These findings suggest that FIV DNA 
vaccines, in combination with feline IL-12 DNA, may provide a promising way of 
inducing a protective immune response against FIV infection. 
3.1.8.2.5 Enhancement Problem
Viruses initiate infection by attaching to host cells via interaction between viral 
surface proteins and specific receptor/co-receptor molecules on target cells. 
Antibodies specific for the viral surface proteins often inhibit this step of the 
infection cycle, resulting in reduced infectivity, and inducing so-called virus 
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neutralization. In some circumstances, such antibodies have been shown to potentiate 
viral infection. This phenomenon is known as antibody-dependant enhancement 
(ADE). Different mechanisms of ADE have been thoroughly described for several 
virus-cell systems in vitro; however in vivo relevance of ADE remains unclear. Obviously, 
further characterization of ADE is of great interest in the understanding of the 
pathogenesis of diverse viral diseases. 
Several studies have focused on the importance of ADE in retroviral infections. At 
least three different mechanisms (figure 6) for ADE of HIV infection in vitro have 
been hypothesized : a) interaction between antibody and cellular Fc receptor (FcR), 
b) interaction between the cellular complement receptor (CR) and the complement 
factors, induced by activation of the classical complement pathway during viral 
infection, and c) antibody or soluble factor induced conformational change in 
viral envelope, leading to activation of the glycoprotein and facilitating membrane 
fusion. Interestingly, it seems viral infection through ADE uses a more efficient 
intracellular viral replication pathway, which suppresses expression of antiviral 
genes such as tumour necrosis factor and inducible nitric oxide synthase (figure 6). 
Unfortunately, clinical significance of all types of ADE in HIV infection remains 
very controversial. 
In the case of FIV, both antibody dependent and independent responses have been 
associated with viral replication enhancement, thus complicating the understanding 
of immune processes and the development of vaccines. In 1992, Hosie and 
co-workers vaccinated cats either with purified FIV incorporated into ISCOMs, 
recombinant FIV p24 ISCOMs, or a fixed, inactivated cell vaccine in Quil A 
adjuvant, and thereby observed a more rapid viremia in vaccinated cats compared 
to control cats [217]. Group-related elevated or low titers of anti-p24, anti-env and 
neutralizing antibodies in the vaccinated cats seemed to play no role in the outcome 
of the challenge. Instead, 100% of the vaccinated cats became viraemic compared 
with 78% of the controls. In the same way, vaccination with fixed autologous 
FIV-infected cells did not protect cats against challenge infection despite induction 
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Figure 6 : Mechanisms of antibody-dependent enhancement (see text for explanations)
When analyzing such results, it is important to keep in mind that whether 
antibodies enhance or neutralize seems to depend on the balance between various 
factors, including virus strain and dose, host-cell antibody combination, and the 
concentration and epitope-specificity of the antibody. 
Further studies have focused on the importance of the retroviral envelope in 
enhancement, as it is known to be the principal target for viral neutralizing 
antibodies. Indeed, the majority of promising HIV vaccines undergoing clinical 
trials have been based on the viral envelope. However, monoclonal antibodies 
of FIV-specific humoral responses. Again, accelerated virus replication was observed 
[218].
directed against a conserved region of the HIV TM glycoprotein, called the principal 
immunodominant domain (PID), were shown to induce enhancement of infection 
on several cell types, thus raising concern about the efficacy of such vaccines. In 
this sense, immunization of cats with recombinant vaccinia virus-expressed FIV 
envelope glycoprotein, either incorporated in ISCOMS or adjuvanted with Quil A, 
resulted in enhanced infectivity of FIV. Additionally, as the observed enhancement 
could be transferred to naive cats with plasma collected at the day of challenge, the 
authors proposed that enhancement was mediated by anti-env antibodies [219]. 
With the intention to further develop this hypothesis, Richardson and co-workers 
undertook an evaluation of the effect of vaccination with the FIV env gene on the 
development of infection in cats after challenge [220]. Three groups of cats were 
thereby immunized using plasmid DNAs expressing either the wild-type envelope 
or two envelopes bearing mutations in the PID of the TM glycoprotein. This genetic 
immunization elicited low or undetectable levels of antibodies directed against 
envelope glycoproteins, hypothetically due to the vaccination protocol used. Upon 
homologous challenge, determination of plasma virus load showed that the acute 
phase of viral infection occurred earlier in all three groups of cats immunized with 
FIV envelopes than in the control cats. Although the influence of antibodies could 
not be completely excluded, the authors found no evidence of presence of antibodies 
or other soluble factors capable of augmenting viral infection in vitro, and therefore 
speculate that other immune phenomena, such as cellular activation, may have 
caused the acceleration of infection. FIV is known to replicate more efficiently in 
activated cells both in vitro and in vivo, as has been shown for HIV-1, and can 
infect B and T lymphocytes. Specific priming of cells of T and B lineages by env 
vaccination, while insufficient for the induction of detectable levels of antibodies, 
may have been sufficient to render cells more susceptible to viral infection. This 
study opens discussion to mechanisms unrelated to enhancing antibodies, linked 
with acceleration of virus replication.
A recent study focused on the influence of antigenic properties of live attenuated 
vaccines in their protection potential against lentivirus infection. Random amino 
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3.2 CpG Oligonucleotide Literature Overview
After a brief introduction on the state of research in the field regarding innate 
immunity and the importance of Toll-like receptors (TLRs) for the early recognition 
of various pathogens, the following chapter will give an overview on important 
discovered facts concerning CpG oligonucleotides, the knowledge acquired on 
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acid substitutions were introduced into the TM envelope glycoprotein of FIV, within 
the PID, which notably bears immunodominant B cell epitopes. Amongst a wide set 
of mutants, those that modified antibody specificity without abolishing infectivity ex 
vivo were selected to infect a group of spf cats. After 1 year of infection, the cats were 
superinfected with a heterologous intraclade primary strain of FIV. One selected 
mutant, designated TN92, thereby succeeded in providing a significant protection of 
the cats against high viral loads. The authors suggested that this protection correlated 
with a decrease, in TN92, of the immunogenicity of a B cell epitope potentially 
involved in antibody enhancement of infection, thus emphasizing the importance of 
PID in the induction of such antibodies [221].
Viral enhancement warrants caution in the design of antiviral vaccines. Moreover, 
there should be considerable concern over the use of vaccines against viruses that 
induce infectivity enhancing antibodies, as these vaccines could then predispose the 
host to persistent infection or lead to selection of « enhancable » virus types. It has 
been shown that antibody responses induced by subunit vaccines tend to be associated 
with severe disease by several retroviruses. A possible approach to the development of 
such vaccines against this virus family might be the induction of cellular immunity 
rather than antibodies. In this way, plasmid DNA and viral vector-based vaccines, 
as well as live attenuated vaccines, can be designed to induce strong CTL responses 
that avoid harmful antibody responses. Indeed, as a prerequisite to the development 
of vaccines against lentiviruses, we must learn which interactions between virus and 
host immunity determine the balance between enhancement and protection and 
how this balance may be displaced in favor of protection.
3.2.1 Insight on Innate Immunity and Toll-like Receptors
All living beings are constantly exposed to microorganisms that are present in 
the environment, and have consequently developed over time a means to cope 
with invasion of microbial pathogens in the body. The vertebrate immune system 
utilizes two general strategies to combat infectious diseases : innate and acquired 
immunity. The latter represents a specific but rather slow process, in which clonally 
distributed T and B cells, expressing highly specific receptors that mediate pathogen 
recognition, need time to proliferate after antigen contact. This highly sophisticated 
system of antigen detection is found only in vertebrates and has been the subject of 
considerable research. Initially thought to be relatively non-specific, innate immunity 
had, in contrast, attracted far less attention. However, the organism’s first line of 
defence reacts immediately in presence of antigen and its considerable contribution 
to the activation of more specific subsequent immune responses, particularly Th1 
cellular responses, must not be underestimated [222]. Not only innate immunity 
discriminates between self and foreign antigens, but its ability to induce rapid 
production of highly potent cytokines, chemokines and polyreactive antibodies 
allows reaction to a wide variety of pathogens with a greater degree of specificity 
than previously thought. Thus, scientists have shown increasing interest over the past 
years in understanding the complex unfolding of innate immune mechanisms, and 
findings have altered global ideas about the pathogenesis and treatment of cancers, 
as well as infectious, immune and allergic diseases.
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their immunological effects, and progress involving their use in different disease 
settings. The medical potential of CpG DNA has attracted high interest from 
scientists worldwide, and hundreds of studies aiming at the further understanding, 
characterization and manipulation of their effects on the host immune system have 
been accomplished in the last 20 years. Among the numerous published projects 
involving CpG ODN, a narrow selection was chosen in order to support the facts 
described below.  
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According to a concept elaborated by Janeway and co-workers [223], early pathogen 
recognition mechanisms within the innate immune system relies on its ability to 
recognize pathogen-associated molecular patterns (PAMPs), which comprise 
essential and evolutionarily conserved microbial structures such as bacterial cell wall 
components, as well as various viral, fungal and parasite structures. The fact that 
these features are essential for the survival of the pathogen ensures that no mutation 
can arise that would avoid their recognition by the host’s immune system. The 
detection of PAMPs relies, to great extent, on a limited set of pattern recognition 
receptors (PRRs), among which a small family, known as the Toll-like receptors 
(TLRs), has proven to allow induction of antimicrobial effector mechanisms, and 
thus play a crucial role in early host defence against invading pathogens [224]. 
Relevance of the TLR family in innate immunity was revealed in 1996, when a 
key Drosophila protein, Toll, was shown to be required not only in embryonic 
development for flies, but also in order to provoke an effective immune response 
against the fungus Aspergillus fumigatus [225]. To date, 11 Toll-like receptors 
(TLR1-TLR11) in human and 12 in mice have been identified. The TLRs are type 
I transmembrane proteins expressed primarily in immune cells responsible for the 
first line of defence, including macrophages, dendritic cells, mucosal epithelial cells, 
neutrophils and dermal endothelial cells [226]. Due to considerable homology 
in the cytoplasmic region, they are members of a larger family that includes the 
interleukin-1 receptors (IL-1Rs). TLRs and IL-1Rs have a conserved region of 
about 200 amino acids in their cytoplasmatic tails, known as the TLR/IL-1R (TIR) 
domain [227]. Within the TIR domain, the regions of homology comprise three 
conserved boxes, which are crucial for signalling. The signal transduction pathway 
activated by the TIR superfamily is of great importance in evolution because it 
is highly conserved in plants, drosophila, nematodes, avian and mammals [228]. 
Briefly, after ligand binding, TLRs/IL-1Rs dimerize and undergo conformational 
change required for the recruitment of downstream signalling molecules. These 
include the adaptor molecule myeloid differentiation primary response protein 
88 (MyD88), IL-1R-associated kinases (IRAKs), transforming growth factor-b 
(TGF-b)-activated kinase 1 (TAK1), TAK1-binding protein 1 (TAB1), TAB2 and 
tumor necrosis factor (TNF)-receptor-associated factor 6 (TRAF6) [229].  Figure 7 
represents an example of the signals instigated after activation of a Toll-like receptor. 
The TIR signalling cascade eventually leads to activation of several transcription 
factors including nuclear transcription factor kB (NFkB) and activating protein 1 
(AP1), thus allowing expression of their target genes. In this way, presence of PAMPs 
on invading organisms initiates a downstream signal conferring to production of 
reactive oxygen species (ROS), inflammatory cytokines, interferons and chemokines, 
which all represent protective measures to defend hosts. However, it is important 
to keep in mind that hyper or hypo-responsiveness of TLRs or uncontrolled and 
improper signalling from these receptors could have serious consequences in hosts. 
Indeed, given the role of TLRs in the induction of such strong inflammation, the 
plausibility that improper regulations of the signalling pathway mediated by these 
proteins may also be involved in multiple inflammatory diseases such as sepsis and 
cancer should not be underestimated. 
Remarkably, despite high conservation in extracellular regions, different TLRs can 
recognize several structurally unrelated ligands. The subcellular location of different 
TLRs correlates to some extent with the molecular patterns of their ligands. 
Thus, TLR1, TLR2, and TLR4 are located on the cell surface and are recruited to 
phagosomes after activation by their respective ligands. In contrast, TLR3, TLR7, 
and TLR9, all of which are involved in the recognition of nucleic acid-like structures, 
are not expressed on the cell surface [230].  Furthermore, it seems that TLRs are 
not restricted to microbial PAMPs but recognize a wide variety of ligands. Thus, 
they play an essential role in non-infectious sterile inflammation and can detect 
ligands from damaged cells such as b-defensins and oxidized lipids, among other 
endogenous componds [231]. More importantly, low molecular weight synthetic 
molecules, such as imidazoquinolines or polyriboinosinic–polyribocytidylic acid 
(poly IC),  which have no obvious structural similarity to PAMPs, can successfully 
activate signal transduction mediated by TLRs. Natural ligands have been identified 
for most of the TLRs known [232, 233]. Altogether, these facts support the 
hypothesis that synthetic blocking of the TLR pathway in inflammation settings, or 
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3.2.2 Definition of CpGs and Natural Occurence
enhancement of the TLR signal in immune unresponsive diseases might offer new 
ways of therapeutic intervention.
In conclusion, TLR identification is among the most important and fundamental 
discoveries in microbial pathogenesis. Today, innate immunity is increasingly 
recognized as the central defence system because its mechanisms also empower the 
adaptive immune responses. Moreover, possibility of TLR triggering with purified 
compounds or synthetic ligands represents a powerful means to modulate innate as 
well as adaptive immune responses. Many pharmaceutical companies are involved in 
synthesizing small molecules that can serve as TLR antagonists or agonists. Since 
innate immune response is not pathogen-specific, any intervention in the TLR 
pathway could have a broad spectrum of use. Toll opens an exciting new perspective 
in drug development, which will continue to significantly improve the quality of 
human and animal life in a close future.
The term CpG designates a pair of nucleotides, cytosine (C) and guanine (G), 
appearing successively in this order along one DNA strand, separated only by a 
phosphate molecule (p). Within most eukaryotic DNA, CpG dinucleotides are 
encountered far less frequently than the expected ratio of 1:16. It seems this CpG 
suppression in vertebrate gemones is related to undergoing of excessive methylation 
in these dinucleotides of the cytosine residues at position C5. An analysis of nearest 
neighbour dinucleotide frequencies together with the level of DNA methylation 
in animals indeed strongly indicated that 5-methylcytosine (5mC) tends to mutate 
abnormally frequently to thymine (T) [234].
In contrast, unmethylated CpG dinucleotides are abundant in all bacterial as well 
as in some viral [235] and invertebrate eukaryotic genomes (e.g. drosophila) [236]. 
Estimations indicate a 100-fold lower presence of CpG motifs in vertebrate than 
in microbial DNA [237]. This critical difference in frequency and methylation of 
3.2.3 Uptake Mechanisms and Signal Transduction
CpG sequences in the genomes of vertebrates and microorganisms is the origin of 
recognition of CpG motifs by the vertebrate immune system. Since CpG sequences 
are not only far more frequent, but also non-methylated in genomes of bacterial 
pathogens, the number of « free », or available motifs in prokaryotic DNA exceeds 
that in vertebrate DNA. These « free » CpG motifs are sensed by cells of the immune 
system of vertebrates and subsequently signal infectious danger to the host. The 
rare CpG motifs in vertebrate genomes seem not to be accessible for immune 
recognition, probably due to the methylation of cytosine residues. 
The immune system of fish, birds and mammals all recognize and respond to CpG 
DNA. The evolutionary conservation of CpG recognition over millions of years 
strongly suggests that the immune response elicited by these motifs contributes to 
host survival. Further characterization of these responses thus represents great hope 
for future discovery of preventive and therapeutic possibilities for various diseases.
One of the most fundamental steps in defining the molecular mechanism of action 
of CpG DNA was identifying its receptor. In 2000, Hemmi and co-workers from 
Akira’s group noticed stunning similarities between the signalling mechanisms 
observed after cellular CpG DNA activation and the previously described signalling 
cascade linked to Toll-like receptors [238]. They were able to identify TLR9, a 
new Toll-like receptor, capable of distinguishing bacterial DNA from self-DNA. 
In their study, mice genetically deficient in this molecule lacked CpG-induced 
immune activation, indicating that expression of TLR9 is both necessary and 
sufficient for signal transduction after CpG administration. Chuang and Ulevitch 
further characterized TLR9 as a type I membrane protein preferentially expressed 
in immune cell rich tissues, such as spleen, lymph node, bone marrow and peripheral 
blood leukocytes [239]. Similarly to the previously described TLR7 and TLR8, 
the newly described TLR9 was shown to stimulate an NFkB signalling pathway, 
supporting the involvement of all these receptors in cellular responses to stimuli 
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which activate innate immunity.
These observations were rapidly extended, by Takeshita and colleagues, to human 
cells, also indicating human TLR9 expression as a prerequisite for CpG ODNs 
responsiveness [240]. Interestingly, Bauer and co-workers further suggested that 
evolutionary divergence between TLR9 molecules underlies species-specific 
differences in the recognition of bacterial DNA. Transfection of human embryonic 
kidney 293 cells to express the mouse TLR9 protein rendered them optimally 
responsive to a different CpG motif than 293 cells transfected to express the 
human TLR9 analogue. The optimal CpG motif for  human TLR9 activation was 
GTCGTT, whereas the optimal murine sequence was GACGTT [241].
Hemmi, Takeshita and Bauer all suggested presence of both TLR9 and CpG DNA 
in the same endocytic vesicles and hypothesized interaction and start of signal 
transduction in endosomes. It had indeed already been previously demonstrated 
that in living and unfixed cells, ODNs tend to localize in endosomes. It seems 
that the acidic and reducing conditions present in this intracellular compartment 
lead to degradation of double-stranded DNA into multiple single-stranded CpG 
motif- containing regions that subsequently interact directly with TLR9 [230, 
242]. Compounds that block endosomal acidification, such as bafilomycin and 
chloroquine, inhibit CpG DNA-driven signalling [243]. An in vitro experiment 
also demonstrated that TLR9 interacted with CpG DNA more strongly at the 
acidic pH (6.5 or 5.5) condition [244]. However, the requirement of acidic pH in 
CpG recognition has recently been challenged by a study showing that a chimeric 
TLR9 localized to the cell surface is still capable of responding to CpG DNA [245]. 
The authors suggest that the expression of TLR9 in intracellular compartments is 
important for preventing recognition of self DNA. Therefore, although endosomal 
uptake is widely recognized as a prerequisite for CpG-specific responses as well as 
the initiation site for signal transduction through TLR9, further studies are required 
to clarify the role of endosomal acidification in CpG DNA recognition. 
Over the years, discussions about cellular uptake of ODNs have been quite 
controversial. In general, it is now accepted that cellular uptake is a crucial first step 
in CpG-arbitrated effects and that, although probably receptor-mediated, it is not 
specific to CpG motifs, but more affected by the structure of the ODNs. In this way, 
uptake rates were demonstrated to be severely affected by backbone modifications (see 
3.2.2.4) of the applied CpG sequences. It seems indeed that synthetically modified 
CpG ODN are taken up much more efficiently than their natural analogues [246]. 
Additionally, strings of guanosines (polyG) were able to increase the uptake of CpG 
motifs [247]. Although uptake mechanisms remain unclear, this step seems to be 
modifiable by different means and should not be underestimated as an important 
restriction point in CpG signalling.
TLR9 activation results in the induction of a classical TLR signalling cascade 
involving MyD88, IRAK, TRAF6, and finally resulting in activation of MAP kinases 
and NFkB (see figure 7)  [248]. These transcription factors initiate production 
of type I IFN, very important antiviral molecules (see 3.2.4.3), in addition to a 
conserved program of pro-inflammatory signals. In contrast to TLR3 and TLR4, 
which have been described to use additional adaptor proteins apart from MyD88, 
signal transduction in response to TLR9 is critically dependent on MyD88 [249]. 
Although similar transducer proteins are used by various TLRs, the gene profiles of 
recognized PAMPs differ [250]. Thus, CpG DNA activates not only the expression 
of certain genes also triggered by other TLR ligands, but also a set of « CpG-specific » 
genes. Among the latter, importance must be attributed to the high capacity of 
CpG to induce production of Il-12, which plays a crucial role in the immunological 
properties of CpG ODN. 
At this point, it must be noted that natural or synthetic structural modifications 
of ODNs as well as host species in which they are applied greatly influence CpG 
signalling at different stages of the signal transduction cascade. These facts must also 
imperatively be kept in mind when analyzing immunological aspects of CpG DNA 
(see below : 3.2.4).
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Figure 7: Signalling cascade following trigger of the TLR9 
3.2.4 Immunological Effects of CpGs
Several different observations have led to the recognition of immunostimulatory 
DNA motifs. In the 1970s already, the successful treatment of cancer with 
Mycobacterium bovis in experimental animal models and in humans had attracted 
great attention [251]. It took another 10 years before another group identified a 
DNA-rich fraction, which they termed MY-1, as the active compound in M. bovis 
allowing tumour regression [252]. MY-1 was later shown to additionally induce 
IFN secretion from spleen cells and activate NK cells [253]. Moreover, all antiviral 
and antitumor properties of MY-1 were sensitive to DNase. Randomly selecting and 
testing DNA sequences of mycobacteria, Yamamoto and co-workers successfully 
identified a 45-mer ODN that was able to activate IFN secretion and NK cell 
activation [254]. Interestingly, further characterization of this ODN revealed that 
it contained a palindromic sequence motif with a central C-G dinucleotide, which 
appeared to be essential for the effects observed.
More hints to the immunological potential of DNA arose from the findings of 
Messina and colleagues [255]. This group was first to support the assumption that 
DNA from various species differed in their immunological activity. They showed 
that bacterial DNA was mitogenic for B lymphocytes in vitro, while DNA from 
vertebrates was not. Moreover, they demonstrated that methylation of cytosine 
residues of bacterial DNA completely abolished mitogenicity, indicating a 
DNA-sequence-dependent activity on B cells.
Unexpected immunostimulatory effects observed in the course of studies utilizing 
antisense ODNs also attracted particular attention. Initially, antisense ODNs were 
introduced in the cells to specifically prevent translation of target mRNA and, as 
a consequence, expression of the corresponding gene product. Several investigators 
observed however a sequence-specific B cell proliferation and upregulation of MHC 
molecules on these cells. With the aim to define more precisely the motifs inducing 
such effects, Krieg et al. reported that short (approximately 20 bp long) ODNs 
exhibited profound stimulation of B cell activity, provided they contained a central 
Literature
75
Literature
76
3.2.4.1 Cellular Immunology of CpG DNA
CpG motif flanked at the 5’ end by 2 purines and at the 3’ end by 2 pyrimidines [256]. 
Moreover, both reversal of the central CpG dinucleotide to a GpC dinucleotide and 
methylation of the CpG dinucleotide completely abrogated mitogenic effect of the 
ODN on B cells.    
These different lines of observations shed light on the recognition of prokaryotic 
DNA by the vertebrate immune system as well as on its potential to induce important 
immunological responses in the host. Researchers have then concentrated efforts in 
understanding the unfolding of these responses and thus uncovered mechanisms 
which have allowed satisfying use of CpG motifs in various disease settings. The 
following chapter discusses the known immunological effects of CpG DNA. 
CpG motif recognition by the immune system of vertebrates results in a direct 
stimulation of TLR9 expressing cell types, mainly including dendritic cells (DCs) 
and B cells. Activated DCs subsequently mature and produce signals allowing 
stimulation of macrophages and monocytes, increased activation of NK cells, and 
maturation of naive T cells to a Th1 phenotype. Since activated T cells have the 
potential to induce more specific responses to various antigens, CpG also indirectly 
improve the host’s ability to mount a subsequent adaptive immune response (see 
figure 8). 
CpG ODNs thus not only strengthen early immune responses, but additionally 
prepare the adaptive immune components to possible pathogen contact and reaction 
with a Th1-directed response, creating an interesting link between innate and 
adaptive immunity. The more detailed understanding of these immunomodulatory 
properties was crucial to the increasing popularity of CpG ODNs observed over the 
years in research and pharmaceutical fields. 
3.2.4.1.1 B Cells
Krieg and co-workers were the first to describe in 1995, that bacterial DNA and 
ODNs containing CpG motifs could induce murine B cells to proliferate and secrete 
immunoglobulins in vitro and in vivo [256]. Ever since, experiments including 
various species have equally shown extraordinarily strong mitogen effects of CpG 
ODNs for B cells f rom essentially all vertebrates, including humans [257], 
non-human primates [258],  cows [259], as well as most of all common farm and pet 
companion animals [260]. CpG ODNs not only enhance proliferation of B cells, but 
activate their secretion of cytokines (mostly IL-6) and immunglobulins as well as 
the expression on their surface of increased levels of Fcg receptor and co-stimulatory 
molecules, such as class II MHC, CD80 and CD86. Yi and colleagues demonstrated 
that CpG ODN rapidly induce B cells to enter the G1 phase of the cell cycle and 
secrete IL-6 [261]. In vitro treatment of a B cell line with CpG DNA led to an 
increase in the transcriptional activity of the IL-6 promoter. Moreover, within 30 
minutes after CpG DNA stimulation in vivo, IL-6 mRNA levels were increased in 
murine liver, spleen, and thymus cells. Serum IL-6 protein was markedly increased 
within 1 hour of stimulation. Additionally, the CpG-induced IL-6 expression was 
shown to be required for subsequent B cell secretion of IgM. 
Activation of mature peripheral B cells by CpG ODNs was shown to be enhanced 
by simultaneous signals delivered through the B cell antigen receptor (BCR). Indeed, 
Krieg and co-workers had already indicated strong synergy of low concentrations of 
CpG with BCR-triggering signals, leading to an approximate 10-fold increase in B 
cell proliferation and antigen-specific immuoglobulin (Ig) and IL-6 secretion [256]. 
Thus, in the presence of antigen, CpG ODNs have an even greater immunologic 
potential on B cells, and allow under such conditions, the passage to a more specific 
type of immune response.
Finally, Yi and co-workers suggested that CpG-containing ODN motifs provide 
signals not only for cell cycle entry, but also for cellular survival [262]. Specific 
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3.2.4.1.2 Dendritic Cells
and/or cooperative interactions of multiple genes, upregulated by the presence of 
CpG, conferred to the rescue of a murine B lymphoma cell line from anti-IgM-induced 
cell cycle arrest and apoptosis. In another experiment , the same group demonstrated 
that treatment of isolated murine B cells with CpG reversed their tendency to 
spontaneous apoptosis in a sequence-specific fashion [263]. Indeed, reversal of 
the CG to GC as well as methylation of the central cytosine both significantly 
decreased this activity. CpG DNA has also been reported to protect B cells against 
Fas-mediated apoptosis by downregulating Fas expression on CD40-stimulated B 
cells [264].
Dentritic cells play a central role in the effect of CpG on the immune system. Their 
function as antigen-presenting cells (APCs) as well as their ability to produce a 
wide variety of pro-inflammatory cytokines render them the important intermediate 
signals to specific T cell immunity. Thus, they create the link between the innate 
and the acquired immune system and influence the balance between Th1 and Th2 
immune responses. Studies on the effects of CpG motifs on DCs have mainly 
been carried out on mouse and human cellular models. Sparwasser and colleagues 
were the first to demonstrate that bacterial DNA or synthetic CpG ODNs cause 
simultaneous maturation of immature murine DCs, upregulating of MHC class 
II, CD40 and CD86 molecules on their surface, and activation of mature murine 
DCs to produce large amounts of cytokines, such as IL-12, IL-6 and TNF-α [265]. 
Similarly, Hartmann et al. showed that CpG ODNs alone were superior to GMCSF 
in promoting survival and maturation (CD83 expression) as well as expression of 
class II MHC and the co-stimulatory molecules CD40, CD54, and CD86 of human 
DCs [266].
With the identification of TLR9 as cellular receptor for CpG recognition, it was 
rapidly determined that individual subsets of murine and human DCs express 
different TLR molecules which enable them to respond to distinct pathogens and 
3.2.4.1.3 Monocytes and Macrophages
thus induce diverse patterns of immune reactions [267]. Thus, among human DCs, 
a subset termed « plasmacytoid » (pDC), due to its microscopic appearance similar 
to that of plasmablasts, strongly expresses TLR9. Instead, myeloid lineages of DCs 
express mainly other TLRs, rendering them susceptible to other sets of pathogen 
molecules, including Lipopolysaccharide (LPS) for example. 
In humans, only the pDC subset has so far clearly demonstrated direct activation 
by CpG DNA [268]. After stimulation with CpG, these DCs showed an increased 
ability to induce proliferation of naive allogeneic CD4+ T cells. They were also 
shown to express CCR7, which mediates their homing to lymph nodes. Additionally, 
interactions of DCs with NK cells have been reported in mice [253], as well as in 
humans [269]. In the latter study, pDCs enhanced NK cell activity in a cytotoxicity 
assay, both with and without direct contact between DCs and NK cells (further 
details under 3.2.4.1.4). Finally, it must be mentioned that pDC represent the 
primary source of type I IFN, a potent driver of Th1 development and cell-mediated 
antiviral immunity (see 3.2.4.3). 
Subcutaneous administration of CpG DNA also leads to in vivo stimulation of skin 
Langerhans cells to upregulate co-stimulatory molecules and produce IL-12, as well 
as to undergo morphologic changes and migration [270].
In summary, CpG DNA induces maturation of human and murine DCs to 
professional APCs, which in turn secrete a series of pro-inflammatory and Th1 type 
cytokines, favouring maturation of CD4 cells to the Th1 subtype. CpG also activates 
migration of DCs, thus augmenting their rapidity and potential of effect. 
The effects of CpG ODNs on monocyte/macrophage lineages of humans and mice 
have been compared. Interestingly, purified human monocytes do not express TLR9 
and are, as a result, not activated by CPG ODNs. Nevertheless, CpG DNA treatment 
of human PBMCs or whole blood secondarily activates the monocytes to express 
CD40 and CD69, and to produce IL-6 and TNF-α. These findings have been 
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3.2.4.1.4 Natural Killer Cells
mainly attributed to effects of  backbones used in synthetic CpG ODN production 
(see 3.2.6) [271]. In contast, in murine monocytes/macrophages, CpG DNA has 
been shown to trigger induction of nuclear translocation of NFkB, accumulate 
TNF-α mRNA and release large amounts of TNF-α [272]. These findings suggest 
a species-specific response of certain cell types to CpG ODNs. Further details to 
species specificity of CpG ODNs are described in section 3.2.5.
Both murine and human NK cells lack TLR9 expression and are thus not directly 
stimulated by CpG ODNs. Since the initial observation that mycobacterial DNA 
activates murine NK cells to produce IFN-g and to have lytic activity [273], many 
efforts have been concentrated on elucidating the mechanism that generates these 
findings. It remained controversial for a long time, whether it was the structure of 
the ODN or the presence of CpG sequences that induced the observed effects on 
NK cells [274]. An interesting study from Ballas and colleagues showed the explicit 
requirement of an unmethylated CpG motif included in short ODN sequences 
for the induction of NK cell lytic activity in vitro in both human and murine 
lymphocytes as well as in vivo, in mice [275]. Furthermore, in experiments designed 
to determine the cellular and cytokine settings necessary for CpG-mediated NK 
cell stimulation, the same group revealed that ODNs could not augment the activity 
of highly purified NK cells, and that increased NK cell activity depended on the 
presence of  adherent cells or CpG-conditioned supernatants, which contain IL-12, 
TNF-g, and type I IFN. 
A series of subsequent studies permitted the further characterization of the link 
between CpG-related activation and effector mechanisms of NK cells. Cowdery 
and co-workers showed that bacterial DNA induces in vivo release of IFN-g and 
identified NK cells by surface phenotyping as the main IFN-g producing cells [276]. 
Later on, dependence of IFN-g production in PBMCs on CpG ODN-induced 
IFN-α/b was demonstrated by IFN-α/b-blocking antibodies [277]. In this study, 
3.2.4.1.5 T Cells
the potency of CpG ODNs to stimulate IFN-α correlated with their ability to 
stimulate NK cell lytic activity. Recently, the responsibility for the stimulation of 
NK cells with CpG ODNs has been attributed to pDCs. Indeed, partial activation 
of NK cells was mediated by pDC-derived IFN-α, whereas full activation of NK 
cells, indicated by IFN-g production, required cell-to-cell contact of pDCs and 
NK cells in addition to IFN-α[278]. Importantly, as mentioned above (3.2.4.1.2), 
interactions between pDCs with NK cells had been reported earlier in mice as well 
as in humans [253] [269].
The role of pDCs as intermediate signals for NK cell stimulation through CpG 
has recently been extended, as another CpG-induced pDC factor, TNF-α, was 
shown to participate in the production of IFN-g by NK cells in an additive fashion. 
Nevertheless, this particular activity of TNF-α required the presence of a co-factor 
such as IFN-α [279].
Due to their lack of TLR9 expression, it is widely accepted that T cells cannot be 
directly stimulated by CpG ODNs [280]. Thus, activation of T cells by CpG ODNs 
was rapidly linked to an indirect effect involving professional APCs, such as DCs. 
Three mechanisms of indirect CpG-related stimulation of T cells by DCs are known 
to date. First, CpG ODNs have been reported to upregulate co-stimulatory molecules 
and MHC class II molecules on DCs (see 3.2.4.1.2). Such molecules are critical 
for the recognition of antigens by T cells and their enhanced expression on DCs 
can result in a more efficient antigen presentation to CD4+ T cells. Furthermore, 
CpG ODNs stimulate IL-12 secretion by DCs, which is the main factor triggering 
IFN-g production by CD4+ T cells. Finally, CpG ODNs induce secretion of IL-6 
by DCs via TLR9-mediated signalling. The secreted IL-6 blocks at least in part the 
suppressive effect of CD4+CD25+ regulatory T cells (Treg) on CTL [281], allowing 
full activation of pathogen specific CD8+ T cells. Thus, a block of Treg cell functions 
by CpG ODN-stimulated DCs might provide new means to augment specific 
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3.2.4.2 Creation of Th1-like Cytokine Milieu
immunity in infectious diseases. In conclusion, both the molecular modifications and 
the specific cytokine secretion of DCs augment pathogen-specific T cell responses 
and IFN-g release during an ongoing bacterial infection, or following CpG ODN 
stimulation.
Neither enhanced oxidative burst nor increased expression of activation markers has 
been identified on the neutrophil population after CpG treatment in vitro. However, 
Weighardt et al. demonstrated that subsequent to administration of CpG ODNs 
in vivo, mice showed substantially increased resistance against acute polymicrobial 
sepsis, together with a strongly enhanced accumulation of neutrophils at the primary 
site of infection [282]. Additionally, neutrophils of CpG ODN-treated mice 
exhibited an upregulation of phagocytic receptors, an increased phagocytic activity, 
and an elevated production of reactive oxygen metabolites. Thus, CpG DNA does 
not appear to activate neutrophils directly, but may improve their ability to provide 
effective host defence.
3.2.4.1.6 Neutrophils
The activation of immune cells by CpG DNA initiates a complex network of cell-cell 
interactions and cytokine production cascades that result in an overall enhancement 
of immune functions in an antigen-independent manner. This immune stimulation 
is strongly Th1-directed, since these defence mechanisms are originally optimized 
for protection against intracellular pathogens. Put together, the cellular mechanisms 
described above induce production of high amounts of IL-12 and IFN-g, which are 
considered key factors for the development of Th1-deviated reactivity. They directly or 
indirectly promote proliferation and differentiation of Th1 cells, activate phagocytic 
and NK cells against microbial infections, and are required for the development 
of CTL-mediated immunity against viral infections or malignant cells. Moreover, 
IFN-g enhances Th1 antibody production by B cells by inducing IgM to Ig2a isotype 
3.2.4.3 Production of Interferon-α
switching. Klinman and colleagues were the first to describe the ability of CpG 
motifs to induce Th1 and pro-inflammatory cytokine production in vitro and in 
vivo [283]. Systemic injection of CpG DNA was thereby shown to create a systemic 
Th1-like response. Likewise, local injection of CpG subcutaneously into the footpad 
of mice induced IL-12 and IFN-g production in the draining lymph nodes and 
lymphadenopathy that peaked at 7-10 days post-treatment. DCs became a more 
prominent population in the lymph nodes and exhibited an activated phenotype with 
increased expression of co-stimulatory molecules [284]. Intradermal or intranasal 
delivery of CpG DNA also resulted in a localized state of Th1 predisposition [285]. 
The possibility to induce this Th1 environment is of great interest in vaccination 
and treatment of diseases that are characterized by Th2 immune deviations, which 
appear insufficient in clearing the affection.
Probably the most important antiviral property of CpG ODNs resides in their 
potential to stimulate the production of high amounts of IFN-α by the pDCs, also 
known as interferon-producing cells [286]. IFN-α prevents viral dissemination by 
both directly impairing proper viral replication and promoting the functions of 
various cell populations responsible for the first response to invading organisms. 
Indeed, this type I IFN has been shown to considerably enhance NK cell cytolytic 
activity, promote differenciation, maturation and immunostimulatory functions of 
monocytes and DCs [287], induce B cells to produce immunoglobulin [288], and 
induce Th1 differentiation of T cells [289]. Moreover, IFN-α effectively induces the 
synthesis of various cellular proteins, including enzymes, signalling proteins, antigen 
presenting proteins and transcription factors, which initiate its antiviral properties. 
IFN-α effector proteins possess the ability to interfere with several steps of the virus 
cycle, thus preventing virus from replicating in yet uninfected cells. In summary, 
INF-α plays a key role in the mounting of a global « antiviral state » comprising 
potent defence mechanisms against viral infection.
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Figure 8 : The immunostimulatory effects of TLR9 activation in pDCs and B cells
Table 8 : Breadth of the CpG-induced immune response
3.2.5 Species Specificity in CpG DNA Recognition
Early studies proposed a degree of species specificity in the recognition of CpG 
motifs. It was thought that the precise sequence motifs (unmethylated CpG 
dinucleotides and flanking regions) optimal for stimulating immune cells from 
one species differed from those optimal for another species due to evolutionary 
divergences in TLR9 molecules. In this way, the TLR9 molecules in mice were 
shown to differ from those in humans by 24% at the amino acid level, and the terms 
mouse (GACGTT) and human (GTCGTT) CpG motifs were adopted [241]. 
Indeed, the optimal murine CpG motif was shown to have little, if any stimulatory 
activity on cells from humans, chimpanzees and rhesus monkeys [258].
It is crucial to point out however, that initial experiments were restricted to murine 
and human cells. Several studies examining effects of different CpG motifs in a 
larger variety of animals have indicated that the GTCGTT sequence is optimal 
for stimulation of lymphocyte proliferation in many different species. Verthelyi 
and Klinman showed that PBMCs from humans, macaques, chimpanzees and 
orangutans respond to the same class of CpG ODN [290]. Moreover, analysis of 
CpG DNA efficacy in various veterinary and laboratory species, including cattle, 
sheep, goats, horses, dogs, cats and chicken, demonstrated that in all species tested, 
the GTCGTT motif seemed to have stimulatory potential [260]. Not only there 
appeared to be little evidence of divergence in terms of actual motif recognition, but 
other requirements for ODN stimulation, such as the nature and degree of spacing 
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between motifs or requirements for particular 5’ bases preceding the motifs, were 
also similar among the species tested. In addition, there was no apparent variation 
in the stimulatory effect of ODNs based on age, gender, or breed. Interestingly, 
the only apparent exceptions in recognition and immune stimulation potential of 
particular CpG-containing sequences seemed to be laboratory mice and rabbits. The 
authors suggest that inbreeding of the animals used for research purposes may have 
had an important impact on response to CpGs. A subsequent study in dogs and 
cats [291] has confirmed evidence of cross-species activity of the GTCGTT motif. 
Altogether, these observations indicate that CpG motif recognition remains an 
ancient evolutionary adaptation in a broad variety of species, more highly conserved 
than previously thought.  
The cell populations that express TLR9 might differ between species. Again, major 
differences have been mostly identified between mice and primates. Thus, murine 
immune cells of the myeloid lineage (including monocytes, macrophages, and 
myeloid DCs) express TLR9 and respond to CpG stimulation, whereas in humans, 
these cell types generally do not express TLR9 and cannot be directly activated by 
CpG ODNs.
Since studies that are designed to examine the therapeutic potential of CpG ODNs 
are typically initiated in mice, it appears crucial to ascertain the in vivo potential for 
the selected ODNs in the target species. Although activation of both murine B and 
NK cells in vitro are considered excellent predictors of cross-species in vivo activity 
[258], species-specific leukocyte proliferation assays have shown to be a more reliable 
predictive indicator of the in vivo potential of an ODN, and should be used to screen 
ODNs for biologic activity in different species. Since sequence, number, and spacing 
of individual CpG motifs contribute to the immunostimulatory activity of a CpG 
ODN, it is important that broad panels of ODNs be tested for their efficacy. 
3.2.6 Production of Synthetic Oligonucleotides
Synthetic oligonucleotides containing CpG motifs similar to those found in bacterial 
DNA induce comparable immune responses. Moreover, synthetic ODNs can be 
produced in a sequence-specific manner, in large quantities and with high purity. 
These facts render synthetic immunomodulatory ODNs particularly interesting in 
terms of therapeutic use for many diseases. Synthesizing of effective ODNs however 
imperatively requires the consideration of different important variables, including 
stability of the compound in vivo and species-specific recognition of the sequence, 
as well as the possibility of undesired side effects. Finally, establishment of reliable 
assays capable of indicating in vivo potential is crucial.
Most of the DNA sequence-specific information on immunostimulatory DNA has 
been derived from the analyzes with synthetic ODNs. Natural ODNs containing 
phosphodiester linkages (pODNs) are rapidly degraded in vivo and in vitro by the 
action of nucleases. Moreover, nuclease activities seem to be higher in human than 
in mouse cells, with the result that pODNs can appear non-stimulatory unless they 
are administered repeatedly. In order to stabilize them against degradation and 
thus increase efficacy in immune stimulation, ODNs are often made resistant to 
nucleases by chemically modifying the backbone of the DNA molecule. ODNs 
with phosphorothioate linkages (sODNs) are thereby commonly used [246]. It 
has been shown that sODNs are up to 100 times more efficient than pODNs of 
the same sequence in eliciting CpG-dependent immune responses. However, 
phosphorothioate backbone modifications result in various undesired side effects. 
Indeed, it has been shown that such modifications can lead to a prolongation of  the 
blood clotting time [292], acute toxicities via complement activation [293], as well as 
splenomegally, lymphoid follicle destruction and  immunosuppression [294]. Also, 
due to their polyanionic property, sODNs bind non-specifically to various proteins, 
i.e transcription factors, and thus may affect cell signalling [295]. As a result, high 
concentrations of sODNs and long treatment durations should generally be avoided 
when using this agent in vivo. 
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Following evidence that distinct types of CpG ODNs could induce differential 
responses by human cells [296], at least three structurally differing classes of 
synthetic CpG ODNs capable of stimulating cells expressing human TLR9 have 
been described. K-type ODNs (also known as CpG-B) encode multiple CpG 
motifs on a phosphorothioate backbone, and trigger the differenciation of APCs 
as well as the proliferation and activation of B cells [257]. D-type ODNs (also 
known as CpG-A) are constructed using a mixed phosphodiester-phophorothioate 
backbone and contain a single hexameric purine-pyrimidine-CG-purine-pyrimidine 
motif flanked by self-complementary bases that have the potential to form a 
stem-loop structure capped at the 3’end by a poly-G tail. The poly-G tails on the 
individual D-type ODN molecules can interact, resulting in formation of ODN 
clusters. It has been demonstrated that ODNs containing a palindromic CpG motif, 
but lacking the poly-G tail, induce reduced immune activation. D-type ODNs 
directly induce the secretion of IFN-α from pDCs, which supports the subsequent 
maturation of APCs [277]. Finally, C-type ODNs were designed to combine some 
of the important properties of D and K type ODNs. They resemble the K-type 
ODNs in being composed entirely of phosphorothioate nucleotides. Commonly 
expressing a TCGTCG at the 5’end, and containing a K-type motif imbedded in a 
palindromic sequence, this class of ODN can both stimulate B cells to secrete IL-6 
and pDCs to produce IFN-α. Table 9 summarizes structural characteristics and 
immunomodulatory activities of the differently used synthetic ODN types. 
Knowledge in DNA synthesis allows for examination of various modifications and 
their effects on immunological activity. Ongoing studies are directed towards creating 
new ODN structures, varying the numbers and sequences of CpG motifs they 
contain, in an effort to develop ODNs that will be useful therapeutically. In addition, 
determining the ability of the different produced types of ODNs to regulate specific 
elements of the immune system allows achievement of specific therapeutic goals. 
Further clinical trials will lead to a more complete understanding of the potential of 
differently composed CpG ODNs. 
Table 9 : Classes of CpG ODN
3.2.7 Immunotherapeutic Possibilities 
The immunostimulatory potential of prokaryotic DNA has attracted great interest 
over the years. Unmethylated CpG motifs not only stimulate a wide variety of cells 
responsible for the first line of host defence against pathogens, but they deviate this 
early response in a Th1 direction, thus reinforcing the subsequent cellular immune 
mechanisms. Moreover, synthetic CpG DNA analogues have proven to be easy to 
produce and at rather low costs, allowing extended research as well as great hope for 
future clinical use in both veterinary and human medical fields. To date, prophylactic 
and therapeutic potentials of CpG ODNs have been evaluated for various types of 
cancer and states of chronic allergy, as well as against bacterial, viral and parasitical 
diseases. Furthermore, the immunomodulatory effects of CpG DNA have led to the 
assessment of their possible use as adjuvants in immunization. 
The next chapters describe relevant studies and important clinical trials carried out 
in these various settings, highlighting the importance CpG ODNs have gained over 
the past years in medical science. 
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3.2.7.1 Protection of Immunocomprimised Hosts
A considerable benefit of CpG ODNs is their ability to boost immunity in groups 
of individuals with reduced immune function. Indeed, there are several conditions in 
which the activity of the adaptive, but not the innate immune system is compromised. 
Common situations are immaturity of the immune system in neonates, pregnancy, 
and retrovirus infections. 
Pregnancy is associated with a generalized suppression of the adaptive immune 
system, with significant decrease in cell-mediated immunity. These changes 
minimize the risk that the maternal immune system might reject the fetus, but 
simultaneously increase the mother’s risk to infection. Thus, pregnant mice usually 
succumb rapidly to infection by 50 LD50 of Listeria. In contrast, pregnant mice 
treated with CpG ODNs generally survived such challenge. Moreover, in the 
absence of CpG treatment, more than a third of the fetuses became infected within 
a few days of challenge, with the number of infectious organisms per fetus rising 
significantly over time. In contrast, none of the fetuses from CpG ODN-treated 
mothers became infected, indicating a positive effect of the treatment on mother-
to-fetus transmission of Listeria [297].  
Retroviral infections such as FIV, SIV, and HIV induce a progressive deterioration 
in the number and function of the CD4+ T cells accompanied by an increase in 
susceptibility to opportunistic infections. However, retroviral infection does not 
interfere with the activity of the innate immune system until very late in the disease 
process. Indeed, PBMCs from retrovirus-infected primates continue to respond 
strongly to CpG ODN stimulation. In vivo, CpG ODNs designed for human 
use provided significant protection to rhesus macaques infected with SIV, when 
challenged with Leishmania. Parasite load was reduced 300-fold when compared 
with SIV-infected animals treated with control (non-CpG) ODNs [290].
Ongoing studies indicate that CpG treatment also increases the resistance of 
newborns and elderly to infection [298]. Altogether, these findings indicate that 
CpG ODNs significantly reduce susceptibility to infection even in situations where 
the host’s ability to mount an adaptive immune response is compromised. This 
reveals the great prophylactic potential of CpG treatment on a community level : 
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3.2.7.2 Cancer
The decreased capacity of many tumor cell types to induce an appropriate 
immunogenic signal often leads to an insufficient activation of the innate immune 
response and, therefore, to inadequate adaptive immunity resulting in failure to 
eliminate or control cancer. In consideration of the fact that CpG ODNs stimulate 
critical components of the immune system, such as pDCs, B cells, and NK cells, 
involved in recognition and elimination of cancer cells, their use in cancer therapy, 
both alone and in combination with other anti-tumor therapies, has been widely 
studied. In works of recent years, CpG ODNs have indicated promising anti-tumor 
activity in various animal models and in humans. Furthermore, the conferred anti-
tumor activity was shown to be additive or synergistic when CpG ODNs were 
used in combination with various chemotherapies, radiation protocols, surgery, 
monoclonal antibodies and cancer vaccines [299, 300]. 
Observed anti-tumor effects of CpG ODNs depend on the route of application, on the 
CpG ODN class, as well as on the type of tumor. In this way, systemic monotherapy 
with CpG ODNs induced regression of established, highly immunogenic tumors 
[301]. In other tumor models however, systemic injection of CpG ODNs has been 
poorly effective when compared to other routes of applications, such as peritumoral 
injections [302, 303]. A-class CpG ODNs appear to be more effective in 
NK-sensitive tumor models, whereas B-class CpG ODNs indicate anti-tumor 
activity where a broader immune activation, including development of T cell 
responses is required [304].
The combination of CpG ODN-induced TLR9 stimulation with other anti-cancer 
therapies has indicated powerful synergistic properties. Therapy forms that kill tumor 
cells, such as chemotherapy or radiation, lead to the release of tumor cell bodies 
that can be captured by DCs. When such DCs are co-stimulated by CpG ODNs, 
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Targeting susceptible individuals reduces the likelihood of pathogen transmission 
and therefore enhances the community’s resistance to infection.
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the presentation of tumor antigens is enhanced and stronger antitumor CD4+ and 
CD8+ T cell activation is induced as a result. Thus, a combination of CpG ODNs 
with cyclophosphamide or topotecan in an orthopaedic rhabdomyosarcoma model 
resulted in long term survival of the sick mice even when they presented large 
tumors. Interestingly, neither cyclophosphamide nor CpG ODNs alone indicated an 
effect on the  disease [305]. Similarly, CpG ODNs have shown potential to improve 
clinical radiotherapy. Peritumoral administration of CpG ODNs significantly 
delayed tumor growth in combination with single-dose radiation, whereas identical 
CpG ODN treatment alone indicated little or no effect at all. Moreover, in the 
same study, tumors treated with both CpG ODNs and radiation showed histological 
changes characterised by increased necrosis, heavy infiltration by host inflammatory 
cells and reduced tumor density [306]. CpG ODNs also activate NK cells or 
macrophages that lead to enhanced efficacy of antibody therapy by increasing 
effector cell killing of tumor cells decorated with antibody [299]. In a mouse 
model, injection of CpG ODNs thus significantly increased the efficacy 
of monoclonal antibody therapy of lymphoma [307]. These findings were 
linked to the enhancement of antibody-dependent cellular cytotoxicty (ADCC) 
which commonly greatly contributes to the efficacy of anti-tumor antibodies used 
in clinical cancer trials.  Finally, CpG ODNs have also proven to be effective as 
adjuvants in tumor vaccination models. They seem to be the only adjuvants inducing 
anti-tumor responses capable of resulting in the elimination of large tumors [302, 
308]. Compared with other reported adjuvants, they induced increased numbers 
of tumour antigen-specific CD4+ and CD8+ T cells, as well as increased T cell 
INF-g production [309-311]. These vaccine-enhancing effects are probably due 
to both CpG-mediated stimulation of DCs and the generation of Th1-promoting 
cytokines.
Recent clinical trials in humans also indicate that CpG ODNs represent a promising 
agent in the treatment of various cancer types. Several phase I and II clinical 
studies evaluated CpG ODNs either as a monotherapy, or in combination with 
antibody therapy or chemotherapy, in patients with basal cell carcinoma, melanoma, 
cutaneous T cell lymphoma, non-Hodgkin’s lymphoma, renal cell cancer, breast 
cancer or non-small cell lung cancer (table 10). In vivo activation of pDCs and NK 
cells, enhanced ADCC and resulting stabilization of the disease in often more than 
50% of the treated patients could be demonstrated in most of the clinical studies 
after parenteral administration of CpG ODN. Moreover, several studies indicated 
measurable regressions in tumor size after only few low-dose intra-lesional injections 
of CpG ODNs. The immunological properties of CpG ODNs thus indicate a great 
potential in the cancer therapy setting for both animals and humans.
Table 10 : Recent clinical studies using CpG ODN (adapted from Vollmer 2005, [322])
ISS : immunostimulatory sequence, u : Coley Pharmaceutical Group 2004
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3.2.7.3 Allergy
Allergic diseases result from Th2 type immune responses against otherwise harmless 
environmental antigens. Such responses lead to the generation of Th2 cells, which 
produce cytokines such as IL-4 and IL-5 and promote the differentiation of B cells 
into IgE-secreting cells. This IgE binds to the high affinity IgE Fc receptor on the 
surface of mast cells and basophils. Subsequent exposure of these cells to an allergen 
results in the binding of the allergen by surface IgE, cross-linking of the IgE Fc 
receptors, and activation followed by degranulation of the mast cells or basophils. 
A variety of preformed pro-inflammatory and vasoactive compounds including 
histamine, prostaglandins, leukotrienes, and cytokines are released during the process 
of degranulation, which results in a strong, undesired inflammatory response.
There has been an increasing prevalence of allergic diseases in developed countries 
over the last decades. The « hygiene hypothesis » has been proposed as a possible 
explanation for this epidemical trend in allergy : a higher degree of hygiene as well as 
smaller families, inducing less contact of young children to sick siblings and reduced 
microbial stimulation of the TLRs in early life, which could lead to a weaker Th1 
reactivity and a stronger Th2 response to allergens. 
For a long time, therapeutic efforts against allergic disease have been aimed at the 
control of the symptoms triggered by mast cell or basophil degranulation. However, 
preventing the initial generation of the Th2-like immune response against allergens 
seems to be a more fundamental approach to disease therapy. Since Th1 and Th2 
immune responses are typically mutually inhibitory, the induction of a Th1-like 
immune response to an allergen represents a founded alternative to indirectly 
suppress the Th2-like reactivity. On the basis of their potent induction of Th1 
responses, the immunomodulatory properties of CpG ODNs were mainly tested 
in asthma, a common atopic disorder affecting animals and humans. Results of a 
selection of studies are described below.
Numerous reports describe the protective effects of CpG DNA on acute allergic 
inflammation. Kline and co-workers were the first to examine the effects of CpG 
ODNs in a murine model of asthma. They demonstrated that systemic CpG ODN 
administration prevented the development of airway eosinophilia and bronchial 
hyperreactivity in animals sensitized to an allergen [323]. This therapeutic response 
was associated with a decrease in IL-4, and an increase in IFN-g and IL-12 in 
the airway fluid. Broide and colleagues additionally demonstrated that CpG ODN 
administration via systemic or mucosal routes effectively inhibit both systemic 
and airway eosinophilia and that a single such treatment with CpG DNA was at 
least as efficacious as seven consecutive daily injections of corticosteroids [324]. 
Prophylactic effects of CpGs were furthermore shown to last at least 6 weeks after a 
single administration, indicating effective long term prevention of asthma [325].
Reversal of established eosinophilic airway inflammation is more challenging than 
preventing its development.  Nevertheless, Kline et al. demonstrated that systemic 
administration of CpG DNA and allergen was effective at reversing established 
airway eosinophilic inflammation [326]. Mice were thereby sensitized to ovalbulmin 
(OVA), and then challenged repeatedly by inhalation of the same antigen. In these 
animal models, significant airway eosinophilia developed within 48 hours of the first 
challenge, increased with additional challenges, and persisted over several weeks, 
thus allowing the assumption of established OVA-induced airway disease. After 
a course of immunotherapy using low doses of OVA, in the presence or absence 
of CpG ODNs, mice that had been treated with the combination of CpG ODNs 
and OVA were significantly protected against antigen-induced eosinophilic airway 
inflammation. 
Repeated episodes of acute disease or chronic state of inflammation may lead to 
development of irreversible airway alterations collectively referred to as airway 
‘remodelling’. These changes have important functional consequences, including loss 
of distensibility of asthmatic airways, permanent airflow obstruction, and bronchial 
hyperreactivity, all of which persist even in the absence of further exposure to 
antigens. Effects of CpG ODNs on airway ‘remodelling’ have also been examined 
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3.2.7.4 Infectious Diseases
[327]. For this study, a murine model of chronic asthma was created, in which 
OVA-sensitized mice were subjected to repeated inhalational exposure to OVA 
aerosol three times weekly for 6 weeks. These mice developed significant subepithelial 
fibrosis and goblet cell hyperplasia/metaplasia in association with chronic airway 
hyperreactivity. In contrast, mice that were treated with CpG DNA at the time of 
sensitization had significantly fewer features of airway remodelling. These results 
suggest that CpG ODNs associated with a specific antigen may not only be effective 
in reversing established airway disease, but may also prevent chronic inflammatory 
structural changes in the airways seen in chronic asthma.
Early human trials of CpG ODNs for atopic disorders have been promising. The 
immunodominant allergen from ragweed pollen, Amb a1, linked to a CpG ODN 
(Amb a1/immunostimulatory DNA conjugate, AIC), induces a Th1 response in 
PBMCs of patients allergic to ragweed, rather than the Th2 response that follows 
stimulation with Amb a1 alone. Thus, when subjects allergic to ragweed were treated 
out of season with escalating doses of AIC, they demonstrated reductions in ex vivo 
ragweed-specific Th2 responses as well as transient increases in IFN-g [328]. In a 
separate study, six escalating doses of immunotherapy with AIC, administered over a 
short period of time, only moderately suppressed allergy symptoms, but significantly 
suppressed post-seasonal increases in nasal eosinophilia in subjects allergic to ragweed 
[329]. No serious adverse events were observed, and the investigators have since 
reported a « second season » protective effect against ragweed-induced symptoms. 
Other human trials for both allergic rhinitis and asthma are currently ongoing.
Although this field in CpG research is relatively recent, evidence is beginning 
to accumulate for the therapeutic and prophylactic potentials of CpG ODNs in 
infectious disease. Promising effects of immunostimulatory ODNs have been 
described for bacterial, parasitical and viral infection settings. A selection of 
important studies using CpG ODNs in infectious disease models is represented in 
3.2.7.4.1 Bacterial and Parasitical Infections
The first successful experiments concerning therapeutical use of CpGs against 
infectious disease was published in 1998 by Zimmermann and colleagues [330]. 
They studied the infection of mice with the parasite Leishmania major as a model 
for a lethal Th2-driven disease. In a first step, they could demonstrate prophylactic 
potential of CpG ODNs. CpG administration before infection with L. major 
coverted the immmune response in mice to a Th1-dominated phenotype including 
cytokine shift and antibody isotype switch. These responses were then shown to 
be associated with resistance against L. major-induced acute infection and provide 
protection against secondary infection. In a second experiment, Zimmerman and 
colleagues indicated efficacy of CpG ODNs in a post-exposure treatment against the 
infectious pathogen. CpG ODNs were curative when given as late as 20 days after 
lethal L. major infection. In the same way, specific CpG ODNs for the activation of 
human and simian cells were effective in reducing the severity of lesions caused by 
Leishmania infection of macaque monkeys [331]. The latter observations represented 
promising potential of CpGs in the treatment of infections in human beings.
Similarly to the findings linked to the L. major model, CpG ODN treatment has 
been associated with resistance in mice to intracellular bacteria. Inoculation of a 
single dose of CpG ODNs before infection of mice with a lethal dose of Francisella 
tularensis or Listeria monocytogenes induced protection against disease [332]. In 
addition, repeated administration of CpG ODNs conferred long term protection 
against both bacterial species [333]. 
Successful use of CpG ODNs in an infectious disease setting initially seemed to 
be restricted to infections with intracellular pathogens. However, recent works 
have extended these findings, demonstrating efficient treatment of extracellular 
microorganisms. In this way, it was shown that cellulitis in a mature chicken E. 
coli model could be prevented, indicating an immunoprophylactic effect of CpG 
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table 10, and the relevant findings on this exciting topic are summarized below.
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3.2.7.4.2 Viral Infections
ODNs in this context [334]. Moreover, the same group described significantly 
increased survival rates of neonatal chicken challenged with a virulent isolate of  E. 
coli inducing septicaemia, when they were prophylactically treated with CpG ODNs 
either at the stage of embryonated eggs or 2 days after birth [335]. A similar study 
demonstrated reduction of organ invasion by Salmonella enteritidis (SE) in one-day-old 
chickens pretreated with CpG ODNs as well as significantly reduced mortality of 
chickens with acute peritoneal infection due to SE [336].
These successful experiments in mice and birds indicate that CpG ODNs can 
promote both innate and pathogen-specific adaptive immune responses conferring 
to survival of lethal bacterial and parasitical challenges. The precise immunological 
requirements for CpG-induced protection of infection were slightly different in 
the models tested. However, a common feature described in all studies was the 
important antimicrobial function of IFN-g and NK cells. By slowing the early 
growth and spread of pathogens, these CpG-induced features seem to improve the 
host’s ability to mount a subsequent adaptive immune response, which provides 
effective protection against various bacterial and parasitical diseases.
As viruses are intracellular pathogens, the resolution of most viral infections is 
associated with Th1 type immune responses characterized by CTL activity and 
production of IFN-g. Since CpG ODNs are known to promote such responses, it 
appeared feasible to analyze their efficacy in viral infections. 
Pyles and co-workers published in 2002 the first paper on a successful CpG ODN 
therapy against a viral infection [337]. They evaluated the effect of local CpG 
administration in a mouse and guinea pig model of vaginal Herpes Simplex virus 
type 2 (HSV-2) infection. A vaginal epithelial application of CpG ODNs, both 
before or shortly after infection, delayed disease onset and increased survival rates in 
mice challenged with a lethal dose of HSV-2. Furthermore, in the guinea pig model, 
an established infection could be successfully treated. Administration of CpG 
ODNs 21 days after HSV-2 infection reduced the frequency and severity of virus-
induced lesions as well as the magnitude of viral shedding compared with control 
animals. Similarly, application of CpG ODNs was protective against Influenza virus 
[338]. Although mice exhibiting impaired Th1 type immune responses are highly 
susceptible to Influenza virus, treatment of such mice with CpG ODNs enabled the 
animals to rapidly clear virus from their lungs.
CpG ODNs have also been evaluated for their therapeutic potential against 
retroviral infections. The Friend leukaemia virus (FV) infection of mice is a powerful 
model to study general aspects of retroviral immunity. FV is a retroviral complex 
that can induce general immunosuppression and lethal erythroleukemia in mice. 
As with many other viral infections, resistance to FV-induced leukaemia in mice 
was associated with Th1-type immune responses. Enhancement of these responses 
during acute infection by a post-exposure treatment with CpG ODNs beginning 
4 days after FV challenge infection led to prevention of 74% of the mice from 
developing acute leukaemia. CpG-mediated protection was associated with a 
significant reduction of viral loads in treated mice compared to those of control 
animals [339]. However, in stark contrast to the success of post-exposure treatment, 
CpG administration to mice before FV infection accelerated the development of 
virus-induced erythroleukemia. Furthermore, 70% of the animals from a mouse strain 
that was resistant to FV-induced leukaemia developed disease after inoculation with 
CpG ODNs before infection [340]. The explanation for these observations probably 
resides in the stimulation by CpG ODNs of the main target cell populations of FV, 
thus providing an enlarged target cell population for viral infection.
Since HIV in humans induces a Th2 cytokine dominance, it was hypothesized that 
treatment of HIV-1-infected patients with CpG ODNs may be a way to abolish 
the virus infection. Several in vitro experiments have been carried out to assess the 
therapeutic potential of CpGs in an HIV infection setting. Interestingly, the time 
point of CpG treatment of cells greatly influenced the outcome of experiments. 
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Table 11 : Application of CpG ODN in the context of various infectious diseases
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3.2.7.5 Use of CpG ODN as Vaccine Adjuvants
Schlaepfer and colleagues demonstrated that CpG ODNs, administered 2 days 
before or immediately upon infection, inhibited HIV replication nearly completely 
in lymphocyte cultures and prevented loss of CD4+ T cells [341]. Disappointingly 
though, control ODNs without CpG motifs also showed anti-HIV potential, 
indicating that the observed effects were non-specific and not due to TLR9 triggering. 
In another experiment, treatment of a latently infected T cell line with CpG ODNs 
stimulated expression of the pro-inflammatory cytokine NFkB and reactivated 
HIV replication, whereas no effects were evident when ODNs without CpG motifs 
were used. CpG-induced virus reactivation was blocked by chloroquine, indicating 
involvement of TLR9 in these observations [342]. Altogether, the non-specific 
anti-HIV activity of CpG ODNs, their ability to stimulate HIV replication in 
latently infected cells potentially leading to their subsequent elimination, as well as 
their documented ability to link innate and adaptive immune responses make them 
attractive candidates for further study as anti-HIV drugs.
In conclusion, CpG ODN treatment of viral infections seems dangerously 
double-sided in that it could result in an effective therapy but also in an acceleration 
of disease progression, depending on the time point of the treatment. Particular 
attention has to be attributed to treatment against viruses infecting haematopoetic 
cells activated by CpG ODNs, such as HIV, human T cell leukaemia, Measles virus, 
Hepatitis B and Hepatitis C viruses. Thus, the mechanisms of action of CpG ODNs 
must imperatively be precisely analyzed in animal models for such viral infections 
to test for negative side effects before designing clinical studies. An important step 
in this direction is the development of more defined immunostimulatory ODN 
molecules that stimulate only selected cell types of the immune system.
Vaccination remains to date the most effective method to prevent infectious diseases. 
CpG DNA improves the functional activity of professional APCs and triggers the 
production of cytokines and chemokines that support the development of adaptive 
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immune responses. These considerations led many scientists to examine whether 
CpG ODNs could boost the immune response elicited by vaccines, promoting the 
immunogenicity of co-administered antigens.
Early experiments showed that adding CpG ODNs to conventional protein 
antigens, such as OVA, boosted both humoral and cell-mediated responses [350]. 
In these studies however, both OVA and ODNs could freely diffuse from the site 
of injection. The adjuvant properties of CpG ODNs were markedly improved in 
subsequent experiments when proximity of the ODNs to the antigen was maintained. 
Physically binding ODNs to antigen, linking the two with alum, or incorporating 
them into lipid emulsions or vesicles generated specific immune responses 10 to 
1000-fold greater than with antigen alone [351, 352]. The increased adjuvant effects 
observed were attributed by the authors to a more efficient CpG-independent 
uptake, probably mediated by DNA-binding receptors on APCs.
Additional studies established that CpG ODNs could boost the response elicited by 
conventional vaccines. This effect is of particular relevance for pathogens in which 
a strong Th1 response is needed. When CpG ODNs were co-administered with 
vaccines against Influenza virus [353], measles virus [354], Lymphocytic Choriomeningits 
virus [355], Hepatitis B surface antigen [356], or Tetanus toxoid [357], preferential 
production of IFN-g dependent IgG2a antibodies as well as development of 
antigen-specific CTL were observed. However, increased magnitude of 
vaccine-induced immune activity was not always associated with improved vaccine 
efficacy. In this way, mice treated with CpG ODNs plus a Respiratory Syncytial virus 
vaccine, for example, were only modestly protected from virus challenge and were at 
increased risk for pulmonary pathology [358].
Vaccine development was revolutionized by the finding that antigen-encoding 
DNA plasmids could induce cellular and humoral immune responses against foreign 
antigens. DNA vaccines are constructed with an antigen-encoding gene incorporated 
into a plasmid backbone of bacterial DNA. As plasmid vectors typically contain large 
numbers of immunostimulatory CpG motifs, it seemed relevant to examine their 
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contribution to the observed immunological effects linked to DNA vaccination, 
such as production of large amounts of IFN-g and IL-12. Treating plasmids with 
DNAse or Sss I methylase (selectively methylates the cytosine of CpG dinucleotides) 
uniformly eliminated cytokine production, indicating that the DNA is responsible 
for the cytokine release during such vaccination methods [359]. Additionally, the 
isotype of antigen-specific antibodies induced by plasmid vaccination was also 
examined after DNA vaccination, in order to assess possible effects of CpG motifs 
embedded in the plasmid. Mice immunized with a Malaria protein (CSP) emulsified 
in complete Freund’s adjuvant primarily produce IgG1 anti-CSP antibodies. In 
contrast, injection of CSP-encoding DNA vaccines preferentially stimulated IgG2a 
antibody production [359]. As IFN-g promotes IgM to IgG2a isotype switching, 
these findings are consistent with CpG-motif-induced IFN-g production contributing 
to preferential production of IgG2a in immunized animals.
Subsequent studies demonstrated that both co-administration of CpG ODNs with 
DNA vaccines as well as engineering of additional CpG motifs into plasmid vectors 
significantly improved vaccine immunogenicity. Although adding CpG motifs to 
DNA vaccines appears to decrease the amount of vaccine required to induce 
antigen-specific antibody production, it seems that high numbers of CpG 
motifs are not always optimal. In this way, the immune response induced 
by a CpG-optimized plasmid is no greater than that of a conventional plasmid 
when both are administered at high concentrations [360]. Similarly, dose-response 
studies indicate that the ability of CpG ODNs to stimulate spleen cells to secrete 
cytokines and Ig in vitro reaches a plateau, and then begins to fall. In one report, 
introducing 16 additional CpG motifs into a DNA vaccine improved the humoral 
response elicited in vivo, while introducing 50 such motifs reduced the response 
[361]. These findings suggest that the maximal effect of CpG motifs may require 
relatively low doses of DNA. Moreover, the adjuvant effect is greatest when antigen 
dose is limited. Indeed, modest adjuvanticity was observed when large amounts of 
antigen was delivered [362]. This phenomenon is referred to as the antigen-sparing 
effect of CpG DNA.
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3.2.7.6 Safety Concerns
Two main clinical trials in which CpG ODNs were used as vaccine adjuvants have 
been described. The first was a double blind study in which CpG ODNs were 
co-administered many times with Energix B, the licensed Hepatitis B vaccine. 
Healthy adult volunteers immunized with the vaccine plus CpG ODNs developed 
significantly higher mean antibody titres, more rapidly than those immunized with 
vaccine alone. In the second double blind study, CpG ODNs were co-administered 
with Fluarix Influenza virus vaccine. Inclusion of CpG ODNs did not increase 
antibody response of naïve recipients when compared to Fluarix alone, but increased 
antibody titres among individuals with pre-existing Influenza virus-specific 
antibodies. Moreover, PBMCs from CpG ODN-vaccinated subjects responded 
to in vitro re-stimulation by secreting markedly higher levels of IFN-g than the 
PBMCs from control vaccines. 
Altogether, these observations indicate a vast potential for use of CpG as adjuvants 
in immunization studies for a wide variety of diseases in different species. Future 
studies will allow determination of optimal structure and dose of CpG ODN in 
combination with vaccines, thus enhancing efficacy of currently used protocols or 
initiating new possibilities in areas where vaccination methods have to date not been 
successful.  
Several potential safety issues are raised by the use of CpG ODNs as immunoprotective 
agents. Concerns regarding enhancement of the immunogenicity of self proteins 
at the site of delivery, thereby triggering the development of autoimmune disease, 
as well as production of cytokines that may increase host susceptibility to other 
harmful agents, have mainly attracted attention during trials on mice. 
The ability of CpG DNA to promote the development of autoimmune disease 
is supported by studies showing that bacterial DNA can elicit the production of 
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anti-double-stranded DNA auto-antibodies in normal mice [363] and accelerate 
the development of immune disease in lupus-prone animals [364]. CpG DNA 
also stimulates the production of IL-6 and blocks the apoptotic death of activated 
lymphocytes. Both these functions are known to predispose to the development of 
autoimmune disease by facilitating the persistence of self-reactive lymphocytes.
There is also evidence that CpG ODNs enhance the production of TNF-α, a 
cytokine associated with the development of life-threatening toxic shock. When 
CpG ODNs were administered together with other agents that promote TNF-α 
release (such as LPS or D-galactosamine), severe mortality and morbidity were 
observed [365].
A more recent report showed that daily administration of CpG ODNs for three weeks 
can cause dramatic changes in the architecture of the primary lymph organs and 
induce haemorrhagic ascites and multifocal liver necrosis [294]. However, given the 
relatively long duration CpG ODN-induced immunological effects (days to weeks), 
daily treatment over long periods of time should not be required. Earlier studies had 
examined whether toxicity might occur under more normal circumstances: CpG 
ODNs at doses equal to or exceeding that typically used in adjuvant experiments 
was injected weekly for 4 months into normal mice. No adverse health effects 
were observed in any of the animals and none showed macroscopic or microscopic 
evidence of tissue damage or inflammation [360]. Similarly, no undesired effects 
were noted in studies involving delivery of CpG ODNs to non-human primates 
[366]. Thus, although concern remains that CpG ODNs might have adverse effects 
under certain conditions, there is to date no evidence that CpG ODN administration 
is toxic to normal, healthy animals, when following a protocol designed to provide 
protection from infection. 
CpG ODNs have been considered safe enough and are authorized for clinical trials 
in animals as well as in humans. Clinical studies are proceeding with subjects being 
closely monitored for the development of adverse reactions. To date, toxicity has 
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not been observed in normal animals or humans when CpG ODNs were used as 
immunoprotective agents, vaccine adjuvants, or therapeutic instruments, suggesting 
a promising future for more common use of CpGs in various disease settings. 
Literature

4. Material and Methods
4.1 Objectives
The following experiments and objectives were pursued in the course of this study :
	 •	
	 •
 
	 •
	 •
 
	 •
Prophylactic treatment over a period of 5 consecutive days of spf 
cats using either dSLIM™, an optimally synthesized molecule 
containing various CpG motifs, or a placebo substance
Challenge infection of all cats with the FIV-Glasgow 8 (GL8) 
strain
Characterization of the host’s immune response both during 
treatment and after challenge infection, by assessment of relevant 
cytokine responses in whole blood, as well as evaluation of the 
potential to produce various cytokines by PBMCs isolated from 
whole blood of the cats and stimulated in vitro
Determination of the degree of protection elicited by the treatment, 
through analysis of various immunological and virological 
parameters in the cats such as seroconversion, infectious virus 
isolation, proviral and viral load mesurments in peripheral blood 
lymphocytes and plasma
Evaluation of treatment effect on the transmission potential of 
FIV infection, by examination of excreted viral loads in saliva 
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4.2 General Information and Important Methods
Several methods have been repeatedly used in the laboratory during the course of 
the experiment. Brief theoretical indications, including aim and principals of these 
methods, as well as material used, are described below.
4.2.1 Enzyme-Linked Immunosorbent Assay
ELISA is a sensitive immunoassay which uses an enzyme linked to an antibody or 
antigen as a marker for the detection of a specific protein, often another antigen or 
antibody. It is often used as a diagnostic test to determine exposure to a particular 
infectious agent, by identifying antibodies or antigen present in a blood sample. In 
the case of FIV, antibodies against the TM or the SU glycoproteins are commonly 
detected, and have proven to give sensitive indications to the presence of an infection 
in cats [152]. For this purpose, recombinant FIV SU or TM proteins are mixed with 
a coating buffer and allowed to bind to the bottom of microtitre plate wells. The 
plates are incubated for 3 hours at 37°C and then overnight at 4°C, to allow complete 
binding of the antigens. They are subsequently washed with a special ELISA wash 
buffer containing NaCl and Tween-20 (polyoxyethylene sorbitan monolaurate), 
filled with PBS, and stored at -20 °C until use. 
Feline plasma samples are added to the wells and allowed to complex with the 
bound antigen. Unbound products are then removed with several washes of PBS. 
Goat anti-cat antibodies labeled with HRP, are allowed to bind to the captured 
antibodies from the cat plasma samples, and unbound products are again washed 
out several times with ELISA wash buffer. The assay is then quantified by measuring 
the amount of labeled antibody bound to the matrix through the use of ABTS 
(2,2’-azo-bis(3-ethylbenzthiazoline-6-sulfonic acid), a colorimetric substrate of 
HRP. Optical density (OD) of each sample is then determined by an absorbance 
reader, and the results are compared to positive controls in order to confirm or 
reject presence of antibodies to FIV. A major advantage of this technique is that the 
plasma samples measured must not be specifically treated prior to use. Moreover, 
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4.2.2 Nucleic Acid Extractions
Extraction of nucleic acids from the collected samples is necessary for subsequent 
specific quantitative analysis by PCR. For this purpose, the nucleic acid extraction 
apparatus MagNa Pure1 was used in this study, and corresponding protocols, 
recommended by the manufacturer, were followed. The isolation and purification of 
total nucleic acids (TNA), as well as mRNA were accomplished on several occasions 
during the course of this experiment. Both procedures are based on magnetic bead 
particles (MGP) technology.
During TNA extraction, DNA as well as RNA are isolated. In a first step, addition 
of lysis/binding buffer to the sample results in a complete lysis of proteins by 
denaturation. DNA and RNA are released and simultaneously stabilized. Proteinase 
K is then added to the sample and starts digestion of the denaturated proteins. 
Next, TNA molecules bind to the surface of added MGPs, due to the high ionic 
strength of the previously attached lysis/binding buffer. Several washes with specific 
wash buffers remove impurities like denatured proteins and cellular debris from the 
sample to finally allow elution of purified TNA.
Extraction of mRNA relies on the presence of a poly-adenosine (A) tail at the 3’ end 
of mRNA molecules. A first lysis step allows release of mRNA and inactivation of 
nucleases present in the sample. The lysate is incubated with a capture buffer, which 
consists of biotin-labelled oligo dT diluted in a specific hybridization substance. The 
latter allows the biotin-labelled oligo dT to bind to the poly-A residues of mRNA. 
The complexes thus formed are then immobilized onto the surfaces of streptavidin-coated 
magnetic beads (SMP). Unbound substances are removed by several washing steps 
1. Roche Diahnostics, Rotkreuz, Switzerland
these assays are very sensitive, rendering them reliable for diagnostic and research 
purposes. Complementary information about use of ELISA in this experiment can 
be found under 4.4.4.2.1.
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4.2.3 Real-Time Florogenic Polymerase Chain Reaction
The conventional PCR allows exponential increase in the amount of copies of a 
desired gene in a determined number of amplification cycles. Flanking regions of the 
desired sequence must be known in order to design oligonucleotide primers which 
can hibridize to the beginning and the end of the target. A thermophilic enzyme, the 
Taq DNA polymerase, purified from the hot springs bacterium Thermus aquaticus, 
then catalyzes specific DNA synthesis directed from the primers. Amplification 
cycles consist each in temperature variations allowing three fundamental steps :
	 •
 
	 •
	 •
All 3 steps above are considered as one cycle; amplification of a DNA template is 
usually done over 45 cycles. A thermal cycler programmed with a protocol that goes 
through all three steps of a cycle for the desired amount of cycles is used for PCR 
reactions in general.
In order to amplify a RNA sequence, complementary DNA (cDNA) has to be 
Hybridization or annealing of two primers (one is a reverse primer 
and the other is a forward primer) : the solution is quickly cooled 
to 54ºC to let the primers anneal to a DNA strand; one primer 
anneals to the 3’ end of the target while the other primer anneals 
to the 3’ end of the complementary target strand
DNA synthesis or elongation: the solution is then heated to 72ºC, 
the optimal temperature for Taq DNA polymerase 
Denaturation of the DNA strand: the solution is heated at 95ºC 
for 15 seconds
and addition of DNase solution allows to digest DNA present in the sample. Finally, 
the purified mRNA is eluted.
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synthesized using a RT enzyme before initiation of the standard PCR described 
above. Incubation for 1 hour at 37ºC, the optimal temperature for the RT, is needed 
for this additional step.
The real-time PCR is a more recent system allowing not only amplification, but 
also quantification of a DNA or RNA sequence using a fluorescent reporter [367]. 
In addition to a forward and a reverse primer, an oligonucleotide, called probe, 
which specifically binds to the target sequence between the hybridization sites 
of the primers, must be added to the reaction. Importantly, a reporter fluorescent 
dye and a quencher dye are attached to the probe. While the probe is intact, the 
spacial proximity of the quencher greatly reduces the fluorescence emitted by the 
reporter dye. During amplification however, annealing of the probe to its target 
sequence generates a substrate that is cleaved by the 5’ nuclease activity of Taq DNA 
polymerase when the enzyme extends from an upstream primer into the region of 
the probe. This cleavage of the probe separates the reporter dye from the quencher 
dye, increasing the reporter dye signal. Simultaneously, the probe is removed 
from the target strand, allowing primer extension to continue to the end of the 
template strand. Additional reporter dye molecules are cleaved from their respective 
probes with each cycle, inducing a logarithmic increase in fluorescence intensity 
proportional to the amount of template produced. Principles of the real-time PCR 
are shown in figure 9.
 
The ABI PRISM 7700 Sequence Detection System2 is a flexible system designed to 
take full advantage of the benefits of fluorogenic probe detection. The 7700 system 
has a built-in thermal cycler and a laser directed via fiber optic cables to each of 96 
sample wells. The fluorescence emission travels back through the cables to a camera 
detector. At the end of a determined amount of cycles, data is stored and fluorescence 
intensity of each sample can be visualized.
2. Applied Biosystems, Foster City, CA, USA
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Figure 9 : The principles of Real-Time PCR
4.2.3.4 Peripheral Blood Mononuclear Cell Isolation
For in vitro analyses concerning FIV, it is essential to isolate and cultivate successfully 
PBMCs, as they are the targets of infection. For this purpose, the Ficoll-Hypaque 
gradient separation of cells from whole blood is commonly used [361]. Due to the 
density gradient, centrifugation of whole blood carefully layered on Ficoll-Hypaque, 
allows separation of different blood components as shown in figure 10.
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In our experiment, PBMC isolation was accomplished using the following protocol : 
	 •	
 
	 •	
 
	 •	
 
	 •
 
	 •	
 
	 •
 
	 •			
															•
Feline ethylenediaminetetraacaetic acid (EDTA)-treated blood 
was collected in evacuated tubes and centrifuged for 10 minutes at 
1500rpm. Plasma was aspirated and replaced by the same volume 
of HBSS 1x
Hank’s balanced salt solution (HBSS) was carefully mixed with the 
blood and the mixture was slowly poured over 4 ml Histopaque®3 
previously displaced in a 15ml conical centrifuge tube
A gradient was created by centrifugation at 2000rpm for 25 
minutes
The buffy coat fraction was collected and washed in 10ml HBSS 
previously aliquoted in 15ml centrifuge tubes
The cells were pelleted by centrifugation at 1200rpm for 10 
minutes
Complete Roswell Park Memorial Institute (RPMI) medium (RPMI 
1640 supplemented with 10 % feotal calf serum (FCS), Glutamin, 
1U Penicillin, 100μg/ml Streptomycin, 2,7% Sodium Bicarbonate) 
was used for resuspension and further cultivation of the cells
10μg conA4/ml of cell culture were added to promote IL-2 receptor 
expression on the surface of the cells
3. Sigma, St.Louis, MO, USA
4. Sigma, St.Louis, MO, USA
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After 24 hours incubation of the cells at 37°C, 5% CO2, 20U 
4.3 Pre-experiment Formalities
4.3.1 Cats
A total of 20 male spf domestic cats were shipped from Liberty Research Inc.5 
at approximately 10 weeks of age. They were divided at their arrival into 2 groups 
of 10 cats each, equally distributing individuals according to their age and litter 
5. Waverly, NY, USA
 
	 •
PBMCs treated in this way generally survive a total of 4 to 6 weeks.
Medium was partially replaced by fresh IL-2-supplemented 
complete RPMI every 3 days
Figure 10 : PBMC isolation by Ficoll-Hypaque® gradient
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IL-2 / ml culture was added in order to stimulate proliferation and 
survival of the cells
4.3.2 Adaptation Period and Assessment of Health Status
An adaptation period of 8 weeks permitted the establishment of essential social 
trust between the cats and the persons responsible for the experiment. With the 
intention of ensuring minimal levels of stress for the animals, great importance was 
attributed to daily visiting and playing with the cats during this period as well as 
during the entire duration of the experiment. 
In order to certify their health status was in conformity with the standards of the 
experiment, the cats were clinically examined by a veterinarian shortly after their 
arrival. At the same time, EDTA-supplemented and heparin-supplemented blood 
samples were collected under light anaesthesia (see 4.4.3) to rule out possible 
haematological and biochemical deviations, as well as direct presence of FeLV or 
FIV infections. Serum samples were also tested for presence of antibodies to feline 
parvovirus (FPV), feline coronavirus (FCoV), feline herpesvirus (FHV), and feline 
calicivirus (FCV) and FIV as well as presence of p27, a marker protein for FeLV 
viremia. Additionally, oropharyngeal, ocular and rectal swabs were collected, in order 
to test for undesired occurrence of FPV, FCoV, FHV,  FCV. 
Haematological status was assessed from EDTA-supplemented blood using 
the Cell Dyn 3500 (CD 3500) Haematology Analyser6 and clinical chemistry 
parameters were tested in heparinated plasma by the Cobas Integra 800 Analyzer7 
after centrifugation of the blood samples at 3000rpm for 10 minutes. For the 
testing of presence of retroviral infections (FIV and FeLV), TNA was extracted 
5. Waverly, NY, USA
6. Abbott Diagnostics, Santa Clara, CA, U 
7. Roche Diagnostics, Rotkreuz, Switzerland
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provenance. Thus, the average age of the cats in both groups was 9.9 weeks. Each 
group was housed separately, in an animal-friendly environment and under optimal 
ethological conditions.
8. MagNA Pure LC TNA isolation kit, Roche GmbH, Mannheim, Germany
9. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA
10. MagNA Pure LC TNA isolation kit, Roche GmbH, Mannheim Germany
11. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA 
4.4 Course of the study
The total duration of the present experiment was of 12 weeks. Treatment protocols, 
challenge method, as well as description of subsequent sample collections and 
from EDTA- supplemented whole blood samples according to the manufacturer’s 
recommendation8, and real-time PCR analyses9 were subsequently carried out under 
conditions described elsewhere [369, 370].
Cotton swabs with plastic stems were either applied to the medial corner of both 
eyes for the collection of ocular secretions, rubbed against the gums and inner cheek 
pouches in the mouth or introduced into the rectum for collection of oropharyngeal 
and rectal material respectively. Persons responsible for collecting these samples held 
only the plastic stems and carefully avoided touching the cotton swab, in order to 
minimize contamination. At the time of collection, the swabs were immediately 
placed in 1,5ml Eppendorf tubes, with the cotton swab thereby facing the bottom 
of the tube. In order to prepare the samples for subsequent TNA extraction, 200μl 
of HBSS were first added to each Eppendorf tube, before incubation at 42°C for 
10 minutes to moisten the swabs. After centrifugation at 8000rpm for 1 minute, 
the swabs were inversed in the tubes so that the cotton part was facing upward, and 
centrifuged again for 1 minute at 8000rpm, to ensure that an optimal amount of 
material was now contained in the HBSS. The swabs were then discarded and 300μl 
of TNA lysis buffer were added to each sample before proceeding to TNA extraction 
according to the manufacturer’s recommendations10. Extracted material from rectal 
swabs was analyzed for the presence of FPV and FCoV, and extracted material from 
ocular and oropharyngeal swabs was tested for presence of FCV and FHV using 
real-time PCR11. The assays and PCR conditions used for these measurements have 
been published in the past 10 years [371-373].
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Figure 11: Schedule of the study
4.4.1 Treatment Protocol
For the prophylactic treatment of the cats against subsequent FIV challenge, 
dSLIM™ was provided by Mologen AG12. dSLIM™ is a non-coding DNA 
sequence of immunomodulating conformation comprising non-methylated CpG 
dinucleotide motifs. Figure 12 shows the configuration of this covalently-closed 
dumbbell-shaped double stem-loop molecule. The ODN of dSLIM™ are linked 
with a phosphodiester backbone, and its particular dumbbell-shaped structure 
allows protection of the open ends of the ODN against degradation by DNases. This 
additionally permits to avoid the use of phosphorothioate as backbone modification, 
which is linked to a series of unfavourable side effects (see 3.2.6).
12. Berlin, Germany
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Figure 12 : Schematic representation of the dSLIM™ molecule
laboratory work are detailed below.  Time points of these different steps are 
represented in figure 11.     
The 10 remaining cats were treated simultaneously with subcutaneous injections of a 
placebo (phosphate-buffered saline, PBS).
Table 12 : Administration protocol of  dSLIM™ in vivo for the 5-day treatment period prior to 
FIV challenge infection. s.c: subcutaneous, i.v: intravenous, i.p:intraperitoneal (  i.v,    s.c)
4.4.2 Challenge Infection
The challenge infection was carried out 24 hours after the last treatment injection. 
After rapid thawing of the viral stock and preparation of individual doses on ice, all 
cats were infected intraperitoneally with 50 cat infectious doses 50 (50 CID50) of 
the GL8 strain of FIV previously titrated in vivo13.
13. kindly provided by Dr. Magaret Hosie and Prof. O. Jarret, University of Glasgow, Great Britain
In vitro and in vivo experiments with dSLIM™ have indicated that this molecule 
possesses the biological and immunological properties of a typical C-type CpG 
ODN described in section 3.2.6. Importantly, successful immunomodulation of 
both murine and human cells have demonstrated that the effect of dSLIM ™ is not 
restricted to one species. Furthermore, repeated injection of dSLIM™ into mice 
induced no adverse reactions or signs of toxicity, and several human clinical trials 
confirmed the safety of its administration in vivo [374].
In this study, 10 cats were treated with dSLIM™ on 5 consecutive days before 
challenge infection, using the following protocol.  
120
Material and Methods
4.4.3 Clinical Examinations, Blood and Oropharyngeal Swab collections 
The cats were thoroughly clinically examined by a veterinarian and blood samples 
were collected just before the first treatment injection in order to obtain base 
values of the parameters subsequently analyzed in the course of the experiment. 
Auscultations were carried out daily during the treatment period and additional 
blood samples were collected on the third day of treatment, allowing assessment 
of any clinical symptoms or haematological and immune alterations initiated by 
the injections of dSLIM™. On the morning before challenge infection, the cats 
were again clinically examined, and one oropharyngeal swab per cat was collected 
in addition to the blood samples. From this time point on, clinical examinations, 
as well as blood and oropharyngeal swab collections were performed weekly for 
a total of 11 weeks, with the exception of the 10th week. 2 ml each of heparin and 
EDTA-supplemented blood were thereby collected, as certain subsequent analyses 
imperatively required either one of these anti-coagulants.
In order to minimize the stress conferred to the cats during the sample collections, 
they were administered a combination of 0,2 ml/kg ketamin14 and 0,02 ml/kg 
midazolam15, inducing short term anaesthesia. The doses were adapted to the weights 
of the growing cats throughout the experiment. Apart from gradual resistance to 
ketamin leading to slightly reduced anaesthetical efficacy over time, no undesired 
side effects linked to this combination were observed.
121
Material and Methods
4.4.4 Laboratory Analysis of Relevant Host and Viral Parameters
On the same day as each blood collection, the blood cell count of each cat was 
measured from 400μl of EDTA-supplemented blood using the CD 3500 
Haematology Analyser16. Clinical chemistry parameters were analyzed by the Cobas 
4.4.4.1 Haematology and Clinical Chemistry
14. Narketan®10, Vetoquinol AG, Belp, CH
15. Dormicum®, Roche Pharma AG, Reinach, CH
16. Abbott Diagnostics, Santa Clara, CA, USA
Antibodies directed against the FIV TM protein were measured with ELISA under 
conditions described elsewhere [152]. Briefly, recombinant FIV TM antigens18 
were pre-coated on ELISA plates, and goat anti-cat IgG conjugated to HRP19 was 
used as conjugate. Presence of anti-TM antibodies in 15μl feline plasma samples 
was determined by absorbance measured in a Spectra max PLUS ELISA reader20. 
To standardize OD values between different runs, standard positive and negative 
control sera respectively collected from an experimentally FIV-ZH2-infected cat 
with high antibody titres, and from a non-infected spf cat were included in every 
run. All samples were tested in duplicates, and OD values of plasma samples from 
our cats were expressed as percentage of the positive control OD value. General 
information about this method can be viewed under 4.2.1.
4.4.4.2.1 Seroconversion
The expression of both IL-12 and IL-10 were tested as indicators for Th1 and 
4.4.4.2.2 Determination of Cytokine Expression
In this study, the induction of immune responses was mainly assessed by the 
determination of seroconversion after challenge infection and by the quantitative 
and comparative analyses of cytokine levels produced during both the treatment 
period and after FIV challenge.
4.4.4.2 Evaluation of Host Immune Parameters
17. Roche Diagnostics, Rotkreuz, Switzerland
18. previously produced in our laboratory by Dr. J. Huder
19. Jackson Immunoresearch Laboratories, Bar Harbour, Main, USA
20. Biotech AG, Basel
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Integra system17 using 500μl heparinated plasma obtained after centrifugation of the 
blood samples at 3000rpm for 10 minutes.
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Th2 immune responses respectively, and quantification of glyceraldehyde-3-
phosphatedehydrogenase (GAPDH), a catalytic enzyme produced by a so-called 
« housekeeping » gene, allowed standardization of these measurements. An inherent 
assumption in the use of housekeeping genes is that expression of these genes 
remains constant in the cells or tissues under investigation. Apart from its important 
role in gylcolysis, GAPDH was reported to be involved in the processes of DNA 
replication, DNA repair, nuclear RNA export, membrane fusion and microtubule 
bundling. Most importantly, GAPDH is known to be ubiquitously expressed in 
stable quantities within a healthy individual. Although its production rate may 
diverge between tissues or cells analyzed and in the course of different pathologies, 
age and gender have been shown not to alter this gene’s expression. 
With the objective to investigate whether treatment and/or infection resulted in 
altered production or « production potential » of these cytokines, their mRNA levels in 
PBMCs were measured in 2 separate experiments described below. It must additionally 
be noted here that presence of IL-12 in our study was determined by detection of 
mRNA for the p40 subunit of this cytokine. The PCR assays and conditions used in 
this study have been developed previously in our laboratory [375, 376].
4.4.4.2.2.1 Cytokine Measurements in Whole Blood
Immediately after collecting the blood from each cat, 100μl EDTA-supplemented 
blood was mixed with 300μl of previously aliquoted mRNA lysis buffer. The samples 
were stored at -80°C until further analysis.
mRNA was extracted according to the manufacturer’s recommendations21. Finally, 
real-time PCR analysis22 of GAPDH, IL-12 and IL-10 in the extracted samples 
was performed simultaneously with previously prepared standard dilutions of each 
cytokine, in order to assure quantitative measurements. 
21. MagNA Pure LC mRNA isolation kit, Roche GmbH, Mannheim Germany
22. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA
The aim of this experiment was to determine whether PBMCs of treated cats 
revealed greater potential to produce specific cytokines in vitro, in comparison to 
PBMCs of control cats. It seemed relevant to further assess the influence of FIV 
infection on this potential.
In order to pursue this objective, PBMCs from each individual cat were isolated at 
2 different time points during the experiment, namely on the day of FIV infection, 
and at week 8 post-challenge. The purified PBMCs were then distributed in 3 
different wells of a 24-well plate, each well containing 5x105 cells in a total volume 
of 1 ml complete RPMI 1640 with Glutamax I™23 (equivalent to L-glutamin) 
supplemented with 20U recombinant IL-2/ml culture. The PBMCs in the three 
different wells were treated as follows :
 1. 
 
 2. 
 
 3. 
ConA is a lectin protein from the jackbean (Canavalia ensiformis), and LPS is a 
major suprastructure of the membrane of  Gram-negative bacteria. Both are known 
to be potent lymphocyte mitogens.
After 24 hours of incubation at 37°C and 5% CO2, the cells were harvested by 
centrifugation of the plates at 2000rpm for 12 minutes, the supernatant was removed, 
and 400μl mRNA lysis buffer was added to the cells. Until further analysis, the lysed 
cells were then stored at -80°C in labelled 1,5ml Eppendorf tubes.
Unstimulated : addition of 10μl complete RPMI 1640 with 
Glutamax™ I
Stimulated with ConA : addition of  10μg ConA24
Stimulated with LPS : addition of 1μg LPS25
23. GIBCO®, Invitrogen, Carlsbad, CA, USA
24. Sigma, St.Louis, MO, USA
25. Sigma, St.Louis, MO, USA
4.4.4.2.2.2 Cytokine Measurements in Stimulated and Unstimulated PBMC
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In order to determine the FIV proviral load in the cats’ PBMCs in a comparable 
manner between individuals, TNA was extracted27 from a whole blood volume 
containing 106 white blood cells (WBC), and subsequently analyzed by real-time 
PCR28. The total WBC count from the weekly haematological analysis permitted 
to estimate the volume needed for extraction. TNA extractions were carried out as 
recommended by the manufacturer, and the maximal blood volume thereby used was 
200μl. In cases where 106 WBC were comprised in less than 200μl, HBSS was added 
to compensate for the missing volume.
The detection of the FIV load in plasma was determined with similar methods. 
4.4.4.3.1 Measurements of Proviral and Viral Loads in Blood
mRNA was later on extracted26, and quantitative analysis of GAPDH, IL-10 and 
IL-12 p40 was performed as described above (4.4.4.2.2.1)  
The degree of protection of the cats against the challenge FIV infection was evaluated 
with indicators for host-virus contact, as well as for both established and productive 
infection. Early detectable host response to foreign antigen can be assessed by the 
presence and level of antibodies in plasma. Further transgression of the host’s early 
immunity barriers is measured by integration of viral genome in target lymphocytes. 
Viremia and presence of virus in saliva indicate in turn effective viral replication and 
liberation of virions. Capacity of these newly produced viral particles to infect target 
cells is crucial to viral survival within the host and transmission to other cats. The 
analyses described below were thus designed to evaluate the effect of treatment on the 
evolution of FIV infection in the host.
4.4.4.3 Evolution of FIV Infection
26. MagNA Pure LC mRNA isolation kit, Roche GmbH, Mannheim Germany
27. MagNA Pure LC TNA isolation kit, Roche GmbH, Mannheim, Germany
28. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA
29. MagNA Pure LC TNA isolation kit, Roche GmbH, Mannheim, Germany
30. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA
31. MagNA Pure LC TNA isolation kit, Roche GmbH, Mannheim, Germany
32. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA
Presence of infectious virus in plasma from our infected cats was determined 
between weeks 2 and 8 of the study, with the exception of week 6. On each of these 
weeks, a PBMC culture with blood from 2 spf cats was established 2 days before 
blood collection. 24 hours after their isolation, the cells were stimulated with 20U 
IL-2/ml culture. On the day of blood collection, the cells were distributed into the 
wells of a 24-well plate, at a concentration of 5x105 cells per well. 500μl of heparin-
supplemented blood collected from our cats was centrifuged twice consecutively 
at 3000rpm for 10 minutes, in order to minimize cellular contamination of the 
samples. 100μl of obtained plasma was then added to one well for each individual 
cat. Plasma of the same spf cats from which the PBMCs were isolated served as 
negative control, and FIV-GL8 from our viral stock was used as positive control. 
After incubation of the inoculated cells at 37°C, 5 % CO2 for 3 hours, 600μl of 
fresh, complete RPMI medium supplemented with 13 U IL-2 were added. The 
cells then remained in culture for 4 weeks. Once a week, 500μl was collected from 
the cultures and replaced by 500μl complete RPMI freshly supplemented with 10U 
IL-2. The samples obtained were centrifuged at 3000rpm for 10 minutes, and the 
supernatant was separated from the cell pellet before storage at -80°C. Later 
on, TNA was extracted31 from the supernatant samples thus collected on the 
fourth week post-inoculation, according to the manufacturer’s recommendation. 
The presence of FIV RNA was analyzed by real-time RT-PCR32.
4.4.4.3.2 Isolation of Virus from Plasma
TNA was first extracted29 from plasma samples obtained by centrifugation of 500 
μl EDTA- supplemented blood at 3500rpm, for 10 minutes. These samples, together 
with previously established standard dilutions, were then analyzed by quantitative 
real-time RT-PCR30.
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The oropharyngeal swabs collected weekly were prepared for TNA extraction as 
described above (4.3.2). TNA was extracted33 according to the manufacturer’s 
recommendations. The samples thus obtained were analyzed for presence of FIV 
RNA by real-time RT-PCR34.
4.4.4.3.3 Measurements of Viral Load in Saliva
All the results obtained in the course of the study were entered in Microsoft® Excel 
2000 for further evaluation. Haematological and biochemical blood values, as well 
as host immune and viral parameters were subsequently analyzed using appropriate 
statistical programs35.
4.4.5 Statistical Analysis
33. MagNA Pure LC TNA isolation kit, Roche GmbH, Mannheim, Germany 
34. ABI Prism 7700 sequence detector, Applied Biosystems, Foster City, CA, USA
35. Stat view for Windows, version 5.0, Graph Pad Prism®, version 3.0   

5. Results
Regular clinical examinations of the cats and fluid laboratory work permitted 
the collection of a great amount of data during the course of this study. Clinical 
examinations and blood collections took place on a weekly basis and for a total of 11 
weeks (with the exception of week 10), starting from the time point of FIV challenge 
infection (week 0, w0). Additional data were collected during the treatment, namely 
3 days before challenge (week 0 -3 days, w0-3d), as well as immediately before the 
onset of the treatment, 5 days before challenge (week 0-5 days, w0-5d). In order to 
allow optimal comparison of clinical observations and experimental results obtained 
from both groups, the collected data were represented first graphically, and then 
thoroughly analyzed by the appropriate statistical tests.
The graphics displayed in this section show mean group values obtained for distinct 
parameters evaluated during the study. For clearer understanding, standard deviations 
are not shown in the graphics. However, particularly high variations within the 
groups, as well as exceptional individual cases are mentioned when necessary. Only 
those graphics either representing the parameters for which significant differences 
between groups were observed, or demonstrating other relevant elements, have been 
selected to illustrate this chapter. 
All collected data were tested for normal distribution using the Kolmogorov-
Smirnov test, and subsequently analyzed according to this test’s results. In this 
way, data from both groups, showing normal distribution in every week, were then 
compared using a Student’s T-test for each week separately. In contrast, data which 
failed to show normal distribution in one or more weeks were evaluated for each 
week separately, by the Mann Whitney U-test. Parametrical data collected for each 
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group was also statistically evaluated for significance in alterations over time. All 
comparative results thus obtained were systematically considered significant when 
p>0.05. Significant differences between the groups are illustrated in the graphics 
by a star (V). Also, selected significant alterations over time are indicated in the 
diagrams by a bracket (        ). All other significant parametrical alterations are 
described in the text only, in order to avoid confusion in the figures.
5.1 Clinical Examination
The cats were weighed during weekly blood collections. The effects of the conferred 
anaesthesia enabled to obtain more precise values. The mean weight values of 
both groups increased continuously during the entire duration of the study, as 
normally expected for young, growing cats. At the beginning of the experiment, 
weight differences between both groups were noted (figure 13). Indeed, during the 
treatment (w0-3d) and at the time point of the challenge infection (w0), the mean 
body weight of the dSLIM™-treated group was significantly lower than that of the 
control group. However, as of week 1 already, the mean body weight values of both 
groups followed very similar curves until the end of the study.
5.1.1 Body Weight
The body temperature of each cat was measured weekly on the occasion of blood 
collections, immediately after the onset of the sedation effects. Although minimal 
fluctuations were observed, the differences between mean values of both groups 
showed no significance during the entire duration of the study (figure 14).
5.1.2 Body Temperature
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Figure 13 : Mean body weights in grams (g)
Figure 14 : Mean body temperatures in degrees celcius (°C)
As dSLIM™ had never before been systemically administered to domestic cats, it 
appeared to be of great importance to closely examine the cats during the treatment 
period, in order to assess any reaction to the injections. Particular attention was 
given to general symptoms of discomfort, such as apathy or loss of appetite, as 
well as to systemic and local inflammatory reactions. Regardless of the method of 
administration of dSLIM™, the treated cats presented no local or systemic adverse 
reactions at any time during the 5 days of treatment, and no behavioral differences 
were observed when they were compared to the control group.
5.1.3 Clinical Symptoms
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As of the time point of FIV challenge, special attention was attributed, during 
weekly examinations, to possible delayed reactions to the treatment, and to typical 
signs of acute FIV infection. The first abnormal clinical symptoms appeared however 
no earlier than 3 weeks after the challenge infection. Most cats of both groups 
presented slightly enlarged mandibular lymph nodes. By week 5 after challenge 
infection, enlargement of the popliteal lymph nodes was also observed. These 
clinical signs persisted throughout the 11 weeks of the study, and no significant 
differences could be determined between both groups, neither in the number of 
cats presenting the symptoms, nor in the number of lymph nodes enlarged per cat. 
Moreover, during the necropsy, which took place 11 weeks after challenge infection, 
no relevant pathological alterations were observed, other than enlarged mandibular 
and popliteal lymph nodes in a majority of cats from both groups, confirming the 
findings of the clinical examinations.
Although most cats did not develop severe symptoms linked to the challenge infection, 
2 cats had to be euthanized at week 8 post-infection, due to early development of the 
AIDS phase of FIV disease. Cat I1 from the control group demonstrated enlarged 
mandibular and popliteal lymph nodes, severe gingivitis, glossitis, pharyngitis and 
conjunctivitis with purulent ocular discharge, accompanied by fever (41, 2°C body 
temperature), apathy and anorexia. Necropsy confirmed these clinical findings. Cat 
S3 from the dSLIM™-treated group was also euthanized, presenting high fever 
(41°C), anorexia and apathy. In this cat however, enlarged mandibular and popliteal 
lymph nodes were the only abnormal findings at necropsy.
Red and white blood cell parameters were measured weekly in all cats. Unfortunately 
the hematological analysis carried out immediately before the onset of the experiment 
(w0-5d) revealed differences in the group mean values for a majority of parameters. 
These differences were however mainly non-significant and therefore not taken into 
5.2 Hematology
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consideration when interpreting the hematological alterations discussed below.
Red blood cell (RBC) counts (figure 15),  hemoglobin concentration, and mean 
cellular hemoglobin concentration (MCHC) indicated stable values in both 
groups throughout the experiment. Only the mean hematocrit values indicated a 
significant decline in the control group between time point of infection and week 
2 post-challenge. Importantly, significant declines in mean hematocrit values were 
already observed for both groups during the treatment period, namely between the 
time points week 0-3d and week 0 (figure 16). No significant differences between 
both groups were noted for any RBC parameter during the entire duration of the 
experiment.
5.2.1 Red Blood Cell Parameters
Figure 15 : Mean red blood cell (RBC) counts (x106 cells/μl)
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Figure 16 : Mean hematocrit values (%) 
5.2.2 White Blood Cell Parameters
The absolute WBC counts measured in both groups indicated similar curves during 
the entire duration of the experiment. However, a significant peak in the values 
obtained for the dSLIM™-treated group at the time point week 0-3 days can be 
seen in figure 17. Although the graphic hints that the WBC values for the treated 
group stay well above those from the control group until week 2, these differences are 
not significant, due to high individual variability in the dSLIM™-treated group. 
For both groups, the mean absolute WBC count decreased gradually between the 
time points of infection and euthanasia. More specifically, the drops observed in the 
first 2 weeks after FIV challenge are significant for both groups.
5.2.2.1 Absolute White Blood Cell Counts
Figure 17 : Mean white blood cell (WBC) counts (x103 cells /μl)
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The graphical representation of the neutrophilic and eosinophilic granulocytes 
indicated curves similar to that of the mean WBC (figures 18 and 19). The mean 
values of both these parameters also decreased progressively and significantly 
during the entire duration of the experiment. Moreover, both during the treatment 
and immediately after challenge infection, increases in absolute counts of both 
neutrophilic and eosinophilic granulocytes were observed in the group treated with 
dSLIM™. 
As illustrated in figure 18, the mean absolute neutrophil counts of the treated group 
peaked rapidly after the onset of the treatment (w0-3d). Both the peak in neutrophil 
count at week 0-3d, and the increase in mean values between week 0-5d and week 
0-3d are significant. This rapid increase was due to neutrophilia in 4 individuals. 
Within a week’s time after this peak however, the mean neutrophil count of the 
treated group dropped to similar values as the control group. Between weeks 3 and 
6 after challenge infection, a highly significant decrease in neutrophils was observed 
in both groups. The decline in mean neutrophil count started earlier in the group of 
treated cats.
The particularly elevated mean levels of eosinophilic granulocytes until week 2 
post-challenge (figure 19) are due to eosinophilia in 2 individuals from this group, 
thus rendering the divergence between the groups non-significant. However, as of 
week 2 after challenge infection, the eosinophil values of these cats returned to a 
normal range. The mean eosinophilc values for both groups hence indicate similar 
curves as of this time point.
5.2.2.2 Neutrophilic and Eosinophilic Granulocytes
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Figure 19 : Mean absolute eosinophilic granulocyte counts (x103 cells /μl)
5.2.2.3 Monocytes
The dSLIM™-treated group displayed elevated mean absolute monocyte counts 
in comparison to the control group for mostly the entire duration of the study. 
However, due to high variability in the measured values between the individuals of 
this group, the differences were significant only at the beginning of the experiment, 
namely between the time points week 0-3 days and week 1 post challenge, as well 
as on week 9 (figure 20). The values measured in both groups always remained in 
the normal range.
Figure 18 : Mean absolute neutrophilic granulocyte counts (x103 cells /μl)
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Figure 21 : Mean absolute lymphocyte counts (x103 cells /μl)
A significant drop in mean lymphocyte values in both groups was due to a 
marked decrease in absolute lymphocyte counts and led to mild lymphopenia in 
most individuals of both groups within 2 weeks after challenge infection. Mean 
lymphocyte values regained normally expected levels by week 3 for the treated group 
and week 4 for the control group. Although the mean absolute lymphocyte counts of 
the treated group stayed below those of the control group during the entire duration 
of the study, the differences measured were not statistically significant (figure 21).
5.2.2.4 Lymphocytes
Figure 20 : Mean absolute monocyte counts (x103 cells/μl)
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The blood glucose levels of the cats at the time of blood collections indicated many 
variations throughout the study. Moreover, in most individuals of the control group, 
hypoglycemic values were measured at the two first blood collections, and the 
differences between the groups at these time points were highly significant (p<0.01) 
(figure 22).
5.3.1 Substrates
Additionally, elevated mean urea values in the treated group indicated highly 
significant differences between weeks 1 and 3 post challenge infection as well as at 
week 5, when compared to the control group (p< 0.01). Moreover, the urea levels of 
Figure 22 : Mean blood glucose levels (mmol/l)
Although always comprised within a normal range, the mean values obtained for 
most parameters of clinical chemistry indicated divergences between the groups 
already before the onset of the study. As these differences were mainly non-significant, 
they were not taken into consideration when evaluating the results. The following 
sections highlight the significant differences encountered during analysis of the 
commonly tested substrates, enzymes and electrolytes in plasma.
5.3 Clinical Chemistry
138
Results
Values for alanin-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), 
alcaline phosphatase (AP) and lipase were evaluated weekly during this study. 
Interestingly, significant differences between the control group and the treated 
group were observed only for blood lipase values. The mean concentration of this 
enzyme in the plasma of the dSLIM™-treated cats indeed remained lower than that 
of the control cats for the entire study, with significance however only during the 
treatment period, that is 3 days before (w0-3d), and at the time point of challenge 
infection (w0) (figure 24).
Several individual cats sporadically demonstrated abnormally high levels of ALAT 
concentrations (> 100 U/l). This was the case for cat Q1 from the control group at 
weeks 8-9 post-infection. After FIV challenge, cats K3 and L4 from the treated 
group indicated similar transiently increased ALAT values at weeks 2 and 7-8 
respectively (figure 25). 
5.3.2 Enzymes
Figure 23 : Mean blood urea levels (mmol/l)
the treated cats indicate a significant increase between the time point of challenge 
and week 3 post-infection (figure 23). 
All the other substrates analyzed in this study, namely bilirubin, creatinin, total 
protein, albumin and cholesterin concentrations indicated no significant divergences 
between both groups, or over time.
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Figure 24 : Mean blood lipase levels (U/l)
Figure 25 : Mean blood alanin–aminotransferase (ALAT) levels (U/l). Values of cat Q1 from the 
control group and cats K3 and L4 from the treated group are illustrated separately.
Although always comprised in the normal range, the mean concentrations of 
sodium, potassium, chloride and phosphate demonstrated considerable variability 
both within the groups and between the different weeks of the study. Significant 
alterations were however only observed for chloride and phosphate levels.
The chloride concentrations of both groups simultaneously increased slightly before 
challenge infection, and indicated a significant drop between weeks 0 and 1. The 
5.3.3 Electrolytes
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chloride concentrations in the treated group continued to decrease until week 2, 
inducing slight hypochloremia in most individuals of this group. However, by week 
3, the values for both groups regained levels similar to those encountered before the 
treatment, and remained relatively stable for the rest of the study (figure 26). 
Figure 26 : Mean blood chloride levels (mmol/l)
Both groups exhibited blood phosphorus values that were over the normal range 
for the entire experiment. However, phosphorus levels in the plasma of treated cats 
demonstrated significantly lower concentrations than the control group during the 
treatment period, and until week 1 post challenge infection (figure 27).
Figure 27 : Mean blood phosphorus levels
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5.4 Immunology
In order to determine the time point of seroconversion and levels of antibodies 
to FIV developed over time after challenge infection, an anti-TM ELISA was 
carried out weekly. Low antibody levels were detected in most individuals of both 
groups already at week 1 and week 2 after FIV infection. By week 3 post-challenge, 
all cats had seroconverted and remained positive to ELISA until the end of the 
study. Generally, the results indicated two distinct peaks of antibody production 
after challenge infection, namely at weeks 5 and 7. These peaks were similar for 
both groups, although the mean antibody level of the treated group was higher than 
that of the control group at week 7. This difference was however not significant, in 
contrast to the divergences at weeks 3 and 8, time points at which the treated group 
displayed higher antibody levels than the control group (figure 28). The variability 
in antibody levels between individual cats was especially high between weeks 3 and 
8 post challenge.
5.4.1 Antibodies to FIV TM
Figure 28 : Mean serum anti-TM antibody levels, indicated using percentage of the positive 
control (Perc. to PC)
Importantly, 2 cats of the dSLIM™-treated group, M1 and T3, presented until week 
4 post-challenge significantly lower antibody levels to FIV TM than the mean values 
measured for both the control group and treated group. These 2 cats also indicated 
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Expression of GAPDH, IL-10 and IL-12 p40 was measured both in whole blood 
weekly, and in PBMCs isolated from the cats at 2 distinct time points during the 
experiment, namely on the day of challenge infection, and at week 8 post-challenge. 
As GAPDH is considered a « housekeeping » gene, the determination of a 
GAPDH :cytokine ratio enabled a standardization of the measurements obtained 
for IL-10 and IL-12 p40 during these experiments. This ratio is used as unit in the 
graphics illustrated in the following sections. 
5.4.2 Cytokine Measurements
Measurement of IL-12 p40 and IL-10 expression in whole blood during treatment 
(w0-3d, w0-5d, w0) and after challenge (w1-w3,w7,w11)enabled to determine the 
expression kinetics of these cytokines throughout the study (figures 29-31).
Figure 29 reflects the mean quantitative results for GAPDH expression obtained 
in both groups. Only slight, non-significant divergences can be observed. However, 
both the drop between weeks 7 and 11 post-challenge in the treated group and 
the difference in expression levels of GAPDH between weeks 3 and 7 after FIV 
infection in the control group are significant. 
The measured IL-10 mRNA expression levels throughout the study are demonstrated 
in figure 30. In both groups, no IL-10 expression could be detected during the 
entire duration of the treatment period. After challenge, IL-10 levels increased 
continuously in both groups until week 7, and decreased again to reach very low 
levels by week 11. As no measurements were carried out at weeks 8 and 9, it is not 
possible to determine both the maximal expression of IL-10, and how rapidly the 
5.4.2.1 Cytokine Expression in Whole Blood
a particularly favourable virological status during the acute phase of infection (see 
section 5.5).
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expression levels effectively drop. The graphic indicates considerably lower levels of 
IL-10 for the treated group in comparison to the control group, especially at weeks 
3 and 7 post-infection. As the results obtained for week 7 presented high individual 
variability in the control group, the latter findings are only significant at week 3.
In contrast to IL-10, IL-12 p40 was detectable during the treatment period. The 
measured expression levels indicate a higher increase post-infection in the control 
group than in the treated group. The augmentation in the control group of IL-12 
p40 expression between weeks 0 and 2, along with the sudden drop between weeks 2 
and 3, are both significant. However, between both groups, no significant differences 
could be measured throughout the whole study (figure 31).
Figure 29 : Mean GAPDH mRNA expression in whole blood (x106 copies/5μl)
Figure 30 : Mean IL-10 mRNA expression in whole blood (IL-10:GAPDH ratio)
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Figure 31 : Mean IL-12 p40 mRNA expression in whole blood (IL-12: GAPDH ratio)
PBMCs were isolated from each cat individually twice during the course of the 
study, namely immediately before challenge infection (week 0), and at week 8 post-
challenge, in order to evaluate the predominant cytokine expression pattern. Figures 
32-34 illustrate the graphical results to these experiments.
Although the GAPDH graphics appear very similar at both time points analyzed, 
the columns representing the results for week 8 are shifted toward a lower level in 
comparison to those of week 0. Higher GAPDH levels were measured after Con A 
stimulation of PBMCs isolated from the cats of both groups, before, as well as after 
challenge infection.
Before challenge, i.e. at week 0, both the control and the treated group show no 
basal expression of IL-10, as is indicated by the measurements accomplished on 
the unstimulated PBMCs of the cats in both groups. However, at this time point, 
the expression of IL-10 by the lymphocytes of the control group was significantly 
increased in response to stimulation with Con A. A similar effect was encountered 
for the cells of the control group after LPS stimulation, although to lesser extent 
and lacking a significant difference to the treated cats. In contrast, at week 0, IL-10 
5.4.2.2 Stimulation of Cytokine Production in vitro
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expression in PBMCs from treated cats could only be insignificantly stimulated by 
Con A, and not at all by LPS. Eight weeks after the challenge infection, only very low 
levels of IL-10 were measured in unstimulated PBMCs from both groups. When 
compared to the results obtained at week 0, the PBMCs isolated from the cats of the 
control group became significantly less responsive to Con A stimulation with regard 
to IL-10 mRNA levels. Lymphocytes from the treated cats expressed significantly 
higher IL-10 levels when stimulated with LPS 8 weeks after FIV challenge, than 
with the same stimulation before challenge, at week 0. 
Although the basal IL-12 p40 expression measured in unstimulated PBMCs at 
week 0 was rather low in both groups, the immune cells from treated cats expressed 
significantly higher IL-12 p40 mRNA levels than those from control cats. Due to low 
variability in the obtained values, this difference is not obvious on the graph of figure 
34. It is however indicated by a star. Similarly in both groups at week 0, stimulation 
of PBMCs with Con A and LPS enhanced expression of IL-12 p40 significantly. 
LPS stimulation thereby indicated far more potency in this effect. There was however 
no significance in the differences between the groups in IL-12 p40 expression levels 
after stimulation with Con A or LPS at this time point. Unstimulated PBMCs 
from the cats in both groups indicated significantly enhanced expression of 
IL-12 p40 at week 8 post-challenge, when compared to values obtained at week 0. 
However, the differences between both groups were thereby not significant. With 
respect to IL-12 p40 expression at week 8, the PBMCs from the control group are 
significantly more responsive to LPS stimulation, whereas those from the treated 
group are significantly less reactive to LPS stimulation, in comparison to the results 
of the same experiments accomplished at week 0. When mean mRNA levels of 
IL-12 p40 from both groups were compared at week 8, no significant differences 
were measured.
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Figure 32 : Mean GAPDH mRNA expression of isolated PBMCs from all cats in both 
groups, either 1) left unstimulated, 2) stimulated with ConA, or 3) stimulated with LPS (x106 
copies/μl). Experiments were carried out at the time point of challenge (W0) and 8 weeks 
post-challenge (W8).
Figure 33 : Mean IL-10 mRNA expression of isolated PBMCs from all cats in both groups, 
either 1) left unstimulated, 2) stimulated with ConA, or 3) stimulated with LPS (IL-10:
GAPDH ratio).  Experiments were carried out at the time point of challenge (W0) and 8 
weeks post-challenge (W8).
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5.5 Evaluation of Viral Infection
FIV proviral load in peripheral blood cells was assessed weekly by real-time PCR 
analysis of TNA extracted from whole blood samples. Throughout the entire duration 
of the study, no significant differences in proviral loads between the groups were 
measured. In a similar manner for both groups, the proviral loads rapidly increased 
until week 3 and remained relatively stable until the end of the study. With the 
exception of week 2, the CT values obtained for the treated group remained slightly 
higher than those of the control group until week 4. Moreover, although presence of 
FIV infection could be assessed in all cats of the control group at weeks 1 to 3 post-
challenge, 2 cats of the dSLIM™-treated group, M1 and T3, remained provirus 
negative by real-time PCR until week 4 after FIV challenge (figure 35).  Although 
the individual proviral loads for these 2 cats stay below those of the control group 
between weeks 5 and 11 post-infection by a factor of more than 15-fold, these 
differences are not significant.
5.5.1 FIV Proviral Loads in Whole Blood
Figure 34 : Mean IL-12 p40 mRNA expression of isolated PBMCs from all cats in both 
groups, either 1) left unstimulated, 2) stimulated with ConA, or 3) stimulated with LPS 
(IL-12:GAPDH ratio). Experiments were carried out at the time point of challenge (W0) 
and 8 weeks post-challenge (W8).
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Figure 35 : Mean FIV proviral loads in whole blood (45-CT values). Values for cats M1 and T3 
from the treated group are illustrated seperately.
Interestingly, in the cats I1 and S3, which had to be euthanized at the 8th week after 
FIV challenge, the proviral load had increased rapidly in the acute phase of infection 
and remained particularly high throughout the experiment. The difference between 
the proviral kinetics of these 2 individuals and those of the respective mean group 
values was however not significant (data not shown).
5.5.2 FIV Viral Load 
FIV viral load in plasma was measured weekly by real-time RT-PCR analysis. In 
both groups, the measured viral loads increased rapidly until week 2 post-challenge, 
similarly to the previously discussed proviral loads. In contrast to the latter however, 
the mean viral loads in plasma diminish gradually until the end of the study. No 
significant differences between the 2 groups were observed at any time point 
throughout the experiment. Also, the 2 cats euthanized at week 8 post-challenge 
presented viral RNA levels in plasma which corresponded to the mean group values 
throughout the experiment.
Importantly, no viral RNA was measured in the plasma of 2 cats, M1 and T3 until 
5.5.2.1 FIV Viral Load in Plasma
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week 4 after challenge with FIV. These individuals equally remained provirus negative 
until this time point (see above : 5.5.1). Although at week 4 post-infection the viral 
loads detected in the plasma of M1 and T3 were not yet quite as high as those from 
both groups, this difference was not significant, and the loads measured onward were 
similar to the means of the control group and treated group values (figure 36).
Figure 36 : Mean FIV viral loads in plasma (45-CT values). Values for cats M1 and T3 from 
the treated group are illustrated seperately.
FIV viral loads in saliva obtained from the collection of buccal swabs were measured 
on a weekly basis by real-time RT-PCR. For both groups, 2 peaks of viral secretion 
in saliva were observed at weeks 5 and 9 post-infection. During the 11 weeks of 
the study, no significant differences with respect to FIV shedding in saliva were 
observed between the groups. However, during both peaks, namely at weeks 5 and 9 
post-infection, the treated group seemingly demonstrated slightly higher mean viral 
loads in saliva, which was due not only to viral secretion by more individuals at these 
time points, but also to shedding of higher amounts of virus by these individuals in 
comparison to the control group (figures 37 and 38).
The 2 cats from the treated group, which presented negative proviral and viral loads 
5.5.2.2 FIV Viral Load in Saliva
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until week 3 post-challenge infection, displayed diverging results : cat M1 secreted 
virus in saliva as of week 9 post-infection, whereas no FIV RNA could be measured 
in the saliva of cat T3 during the entire study. Interestingly, both cats which had to 
be euthanized at week 8 after challenge infection did not secrete virus in their saliva 
during the entire experiment.
Figure 37 : Mean FIV viral loads in saliva (45-CT value)
Figure 38 : Individual FIV viral loads in saliva of all cats for weeks 5, 9, 11 (45-CT values). 
No virus was detected in any cat on weeks 0,1,2,3,4,6,7 (graphs not shown).
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Presence of infectious virus in plasma was evaluated by a cell culture inoculation 
method weekly between weeks 2 and 8 post-challenge. Real-time RT-PCR of 
culture supernatants revealed for both groups a similar peak of infectious virus release 
in plasma at week 4. Although presence of infectious virus could be demonstrated 
in the plasma of 6 treated cats and 8 control cats on week 2 post-infection, it could 
only be detected in 1 treated cat and 7 control cats on week 3 post-challenge, 
rendering the difference at this time point significant. At week 8 post-infection 
however, infectious virus could be isolated from plasma of all cats of the treated 
group, but only from 8 cats of the control group. This difference is also significant, 
to the benefit of the control group (figure 39). Between weeks 2 and 7 after FIV 
challenge infection, the mean amount of infectious virus isolated from plasma of the 
treated cats stayed slightly lower than that of control cats (data not shown).  
5.5.3 Isolation of Virus from Plasma
Figure 39 : Infectious FIV isolation from all cats on weeks 2,3,4,5,7,8 after challenge infection 
(45-CT values, with individual CT values measured in supernatants of PBMC cultures)
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Cats M1 and T3 from the dSLIM™-treated group became viremic at week 4 after 
FIV infection (see 5.5.2.1), and started producing infectious virus rapidly thereafter. 
Indeed, no infectious virus could be isolated from the PBMCs of these individuals 
in weeks 2 and 3 post-challenge, but both indicated production of infectious virus as 
of the week 4 post-infection in quantities comparable to all other cats in the study.
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6. Discussion
6.1 Background of the study
It was the aim of this study to stimulate the innate immune system of the domestic 
cat with a synthetic, CpG-containing molecule and induce short term prophylactic 
resistance to a challenge infection with FIV. Clinical and immunopathological 
parameters of the cats were closely monitored during the acute phase of infection in 
order to assess any indication of resistance to FIV infection or disease. We expected 
to observe an innate immune response capable of either preventing or delaying 
1) establishment of infection in the host’s immune cells, 2) progression to viremia 
and secretion of infectious virus in saliva, or 3) onset or severity of clinical symptoms 
linked to FIV infection. Capability of conferring only partial resistance to domestic 
cats against FIV in this study was to be considered as partial success. Prophylactic 
induction of innate immunity is a relatively novel idea, and such findings would 
open new unexplored paths in preventive medicine in both human and veterinary 
fields. 
A pet cat temporarily placed in a cattery or shelter rarely goes back home 
entirely healthy. Narrow contact of cats from totally different backgrounds in 
such establishments creates an environment highly favorable for transmission of 
various feline viral diseases. Common known feline viruses indeed possess both 
very efficient transmission strategies and the capability to induce latent and/or 
asymptomatic infections of the carrier cat. These properties were hypothetically 
gained over thousands of years by viruses adapted to the feline host, in order to 
survive in a population with a very solitary way of life, probably due to restricted 
food basis. Although modern civilization, starting with the domestication by man 
of cattle, sheep and goats around 5000 years ago, provides the food basis allowing 
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cats to live in groups, feline viruses have conserved their opportunistic behaviour. 
Regroupment of cats in facilities such as agricultural farms, shelters and catteries 
considerably increases the infectious pressure. Also, in shelters for example, the 
animals’ immune systems are already sensitized by the stress conferred by a new 
environment populated with unknown individuals, which additionally favours 
susceptibility to infectious agents. As the onset of disease caused by these viruses 
is often delayed, infection of their cats frequently remains unnoticed by the owners 
for long periods of time. Not only symptoms usually appear in advanced stages of 
disease, when it becomes difficult to cure, but this time span may enable the virus to 
disseminate in new hosts. Unfortunately, owing to the adaptation properties of feline 
viruses, elaboration of effective preventive and therapeutic methods has proven to be 
particularly challenging. The cat is one of the most appreciated companion animals 
worldwide, and catteries and shelters are widely established in the developed 
countries. In the interest of both the owners and of entire populations of pet cats, 
it would be highly desirable to have an effective antiviral agent available, which 
would, on the occasion of regroupment of cats for a short period of time, confer 
the host resistance to a broad spectrum of viral diseases. Moreover, the use of broad 
spectrum antiviral agents could be extrapolated to other animals or to humans, as 
new emerging viral diseases currently constitute a constant threat of pandemic to 
these populations.
  
Inspired by a need in the veterinary medical field, the design of this study was 
based on a modern scientific background. Better understanding the complexity 
of the innate immune system has been a major subject of the last 10 to 15 years 
in medical biology. It became rapidly clear that stimulation of the organism’s first 
line of defence could be exploited to enhance resistance to a variety of infections. 
Stimulation of innate immunity not only initiates immediate reaction to a wide range 
of pathogens, but greatly supports the subsequent development of a specific immune 
response, representing a feasible alternative method to specific immunization. Since 
the complex network of interactions between the cells involved in the organism’s 
first line of defence represents a phylogenetically ancient form of immune response, 
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the molecular participants of innate immunity are encoded in the genome of the 
host and have been conserved throughout evolution. It is today widely accepted, 
that early pathogen recognition of the innate immune system relies on its ability 
to recognize microbial components known as PAMPs [223]. These molecules are 
essential for the survival of the microorganisms and therefore only rarely alter in the 
course of evolution. 
Many research groups have concentrated in recent years on the development of 
synthetic versions of PAMPs and on their testing as new pharmaceutical products 
in various disease settings. CpG ODNs are among the most thoroughly studied 
PAMPs. The innate immune system of fish, birds and mammals efficiently recognize 
and respond to bacterial DNA because it contains, in contrast to vertebrate DNA, a 
high amount of unmethylated CpG motifs. Recognition of CpG motifs is considered 
an ancient defence mechanism of the vertebrates against invading pathogens 
and its evolutionary conservation over tens of millions of years strongly indicates 
that CpG-mediated immune activation contributes to host survival. Feasibility 
of experiments with CpG-containing molecules is furthermore supported by the 
ease in production and modulation of synthetic CpG ODNs. Several generations 
of ODN structures, containing variable numbers and flanking sequences of CpG 
motifs, have been designed and tested, thus allowing the development of highly 
potent immunomodulators capable of targeting specific elements of the immune 
system. Moreover, although response to CpG motifs was originally predestined 
for early combat against bacterial infection, exposure of immune cells to natural or 
synthetic CpG-containing molecules generally triggers the creation of an immune 
environment highly favourable to antiviral mechanisms, comprising deviation to 
cellular responses as well as liberation of Th1-derived cytokines and considerable 
amounts of IFN-α [283]. This type I IFN is known for its capacity to induce, in 
yet uninfected cells, the expression of various proteins including enzymes, signaling 
proteins, antigen presenting proteins and transcription factors, which directly 
interfere with viral replication and thus establish an intracellular antiviral state [377]. 
Considering the immunopotency of CpG ODNs, a carefully selected synthetic 
compound containing CpG motifs thus appeared optimal for the mounting of an 
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immune response capable of competing with viral challenge in the cat. 
Among the most common feline viruses, FIV appeared to be the most reasonable 
choice of challenge when experimenting the prophylactic properties of CpG 
ODNs. Both the elevated worldwide prevalence of this persistent lethal infection 
in populations of domestic cats and the lack of an appropriate vaccine and effective 
therapeutic agents on the market pressure development of novel strategies to 
diminish dissemination of the disease. Investigations on the genes of the lentivirus 
subfamily of retroviruses, including HIV, SIV, FIV, equine infectious anemia (EIAV) 
and ovine lentivirus Visna have indicated comparatively extremely low frequencies 
of CpG dinucleotides in their DNA [378]. Boosting the defence mechanisms 
elicited by CpG motifs may help compensate the insufficient natural stimulation 
of this immune pathway and therefore appeared especially feasible in the context 
of such infections.  Moreover, FIV appeared especially sensitive to IFN-α in several 
studies, considerably increasing chances that immunomodulatory effects of CpG 
ODNs could contribute efficiently to the mounting of resistance to FIV infection 
[61, 175]. Finally, FIV infection in the cat is considered a close model of HIV in 
humans [57], and such experiments may reveal precious information on various 
biological and immunopathological properties of these retroviruses and open the 
way to unexplored paths in HIV research. 
The design of the present experiment involved preliminary determination of 
important parameters, which are discussed below.
In order to improve reliability of the results obtained, high importance was attributed 
to provenance, amount, age, gender, and health status of the cats used for the study. 
The experiment was accomplished with 20 spf cats, divided into 2 groups of 10 
cats each. We have chosen to utilize the minimal amount of individuals enabling 
to determine significant divergences which would have future clinical relevance. 
6.2 Design of the Study
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Moreover, all cats were ordered from a specialized facility breeding domestic cats 
under spf conditions, and the perfect health of the animals was ensured through 
professional examination by a veterinarian at their arrival. Influence of the genetic 
background of the cats on the reactions linked to the treatment was considerably 
diminished by selecting cats from different litters and with different parents. Also, 
as the immune system of young cats is more prone to react to various stimuli, kittens 
of approximately 2 months of age were requested. Finally, to increase accuracy when 
comparing parameters measured throughout the experiment, balanced distribution 
of the individuals into the two groups was considered crucial. Thus, the cats were 
divided in the groups according to litter provenance and age, and we insisted on 
receiving only male cats. To avoid risks of bias in attribution of individuals to the 
respective groups, the distribution was effected blindly before the arrival of the cats. 
Unfortunately, certain cats turned out to be considerably smaller than the others 
despite similar birth dates, and significant differences in the mean body weights 
were measured between both groups already before the onset of the experiment. 
This is probably the explanation for the slight divergences observed early in the 
study in many hematological and biological parameters tested in the cats. As this 
data confers important indications on side effects or pathological alterations, greater 
value should be attributed to similar average body weights in both groups at the start 
of future experiments.
Treatment of the cats was performed with dSLIM™, a carefully selected molecule 
with multiple advantages for the present study. First, this non-coding DNA 
molecule contains several unmethylated CpG motifs and possesses the broad 
spectrum immunomodulatory properties of Class C CpG ODNs. Thus, dSLIM™ 
is capable of simultaneously mobilizing many different components of the 
immune system [379]. Secondly, dSLIM™ is protected in vivo from destruction 
by cellular nucleases through its special covalently-closed, dumbbell shape. This 
configuration not only confers dSLIM™ high stability when administered in 
the host, but represents a feasible alternative to synthesis of the molecule with a 
phosphorothioate backbone, known to induce many undesired side effects when 
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applied in vivo. Finally, immunomodulatory effects and safety of dSLIM™ have 
been systematically demonstrated in both in vitro and in vivo studies, in humans, 
non-human primates, dogs and mice, indicating efficacy in many species [374, 380]. 
Moreover, this molecule has indicated such promising results that it is currently 
being clinically trialed in various human disease settings [381]. 
The administration protocol of dSLIM™ was adjusted to published facts on 
duration and extent of immunomodulation by CpG ODNs. The innate immune 
response elicited by CpG DNA was previously shown to peak within days and 
promote effective defence mechanisms within the host for about 2 weeks [359]. 
Also, repeated administration of CpG ODNs as stand-alone protective agent was 
shown to maintain the host’s resistance to infection [382]. Finally, administration of 
CpG ODNs by many different routes, including i.v., i.m., i.p., s.c., p.o. have indicated 
systemic immunostimulation. Thus, the cats were treated using a combination of 
administration methods over a period of 5 consecutive days. The combination of 
s.c, i.p and i.v administration of dSLIM™ favored a broad in vivo distribution. 
Moreover, subcutaneous injections of dSLIM™ were specially foreseen to activate a 
maximal amount of dentritic cells present in the layers of the skin. As the challenge 
infection was accomplished i.p, it seemed reasonable to include this mode of 
administration, in order to enable accumulation of dSLIM™ at the site of infection. 
The combination of several modes of administration in the same in vivo experiment 
however prevents from determining which is the most successful. We were aware that 
further experiments would be necessary to determine the optimal route of injection 
in the cat. Additionally, five consecutive days of treatment enabled to potentiate the 
immunostimulatory effects of dSLIM™ for the time point of challenge, which took 
place 24 hours after the end of the treatment, and for the acute phase of infection, 
when the host’s immune status highly influences the future outcome of disease.
The challenge infection is another determining factor in the outcome of the 
experiment. The cats were challenged i.p., widely accepted to be the mode of 
administration of the virus which best mimics natural infection. Also, the time point 
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of challenge infection was selected according to the time when optimal host defence 
mechanisms stimulated by the treatment were anticipated. FIV-GL8, used for the 
challenge infection in this experiment, is known to be a particularly virulent strain. 
However, the viral stock utilized had previously been titrated in vivo by another 
laboratory, and the lowest titre effectively infecting 100% of the cats was chosen, 
both ensuring reliability in interpretation of the prophylactic effects induced by the 
treatment, and leaving space for the observation of the slightest effects. As several 
vaccine studies [189, 214] have previously indicated that FIV-GL8 seems more 
resistant to vaccinal immunity than other known FIV strains, this type of challenge 
may have been too aggressive in the context of unspecific host defence mechanisms. 
However, in consideration of these facts, we measured a broad selection of 
immunological parameters in the cats during the course of the study, thus analyzing 
several levels of the viral-host interactions, and increasing the chances to observe 
hints of resistance to FIV infection. Also, the elaboration of a preventive measure 
against a virulent strain is particularly challenging, and promising results would 
reveal solid optimism for its clinical application.
For several reasons, we have decided to test the prophylactic effect of dSLIM™ 
directly in vivo. As already mentioned, it is a common property of all vertebrates 
to have acquired throughout evolution the capability to recognize and respond to 
CpG ODNs. Detailed studies have shown that the innate immune system of many 
out-bred domestic and non-domestic animals respond to the same CpG-containing 
DNA sequences [260, 296]. Moreover, in recent years, great scientific interest in 
this field has enabled the development of highly specific molecules as well as their 
testing in a wide variety of species in vitro and in vivo. Finally, many physiological 
and immunological parameters which greatly influence the success of a prophylactic 
agent cannot be taken into consideration when tested in vitro. Unfortunately, despite 
thorough preparation and realization of the experiment, the immunopathlogical 
and virological parameters evaluated did not indicate significant resistance against 
infection or disease in the treated group. Previous in vitro optimization of dSLIM™ 
would have permitted a more precise prediction and modulation of the in vivo 
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In order to enable an accurate follow-up of the clinical status of each individual, 
examinations of the cats were carried out weekly, and always by the same veterinarian. 
In this way, important clinical findings, such as number of enlarged lymph nodes 
and grade of enlargement, could be somewhat standardized. Although this was not 
a blind study, great importance was attributed to the objective assessment of the cats’ 
health conditions.
The present study represents the first evaluation of the effects of dSLIM™ in vivo 
in the cat. Thus, it appeared imperative to closely examine the cats for any signs of 
undesired side effects or toxicity caused by the treatment, and to assess any specific 
indication of intolerance to the different routes of administration of dSLIM™. 
Safety concerns linked to the administration of CpG ODNs in vivo have been 
mostly depicted after either particularly high dosage, repeated administration in 
short intervals over several weeks or months, or phosphorothioate modification of 
the DNA backbone. Previously described symptoms include general apathy and 
discomfort, excessive bleeding due to prolonged blood clotting time, splenomegally, 
6.3.1 Results of the Clinical Examinations
6.3 Relevant Results
experiment. Moreover, as the risk of acceleration of retroviral disease development 
has been described in earlier studies and attributed to the replication-enhancing 
effect of virus target cell populations by the treatment [331, 340], an in vitro testing 
of dSLIM™ on feline peripheral blood immune cells would have enabled to more 
surely exclude the risk of such an occurrence. This fact will be seriously considered 
for future experiments. 
Nevertheless, interesting findings in this study may shed light on various aspects 
of the pathogenesis and immunoprophylaxy of FIV disease, as well as on the use of 
CpG ODNs in the feline species. These issues are discussed in further detail below.
162
Discussion
autoimmune diseases and toxic shock as a result of over-production of TNF-α 
[292-294]. The choice of dSLIM™ as immunomodulatory agent considerably 
minimized the risk of encountering such adverse reactions in this study. Quantities 
and frequency of dSLIM™ administration were derived and adjusted from dosage 
protocols used in human clinical trials. Also, the configuration of dSLIM™ protects 
this molecule enough from cellular nucleases to avoid the need of a phosphorothioate 
backbone. However, as dSLIM™ is known to induce enhanced production of 
IL-6, a potent pro-inflammatory cytokine, special attention was attributed to body 
temperature of the cats during treatment. The mean body temperatures of the treated 
group surprisingly remained lower than those of the control group during the 
treatment period, and no individuals had fever during the treatment. The cats were 
also methodically checked for indications of local toxicity, allergy or inflammation at 
the site of injection. Regardless of the mode of administration, no local or systemic 
adverse reactions obviously linked to the treatment with dSLIM™  were observed 
during the entire experiment. 
Since FIV-GL8 is known to be a particularly virulent strain, it was expected that at 
least the control cats would exhibit early, marked symptoms of acute infection and/or 
rapid progression to AIDS-related disease. Typical symptoms of acute FIV infection, 
mainly slight apathy and enlargement of palpable lymph nodes, were recognized in 
all cats between weeks 3 and 6 post-challenge. Neither more rapid onset of disease 
nor more pronounced symptoms were observed in the control cats in comparison 
to the treated individuals. Moreover, one cat in each group had to be euthanized for 
ethical reasons at week 8 after FIV challenge. Both animals demonstrated apathy 
and particularly high fever. These symptoms were accompanied by severe, typical 
symptoms of AIDS-related disease in the cat belonging to the control group. As 
the immunomodulatory effects of CpG ODN administration in vivo have been 
shown to last no longer than a few weeks, it is highly unlikely that the further 
development of disease would have differed between the groups if we had extended 
the experiment. The particularly bad clinical state and the pathological findings at 
necropsy of one cat in the control group are insufficient indications of more rapid 
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Both haematological status and parameters of clinical chemistry were systematically 
evaluated during this study. These examinations permitted to 1) keep a valuable 
overview on the health status of the animals during the entire duration of the study, 
2) screen any hematologic or metabolic abnormalities linked to treatment with 
dSLIM™ and 3) characterize the hematosuppressive effects of FIV-GL8 infection 
as well as the extent of possible secondary affections.
Unfortunately the analyses of parameters of haematology and clinical chemistry 
carried out immediately before the onset of the experiment (w0-5d) revealed 
differences in the group mean values of a majority of parameters. This is probably 
due to the distribution of the cats in the groups according to age and not to body 
weight. Although mainly non-significant, these differences unfortunately complicate 
the interpretation of the data. The main divergences encountered during the study 
regarding these parameters are nevertheless discussed below.
6.3.2.1.1 Deviation in Red Blood Cell Parameters
6.3.2.1 Haematology
6.3.2.1.1.1 Hematocrit
The hematosuppressive effects induced by retroviral infection may include mild to 
moderate anemia in the acute phase of infection [383]. Thus, the temporary and 
significant decrease in the mean hematocrit values of the control group was probably 
linked to the challenge with FIV. Interestingly, the mean values for this parameter 
remained relatively stable in the treated group after infection.
 
6.3.2 Blood Parameters
disease progression in this group. These facts altogether indicate that dSLIM™ 
unfortunately failed to confer even partial protection from disease in this study. 
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6.3.2.1.2.2 Neutrophilic Granulocytes
6.3.2.1.2. Deviation in White Blood Cell Parameters
6.3.2.1.2.1 Leucocytes
In a similar way to those of the total WBC, the mean neutrophil counts of the 
control group shortly increased two weeks after challenge infection, and decreased 
rapidly between the third and sixth week post-infection. This finding has already 
been described and has been related to FIV infection [384]. Interestingly, the same 
pattern appeared 2 weeks in advance for the treated group. 
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Although both groups exhibited a significant decrease in mean absolute leucocyte 
counts during the first 2 weeks after challenge, the values obtained in this experiment 
did not comply with the previously described acute phase leucopenia in FIV 
infection [146]. However, the drop in leucocyte counts mentioned above, as well 
as the subsequent gradual decrease observed during the rest of the study, are most 
likely related to infection with FIV. 
During the treatment period and until week 2 post-infection, higher average 
leucocyte values were measured for the treated group, with significance only on 
the third day of treatment. All the other subpopulations of white blood cells 
measured for the treated group in this study, namely neutrophilic and eosinophilic 
granulocytes, lymphocytes and monocytes, indicated simultaneously increased 
absolute counts. The proliferation of these cell populations will be discussed in more 
detail in the corresponding sections below, enabling a better interpretation of the 
observed augmentation in leucocytes.
The collection of 3 times 4ml of blood with a period of 5 days is mostly to be 
the cause of the significant decline in mean hematocrit values observed during the 
treatmet period between both groups.
6.3.2.1.2.4 Monocytes
The cats from the treated group showed higher levels of monocytes during the 
treatment, and until week 1 post-challenge infection. Moreover, until the end of the 
study, the mean monocyte values for this group remained slightly higher than those 
of the control group. The divergences between both groups for this parameter were 
surprisingly greater than in all the other white blood cell subpopulations (p<0.007). 
Thus, treatment with dSLIM™ seemingly activated proliferation or circulation of 
monocytes in the cats. Interestingly, direct activation of this cell population with 
CpG ODNs has been described only in experiments with mice [365]. Human 
monocytes, in contrast, lack expression of TLR9, and the observed activation of 
this white blood cell type has been attributed to the effects of phosphorothioate 
backbones [271]. These facts taken into consideration, the activation of monocytes 
6.3.2.1.2.3 Eosinophilic Granulocytes
As dSLIM™ was shown to be a potent mediator of Th1 immune responses, 
proliferation of eosinophils was not expected in the treated group. Indeed, this 
eosinophil activation is commonly linked to a Th2 immune environment, which 
should be suppressed by the effects of dSLIM™. However, two cats of the treated 
group presented considerable eosinophilia during the treatment period and until 
shortly after infection. As these individuals already presented high eosinophil values 
before the onset of the experiment, the observed alterations cannot be considered a 
consequence of the treatment. The return to normal values in these 2 cats as of week 
2 post-infection remains unclear.
The mean neutrophil counts of the treated group were influenced by neutrophilia 
in four individuals 3 days after the onset of the treatment. The recruitment of 
non-circulating neutrophils in these cats may be due to induction of an inflammatory 
environment by the administration of dSLIM™, known to increase production of 
IL-6, or to a particularly high level of stress during that blood collection. 
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Most individuals from both groups demonstrated a significant drop in lymphocyte 
counts immediately after FIV infection leading to mild lymphopenia by week 2 post-
challenge, but returning to normal values shortly. Lymphopenia more commonly 
characterizes chronic, symptomatic FIV disease. However, a mild, temporary 
lymphopenia, similar to that encountered in acute HIV and SIV infections, has also 
been described in the acute phase of FIV infection [125].
Mean lymphocyte counts of the treated group remained slightly higher than those of 
the control group throughout the whole study. However, this difference was already 
measured before the onset of the study, and the divergences lacked significance 
during the whole experiment, rendering the interpretation of this finding particularly 
difficult. As CpG ODNs are known to activate B lymphocytes and NK cells directly, 
as well as T lymphocytes indirectly, it was initially expected to observe an increase in 
absolute lymphocyte counts in the treated cats [289].
6.3.2.2.1 Substrates
6.3.2.2 Clinical Chemistry
6.3.2.2.1.2 Blood Glucose Levels
The blood glucose levels of the cats at the time of blood collections vary considerably 
6.3.2.1.2.5 Lymphocytes
in cats after administration of dSLIM™ observed during the present study is rather 
surprising. Indeed, as most species respond in a similar manner to CpG ODNs, it 
was suggested that the divergences observed in several murine experiments could 
be in relation to the inbreeding of these animals. Moreover, the dSLIM™ molecule 
contains no phosphorothioate or other synthetic modifications. Further experiments 
would be required to both determine whether feline monocytes express TLR9, and 
to characterize the molecular and cellular mechanisms linked to this activation. 
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throughout the entire study. Moreover, during the treatment period, hypoglycaemic 
values were measured in many individuals of the control group, leading to highly 
significant differences when compared to the normal values of the treated cats. 
This significance was however already observed in the measurements carried out 
immediately before the onset of the treatment. Thus, it is unlikely that dSLIM™ 
played a role in this observation. As kittens lack fat reserves, they are particularly 
susceptible to hypoglycemia when not fed regularly. The cats from both groups were 
fed several times a day in similar quantities adapted to their physiological needs. 
Moreover, in order to both diminish time between two meals and avoid vomiting 
and aspiration risks during sedation, the blood collections always took place early 
in the morning. The cats were systematically fed as late as possible the night before, 
namely about 12 hours prior to the administration of the sedatives. For organization 
purposes, the blood collections always took place with the control group first, then 
carried on with the treated group. Thus, lower blood glucose levels were accordingly 
expected in the treated cats, as this group was left to fast for a couple more hours 
than the control group. The slight differences in mean body weight from both 
groups at the beginning of the study is unlikely to be the reason for this observation, 
since the treated group contained a greater amount of small individuals and was 
constrained to longer durations of  fasting. Although stress factors could be an 
explanation for increased blood glucose levels in cats, stressed animals commonly 
indicate hyperglycemia, which was not the case for the individuals in the treated 
group. It is important to mention here that as the time between blood collections 
and measurements was inferior to 2 hours, the use of fluoride tubes did not seem 
necessary in this experiment; this strategy will however be considered in future 
experiments. 
Altogether, the reasons for the state of hypoglycaemia in the kittens of the control 
group, and the meaning of the highly significant differences between both groups 
during the treatment period remain difficult to explain. 
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6.3.2.2.2.2 ALAT
One individual cat in the control group and two from the treated group sporadically 
demonstrated abnormally high levels of ALAT concentrations, most likely indicating 
transitory liver alterations. This observation is most likely due to individual responses 
to FIV challenge infection. Surprisingly, both cats euthanized at week 8 post 
infection (I1 and S3) had normal ALAT values for the entire duration of the study, 
including when they developed FIV disease.
Significantly lower lipase values were measure in the blood of the treated cats during 
treatment period. However, the lipase levels measured immediately before the onset 
of treatment were also lower in this group, than in the control group. Although the 
difference at this time point was not significant, it renders the interpretation of these 
findings rather difficult, and the explanation for these divergences remains unclear. 
6.3.2.2.1.3 Blood Urea Levels
A significant increase in mean blood urea levels was observed immediately after 
FIV challenge in the treated group, and elevated blood urea values induced highly 
significant differences between the groups between weeks 1 and 3 post challenge as 
well as at week 5. Since blood creatinin values were normal in all cats during the 
entire experiment, alterations in the kidneys could be excluded. As all cats received 
the same quantity and the same brand of food, this was unlikely to an influencing 
factor. These observations may indicate a delayed effect of dSLIM™ treatment on 
protein metabolism. However, it is difficult to say whether this effect is linked to or 
influenced by the challenge infection.
6.3.2.2.2 Enzymes
6.3.2.2.2.1 Lipase
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In order to test the efficacy of prophylactic treatment using dSLIM™, the outcome 
of FIV challenge was closely monitored in all cats. No trace of virus in the treated 
cats after challenge infection would have indicated optimal prophylactic stimulation 
of the immune system and dSLIM™-mediated resistance to infection and disease. 
However, considering that this CpG-containing molecule had never before been 
6.3.3 Evaluation of Viral Infection
6.3.2.2.3 Electrolytes
6.3.2.2.3.1 Blood Chloride Levels
The simultaneous highly significant decrease in blood chloride concentrations 
immediately after challenge infection, leading to hypochloremia in both groups 
within two weeks, remains unclear. No symptoms of vomiting or diarrhoea, which 
could be a hint to metabolic alkalosis, were observed in the cats during this time. 
Moreover, the mean values for both groups regained normal levels within an 
additional week. Alterations in the blood chloride concentrations in the acute phase 
of FIV infection have to date not been published.
6.3.2.2.3.2 Blood Phosphate Levels
The cats from both groups indicated increased phosphorus levels in blood during the 
entire duration of the experiment. This can be expected in young, growing animals. 
Moreover, increased phosphorus levels can be due to delayed serum separation after 
blood collections.
Significantly lower blood phosphorus levels were measured in the treated group 
during the treatment period and until week 1 post-challenge. As with many other 
parameters, slight divergences were already measured for this parameter before 
the onset of the treatment, rendering interpretation of this observation difficult. 
The increased values were still comprised in the normal range and therefore lacked 
clinical relevance.
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6.3.3.1 FIV Proviral Loads in Whole Blood
Generally, FIV provirus could be detected by quantitative real-time PCR in 
lymphocytes from the cats of both groups as of week 1 post-challenge infection 
administered to the domestic cat, we were aware that many variables in the procedure 
of the experiment could affect the outcome of FIV challenge, rendering chances of 
observing the ideal scheme of total protection against infection relatively low. In the 
foreseeing of the more probable advent of partial protection, precise understanding 
of viral kinetics subsequent to treatment with dSLIM™ appeared to be of great 
importance. Thus, we chose to evaluate several parameters of viral infection, enabling 
the differentiation of biological levels of protection :
	 •
 
	 •
	 •	
Quantitative evaluation and follow-up of the evolution of these parameters separately 
permitted precise comparison of viral kinetics between the groups and enabled 
accurate interpretation of the immunological processes induced by treatment with 
dSLIM™ (see section 6.3.4), providing hints about strength and mechanisms of 
protection. The results obtained by the measurements of these parameters in the 
course of the study are discussed in the following sections.
Assessment of proviral loads in the lymphocytes of the cats enabled 
to determine both occurrence and time point of the establishment 
of infection
Measurement of viral loads in plasma and saliva provided indications 
on the potential of the established provirus to induce production and 
liberation of new virions
Evaluation of the infectivity of the viral particles present in plasma 
allowed accurate estimation of the risk of viral transmission by the 
infected cat 
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After rapidly increasing until week 2 post-challenge, the FIV loads measured in 
plasma by quantitative real-time PCR diminished gradually until the end of the 
study in both groups, indicating less active release of viral particles by the infected 
peripheral blood cells over time. This finding may coïncide with an increase in 
cytotoxic CD8+ T lymphocytes commonly observed at this stage of FIV infection 
[46, 385]. However, this statement remains speculative, as both quantitative 
6.3.3.2 FIV Viral Loads
6.3.3.2.1 FIV Viral Load in Plasma
already. The measured mean loads increased rapidly to reach a plateau level at week 
3, and then remained stable for the rest of the experiment. For 2 individuals of the 
dSLIM™-treated group however, provirus could not be detected until week 4 after 
FIV challenge. Measures were repeated separately, in order to confirm the observed 
absence of FIV DNA in the samples. This 3-week delay before establishment of 
infection in the 2 cats M1 and T3 indicates a short term antiviral effect of the 
treatment. Hypothetically, prophylactic administration of dSLIM™ induced a 
favourable immunological status in these cats at the time point of FIV challenge, 
capable of controlling viral replication in the early phase of infection (see also 
6.3.4). Unfortunately however, the induced immune mechanism was insufficient to 
permanently prevent establishment of infection, as proviral loads were comparable 
to those of control cats and the virus could replicate unhindered as of week 4 post-
infection (more details in chapter 6.3.3.2). 
The innate immune response elicited by CpG ODNs is known to enhance the 
host’s defence mechanisms for about 2 weeks [359], and the effect of dSLIM™ was 
possibly of too short duration. Moreover, challenge infection with the particularly 
virulent FIV-GL8 strain may have been too aggressive in relation to the potency of 
the induced immune mechanisms. 
Success in delaying the establishment of FIV infection in 2 cats of the 
dSLIM™-treated group can nevertheless be interpreted as partial protection of 
these 2 individuals in our experiment.
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6.3.3.2.2 FIV Viral Load in Saliva
As biting is considered the main mode of FIV transmission between cats, it seemed 
relevant to evaluate the effect of treatment with dSLIM™ on the shedding of FIV in 
saliva. Throughout the experiment, FIV RNA was quantitatively measured in saliva 
samples in weekly intervals. For both groups, 2 peaks of viral secretion in saliva were 
observed, namely at weeks 5 and 9 post infection. Between these time points, no 
FIV RNA could be detected in the saliva of any individual. Surprisingly, during the 
observed peaks, secretion of FIV was not only measured in more individuals from 
the dSLIM™-treated group, but the concerned animals also shed higher amounts 
of virus. With p-values of 0.09 for week 5 and 0.065 for week 9, these findings 
were relatively close to statistical significance. Altogether, these results remain rather 
difficult to interpret. Probably, a longer observation period would have enabled 
clearer understanding of the meaning and relevance of these peaks in viral secretion 
in saliva. Moreover, as little is known to date about the kinetics of FIV secretion 
in saliva, shorter intervals and study of various biological and behavioural factors 
would have been necessary to more precisely define shedding patterns and possible 
relation of the findings to the treatment with dSLIM™. An earlier study described 
measurements and evaluation of the function of this cell population have not been 
carried out in this study. 
No virus could repeatedly be detected in the plasma of the 2 cats M1 and T3 which 
remained provirus negative until week 4 post-infection (see also 6.3.3.1). As of this 
time point however, similar viral loads as measured in the control group could be 
detected in plasma of these cats, not only confirming establishment of infection, 
but also indicating effective production and liberation of new viral particles by 
the infected lymphocytes. These observations altogether point to the induction of 
immune mechanisms capable of suppressing viral dissemination in the early phase of 
infection, insufficient however, in conferring total protection. The immune processes 
involved in the partial resistance to FIV observed in the 2 cats M1 and T3 are 
discussed in chapter 6.3.4.
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Preseeded PBMCs isolated from a spf cat were weekly inoculated with the plasma 
of the cats enrolled in the study. The aim of this experiment was to test whether 
prophylactic treatment of the cats with dSLIM ™ affected the overall infectiosity 
of the viral particles present in plasma, i.e. their capacity of disseminating infection 
within the host by infecting new lymphocytes. This technique was preferred to others 
previously described using CRFK [386], MYA-1 [387], MBM [28], and Fet J [61] 
target cell lines because PBMCs closest reflect in vivo mechanisms. It should be 
mentioned that isolation of virus may be hampered by FIV neutralizing antibodies 
and cytokine activity present in the plasma used as substrate. As these parameters 
may vary over time and between individuals, this fact should be kept in mind when 
interpreting the results obtained with such an experiment.
Presence of virus in supernatants was determined by real time RT-PCR after 4 weeks 
of culture, as this amount of time ensures liberation of FIV by infected PBMCs in 
vitro. In order to certify that they reflected the presence of newly produced virus, 
6.3.3.3 Isolation of Virus from Plasma
continuous segregation of FIV in salivary gland tissue as of week 1 post-challenge 
infection, yet without obvious relation between the isolation rate from saliva and 
either clinical stage of disease or level of neutralizing antibodies in plasma [157]. 
Secretion of FIV in saliva may thus be correlated to triggers such as the occurrence 
of stressful situations or the act of biting. Such assumptions remain however purely 
hypothetical and require more detailed study. 
Finally, our experiments indicate presence of virus in saliva, but not its infectivity. 
Isolation and subsequent quantitative measurements of infectious virus in saliva, in 
a similar manner as carried out in this study for the determination of infectious viral 
loads in plasma (see 6.3.3.3), would provide more accurate information on the odds 
of viral transmission at a given time point, and could be foreseen in the preparation 
of future studies. 
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results were compared quantitatively to real time RT-PCR measurements of a 
control consisting of infectious viral stock added to medium without cells, and held 
under same culture conditions. 
For cost and time purposes, the experiment was carried out over 6 weeks, namely 
between weeks 2 and 8 after challenge infection. This short period of time seemed 
nevertheless sufficient, as it covers the acute phase of FIV infection with the 
particularly virulent GL8 strain used in this experiment. Infectious virus could be 
isolated from the samples obtained in the second week post-infection already in 
cats from both groups. By weeks 4 and 5 after challenge infection, production of 
infectious virus was detected in all cats from both groups, and in all but 1 individual 
from the dSLIM™-treated group at week 7 post-infection. Also, higher quantities 
of virus were generally measured for these time points, in comparison to weeks 2, 3 
and 8 post-infection. Although the experiment was not carried out for week 6 post-
challenge, the latter results seem to indicate a peak in infectious virus production 
between weeks 4, 5 and eventually 6 after experimental infection with FIV-GL8. 
Higher mean amounts of infectious virus were detected in a greater number of 
individuals of the control group at both the second and third weeks after challenge. 
It could thus be speculated that treatment with dSLIM™ slightly delayed effective 
production of infectious virus in the cats. Such findings indicate a successful 
modification of the immunological status of the cats subsequent to treatment; 
the characterization of immune mechanisms carried out throughout this study 
can unfortunately only partially confirm such a hypothesis (see section 6.3.4). 
Somewhat significantly higher infectious viral loads were observed at week 8 after 
challenge infection in the treated group. The reasons for this finding remain unclear. 
Sample measurements in following weeks would have probably been necessary for a 
thorough interpretation of this result.
No infectious virus could be isolated until week 4 post-challenge from the 2 cats 
M1 and T3, which remained negative for proviral and viral loads during this period 
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Characterization of the immune response induced by the treatment with dSLIM™ 
was foreseen to enable both a precise evaluation of the in vivo immunomodulatory 
potential of this molecule in the domestic cat, and analysis of the background to the 
observed alterations in viral kinetics after FIV challenge.
The differentiation of naïve T cells in the course of an immune reaction to CD4+ Th1 
cells or Th2 cells determines the network of defence mechanisms which is used by the 
organism to combat against infection. Manipulation of the innate immune system 
allows to influence the direction of this differenciation and this concept is today 
generally seen as feasible approach to help the body mount optimal responses against 
a very broad spectrum of pathogens [388, 389]. Promotion of Th1 immune responses 
is highly desired in the setting of viral diseases, because the cytokines produced by the 
Th1-differentiated CD4+ T cells enhance cellular defence mechanisms and suppress 
Th2 deviations, which rather induce humoral immunity. Th1 cells are known to 
produce high amounts of Il-12, IFN-g and TNF-α, whereas Th2 cells mainly produce 
IL-4, IL-10 and IL-13. 
Retroviral infections such as HIV, SIV and FIV naturally induce an early cellular 
immune response in the host, which reacts to viral proteins with a CTL response. This 
Th1-biased mechanism is unfortunately unsuccessful in inhibiting viral replication 
6.3.4 Immunological Measurements
of time (see 6.3.3.2). Importantly, several control animals, which were positive with 
real-time PCR for both provirus and virus, also did not produce infectious virus 
until the fourth week post-infection. Presence of provirus or of virus in plasma thus 
did not always correlate with production of infectious virus. Unfortunately however, 
we could not significantly demonstrate suppression of infectious virus production by 
treatment with dSLIM™. Absence of infectious virus in the plasma of the 2 cats M1 
and T3 nevertheless confirms their state of partial protection against FIV infection 
until week 4 post-challenge.
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and dissemination. With progression of disease, chronic changes to the immune 
system appear, of which gradual increase in specific antibodies and decline in Th1 
cell activities. This Th1 to Th2 orientation switch in active immune responses involves 
critical changes in the cytokine balance and has been described as potential influencial 
factor for the contraction of AIDS [390]. Moreover, Th2 immune responses have been 
repeatedly shown to either fail in protecting cats from an  FIV challenge infection 
[391], or not to correlate with observed vaccine-induced protection [392]. The 
importance of supporting the early cellular immune responses in attempts to combat 
retroviral infections is thus widely accepted. In this way, prophylactic treatment of 
domestic cats with a potent CpG-containing molecule was intended to stimulate 
those components of the innate immune system which could emphasize and possibly 
maintain the early Th1 deviation of the immune mechanisms engendered by FIV 
challenge infection. 
For a thorough interpretation of the viral kinetics observed in both groups during 
the present study, it seemed imperative to compare the balance between Th1 and 
Th2 immune reactions in treated and non-treated cats. Thus, we focused our 
immunological measurements on typical components of both Th1 and Th2 immune 
deviations. Antibody production, eosinophil granulocyte counts, as well as expression 
levels of IL-10 were analyzed in order to characterize the extent of a Th2 deviation. 
Detection of IL-12 p40 subunit mRNA levels was foreseen to typify a Th1-deviated 
immune response. Further possibilities to evaluate cellular immune responses include 
determination of specific CTL and NK cell counts along with analysis of their effector 
mechanisms. These parameters would have enabled a more precise illustration of the 
immune status of the cats during treatment and after FIV infection.
Through the determination of anti-FIV TM antibody titres with ELISA and the 
accomplishment of two separate cytokine experiments, we expected to show the Th1 
effects of dSLIM™ in vivo in the domestic cat model and to demonstrate positive 
consequences on the immumological outcome of FIV challenge infection subsequent 
to administration of this molecule.
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Weekly measurements of antibodies to FIV TM protein by ELISA were foreseen to 
compare the time point of seroconversion as well as the antibody titres in both groups 
throughout the experiment. In all cats of our study, seroconversion occurred by week 
3 post-challenge. No significant differences were thereby observed between both 
groups. At several time points during the experiment, the individuals of the treated 
group indicated significanty higher antibody titres when compared to those of the 
control group. These findings were rather surprising, as humoral responses represent 
effective Th2 deviations, and treatment with dSLIM™ was foreseen to favor cellular 
immune mechanisms. The observed prolonged resistance to FIV infection in the 
2 individuals from the treated group appeared to be nonetheless attributable to 
enhanced cellular immune responses, as these cats produced comparably low levels 
of antibodies until the fourth week post-challenge. NK cell and CTL cytotoxicity 
assays would have given more precise information on the nature of the immune 
mechanisms present in these cats and may be considered for future experiments.
In both groups, two clearly defined peaks of antibody production were observed at 
weeks 5 and 7 post-challenge. The mean titres seemed to stabilize towards the end 
of the experiment; analysis of this parameter at further time points would however 
be required to determine the presence of more peaks, and to enable their correct 
interpretation.
6.3.4.2 Cytokine Measurements
Measurements of cytokine expression in whole blood, as well as determination of the 
responsiveness to stimulation of isolated PBMCs from all cats allowed evaluation 
of both the systemic immune environment induced by dSLIM™ treatment and its 
effects on the course of subsequent FIV infection. Real-time RT-PCR techniques 
for the measurement of gene expression allowed the accurate determination of 
mRNA levels of the target genes Il-12 p40 and IL-10. In order to avoid experimental 
6.3.4.1 Anti-TM ELISA
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Although great attention was attributed to the precision of the measurements of 
IL-10 and IL-12 p40 expressions in whole blood of the cats, it remained difficult to 
ensure the use, for TNA extractions prior to RT-PCR analysis of an amount of blood 
containing the same amount of cells for each cat. Thus, the measured divergences 
in GAPDH mRNA levels were most likely a result of unequal samples rather than 
of individual expression variations. As a result, comparative analysis regarding 
GAPDH expression for different individuals or between different time points gives 
little valuable information. Nevertheless, the graphical representation of GAPDH 
mRNA levels in this study hints that both dSLIM™ treatment and FIV infection 
had little or no effect on GAPDH expression, emphasizing the « housekeeping » 
state of the GAPDH gene. Moreover, the use of the TNA obtained from the 
extractions accomplished with the whole blood samples for the determination of 
all 3 parameters (GAPDH, IL-12 p40, IL-10), enabled to calculate the GAPDH : 
cytokine ratio and thus to feasibly standardize the results from the individual cats. 
The expression of IL-10, a typical Th2 cytokine, could not be measured during the 
treatment period for both groups. In treated and non-treated cats, FIV challenge 
infection induced a rapid increase in IL-10 levels, which reflect the previously 
6.3.4.2.1 Cytokine Expression in Whole Blood
variations in the amount of RNA used in each real-time RT-PCR as well as eventual 
batch-to-batch variations in PCR reagents, coincident measurement of  GAPDH, 
a catalytic enzyme produced by a so-called « housekeeping » gene, was used for the 
normalization of target gene expression data. An inherent assumption in the use 
of housekeeping genes is that their expression is ubiquitous and remains constant 
in the cells or tissues under investigation, regardless of age, gender or pathological 
alterations. Although the « house-keeping » status of GAPDH is relatively 
controversial, measurement of the expression of this gene remains to date the most 
commonly used method to standardize the analysis of expression of other cytokines 
[375, 376, 393].
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6.3.4.2.2 Stimulation of Cytokine Expression in vitro
In order to assess to which extent PBMCs from treated cats can be more or less 
effectively stimulated to express certain cytokines, as well as to evaluate the effect 
of infection on their responsiveness to stimulation, various in vitro analyses were 
carried out at two strategic time points during the experiment, namely at week 0, 
before FIV challenge infection of the cats, and at week 8 post-challenge. Thereby, 
isolated PBMCs from each cat were either left unstimulated, or separately stimulated 
with Con A or LPS. These substances are known for their mitogenic potentials on 
T lymphocytes, and both have previously been shown to enhance the production 
of Th1 and Th2 cytokines in vitro [394]. Levels of GAPDH, IL-10 and IL-12 
p40 subunit mRNA present in the isolated cells were measured by RT-PCR. This 
described development of Th2-deviated immune responses after infection with 
immunosuppressive retroviruses. However, the treated group presented lower mean 
IL-10 expression levels after challenge infection, indicating an expected Th2-
suppressive effect of dSLIM™.
Disappointingly, very similar levels of IL-12 p40 subunit mRNA were measured 
in both groups during the treatment period. Moreover, rather unexpectedly, the 
IL-12 p40 expression levels of the treated group remained relatively unchanged 
after challenge, whereas the control group indicated a significant increase in mean 
expression levels of this cytokine. The presence of an early cellular immune response, 
as expected in the acute phase of infection, is most likely responsible for the 
observed IL-12 expression in the non-treated cats. However, as various experiments 
with dSLIM™ have shown potent induction of a Th1 environment in vitro and 
in vivo in different species,  an insufficient duration of treatment or a suboptimal 
administration protocol of dSLIM™ could possibly be the reason for the apparent 
lack of IL-12 stimulation by the treatment. Moreover, as IL-12 is a typical Th1 
cytokine, it seems unlikely that these results are a consequence of a suboptimal 
choice of target cytokine for these measurements. 
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experiment was designed with the intention to confirm the results obtained by the 
measurements of these cytokines in whole blood, and to demonstrate a predisposition 
of lymphocytes from dSLIM™-treated cats to produce cytokines favouring Th1 or 
cellular immune mechanisms.
The graphics representing GAPDH levels appeared very similar for both time 
points. However, the columns for week 8 seemed to be generally shifted toward a 
lower level in comparison to those of week 0. Probably, by mistake, more cells had 
been isolated for the experiments on week 0 than for those on week 8. The higher 
GAPDH levels measured after Con A stimulation, at both weeks, is most likely due 
to proliferation of the cells between stimulation and harvesting time points. As a 
reminder, cell counts were only determined at the time point of isolation, and not 
after stimulation. Taking this hypothesis into consideration, GAPDH expression 
was most likely not influenced by stimulation. Moreover, FIV infection did not 
affect basal GAPDH mRNA levels in PBMCs and these infected cells could not 
be stimulated to increased production of this enzyme. Altogether, the well-known 
stability of GAPDH within the same individual and cell type cannot be questioned 
through these results. 
In all cats, IL-10 could not be detected at week 0 in unstimulated PBMCs, indicating 
absence of a basal expression level of this cytokine. This observation confirms the 
measurements carried out for IL-10 in whole blood (see 6.3.4.2.1). Interestingly, 
stimulation of the PBMCs isolated from the control group at this time point, by both 
ConA and LPS, increased IL-10 liberation considerably. This was however not the 
case for the PBMCs isolated from the treated cats, as they could not significantly be 
stimulated to produce IL-10. Thus, as initially expected, it seems that the treatment 
with dSLIM™ suppressed expression of this Th2 cytokine. Surprisingly however, 8 
weeks after FIV infection, known to induce in the host the progressive development 
of a Th2-deviated immune response, isolated PBMCs from the control cats were 
less, and PBMCs from treated cats more responsive to stimulation, when it came 
to IL-10 production. Cells isolated from the dSLIM™-treated cats were thereby 
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particularly sensitive to stimulation with LPS. Generally, IL-10 expression by the 
PBMCs of both groups seemed more effective with Con A before and with LPS 
after FIV challenge. Partially similar observations have been formerly reported as 
responses of lymphocytes from infected cats were shown to less consistently respond 
to stimulation with Con A than cells from non-infected cats [59]. 
In accordance with the measurements accomplished in whole blood, a basal production 
of IL-12 p40 mRNA could be detected before FIV challenge in both groups. 
Significantly higher expression of this cytokine was observed in the treated group at 
week 0, supporting the hypothesis that administration of dSLIM™ to the cats in our 
experiment rapidly favoured the mounting of a Th1-oriented immune response. 
IL-12 p40 production by the isolated PBMCs could generally be stimulated slightly 
by Con A and considerably by LPS; disappointingly, PBMCs from the individuals 
of both groups thereby reacted similarly. As noted in the measurements completed in 
whole blood, IL-12 p40 levels detected in PBMCs post-infection were higher than 
at week 0 for both groups. Moreover, when compared to results obtained at week 0, 
PBMCs from the control group were significantly more susceptible to stimulation 
with LPS, whereas PBMCs from the treated group produced significantly less 
IL-12 p40 subsequent to the same stimulation at week 8 post-infection. These 
findings indicate that although treatment with dSLIM™ seems to have boosted early 
cellular defence mechanisms, the observed immunomodulatory effect  lasted about 
4 weeks in duration. Additional experiments during the acute phase of infection, at 
time points between weeks 0 and 8 post-challenge would most likely reveal valuable 
information in this respect. 
Altogether, we could demonstrate a Th1-deviating immune effect subsequent to the 
5-day administration of dSLIM™ to the cats. Indeed, before challenge infection, 
the PBMCs isolated from the treated cats not only produced significantly higher 
amounts of IL-12 than those from the control cats, but could not be stimulated 
to express IL-10. However, 8 weeks after experimental infection with FIV, the 
situation seemed to be somewhat inversed: The isolated lymphocytes from the 
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In an era of permanent emergence of new health-threatening viral diseases which 
sporadically enter the human population from animal reservoirs, such as the severe 
acute respiratory syndrome (SARS) and avian influenza (avian flu), the development 
of novel strategies to diminish risks of pandemics is under great pressure. Although 
vaccination already commonly confers long term protection to a large variety of 
familiar infectious agents, the development of an effective, safe vaccine requires an 
enormous amount of time, allowing yet uncharacterized viruses to disseminate and 
lead to considerable damage. With respect to emerging viral pathogens, manipulation 
of the innate immune system has gained, in the last 10 years, incredible popularity 
as alternative to elicitation of specific immunity. Indeed, innate immunity not only 
initiates immediate reaction to a wide range of pathogens, but greatly supports the 
subsequent development of specific immune mechanisms. Moreover, the organism’s 
first line of defence is known to possess the fantastic potential to instigate the 
production of powerful antiviral substances. Research groups worldwide are 
concentrating on elaborating the recent idea of inducing innate immune responses 
as prophylactic or therapeutic measures in the setting of infectious diseases. The 
availability of an appropriate outbred small animal model for such research purposes 
is therefore currently highly desirable. 
The present work in is line with the scientific trend of this decade. We demonstrated 
that prophylactic stimulation of the innate immune system with a CpG-containing 
molecule is able to induce partial resistance against FIV infection. For the first time, 
the immunomodulatory potential of dSLIM™, a specifically constructed molecule 
exhibiting several CpG motifs, was evaluated in vivo in the domestic cat. Clinically 
6.4 Conclusion and Future Perspectives
dSLIM™-treated cats displayed a higher tendency to express IL-10, and the 
levels of IL-12 p40 detected in these individuals were similar to those measured 
in the control group. These observations contradict the facts published on cytokine 
responses to infection with FIV and remain difficult to explain.
183
Discussion
very well tolerated, dSLIM™ induced only slight haematological alterations, 
namely transient increase in absolute neutrophil and monocyte counts. The partial 
protection observed in 2 cats from the dSLIM™-treated group was uttered by a 
3-week delay in detection of both proviral and viral loads in blood. Additionally, 
no infectious virus could be isolated from the PBMCs of these individuals during 
this lapse of time. The virus was thus hindered in its establishment in the host 
for several weeks after challenge infection. These observations could be linked to 
suppressed anti-FIV antibody titres measured in these individuals in the acute 
phase of infection. Moreover, comparatively higher mean levels of IL-12 at the time 
point of challenge and lower mean IL-10 expression levels shortly after challenge 
infection were detected in the treated group. Altogether these findings emphasize 
the role of Th1-deviated immune mechanisms in the partial resistance against FIV 
infection observed in these 2 cats. As NK cells and CTL represent the main cell 
populations directly responsible for cellular immune responses, evaluation of their 
effector functions with NK cytotoxicity assays or detection of cytokines such as 
perforine and granzyme B would enable, in future experiments, to confirm and 
further characterize the immune processes involved in this protective mechanism. 
The evaluation of various IgG subclasses would also hint the presence of either Th1 
or Th2 immune deviations. Such differentiation is however to date not possible due 
to the unavailability of tests for these feline antibodies on the market. 
The complex network of feline innate immunity remains to date under-explored. 
Prophylactic stimulation of innate immune mechanisms with stand-alone agents is 
not only a very recent inspiration in medical research, but represents a true novelty 
in experiments concerning the domestic cat. Also, the immunomodulatory effects of 
dSLIM™ on the feline model had never before been investigated. As a consequence, 
this study was mainly based on hypothetical extrapolations from knowledge acquired 
through published experiments regarding other species and/or types of synthetic 
ODN. Many critical parameters thus most likely greatly affected the outcome of the 
present work. In this way, an in vitro optimization of dSLIM™ on feline immune 
cells, as well as a series of pre-experimental in vivo administration tests would help 
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revise important factors such as viral challenge and injection protocols for future 
trials.
The promising results obtained despite the inevitable accumulation of such variables 
in our study adds up to several other factors favouring the use of a feline model 
for research on modulation of the innate immune system. As inbreeding and other 
detention conditions seem to have influenced their innate immune responses over 
time, laboratory animals like mice or rabbits somewhat deviate from ideal models 
for experiments concerning innate immunity. The domestic cat is an outbred species 
moreover affected by a variety of viral infections, such as FIV, FHV and FCoV 
which closely resemble in their biological properties those affecting humans or 
other species. Finally, host-virus interactions acquired throughout evolution render 
induction of antiviral resistance particularly challenging in the cat, thus increasing 
relevance of promising results for the human population. Collectively, these facts 
emphasize the feasibility to extend knowledge on the feline model as basis for further 
investigations concerning modulation of innate immunity. Our study suggests that 
non-specific prophylactic manipulation of the cat’s early immune mechanisms holds 
the potential to induce resistance to a challenge viral infection. These findings open 
the way to future experiments which could change the face of medical science.
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